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Abstract 
 
Ebola and Zika viruses have been brought to the world’s attention in recent years due to 
widespread outbreaks and the devastating diseases they cause in humans. Hence there is 
an urgent need to develop vaccines which can protect from disease.  
Salmonella vaccine strains have been genetically attenuated so as not to cause disease. 
These vaccine strains can be engineered to deliver heterologous antigens from viruses, 
bacteria, and worms to the host’s immune system to elicit protective immunity. Such 
vaccines can be orally administered and would not need cold storage. A successful vaccine 
using this platform would have the additional advantages of being trivalent, protecting 
against Salmonella, Tetanus and Ebola or Zika virus. 
The Ebola Glycoprotein (GP) and the Zika envelope protein (ZE) contain important 
protective epitopes, which are targets for neutralising antibodies, and therefore 
considered prime targets for vaccine development. Using the Salmonella based delivery 
systems we have successfully expressed these Ebola and Zika virus vaccine candidate 
proteins for delivery to the immune system.  
A large panel of 19 variant constructs has been generated, which express these viral 
antigens, or sub-fragments containing important protective epitopes, as fusions to the C-
fragment of Tetanus Toxin (TetC). TetC is a potently immunogenic molecule, which can be 
expressed to high levels by Salmonella and helps to solubilise the expressed fusion protein 
partner and act as an adjuvant. Expression of proteins in this vector is driven by the in vivo 
inducible promoter, nirB.  
The panel of GP and ZE genes and cassettes were synthesised to be codon optimised, with 
toxic hydrophobic signal sequence and transmembrane regions removed, for expression 
in Salmonella Typhimurium. By testing with western blot, it was found that TetC rescued 
expression of the GP and ZE proteins, which were either expressed at much lower levels 
or not at all in constructs lacking the TetC fusion partner. The most promising candidates 
were then taken forward to in vivo testing. These strains have been shown to be stable 
both in vitro and in vivo, retaining the expression vector, and still expressing the antigens 
after passage in BALB/c mice.  
Vaccination experiments were then carried out in BALB/c mice and have unfortunately 
shown that after a single immunisation, there was no significant IgG antibody response to 
the GP or ZE antigens.  
An alternative non-living Salmonella vaccine delivery platform has also been investigated. 
By making tolR and mlaA gene knockouts in Salmonella Typhimurium strain SL1344, these 
strains have been shown to produce elevated amounts of outer membrane vesicles 
iii 
 
(OMVs) than their wild type counterparts. These immunogenic vesicles could then be used 
to carry antigen as cargo for vaccine delivery and subsequently purified for immunisation.  
Constructs were made to target the expression of the Zika envelope protein to the outer 
membrane or periplasm, using signal sequences from OmpA and DsbA respectively. The 
knockout strain SL1344 ΔtolR, harbouring these plasmid constructs, was able to express 
ZE in OMVs, hopefully either decorating the OMV surface, or contained within the lumen.  
It is hoped that this could lead to an improved immune response compared to the live 
platform, as an adequate antigenic dose could be pre-determined and administered 
accordingly. The outer membrane components (such as LPS) which are naturally included 
in the OMVs, act as an adjuvant, and thus can increase the immunogenicity and efficacy 
of such a platform. A wider range of potential recipients could also be reached with such 
a vaccine, as vulnerable populations such as the very old, very young or 
immunocompromised patients cannot receive live vaccines. This study has shown the 
feasibility of such an approach of targeting antigen cargo to the OMVs, and will hopefully 
pave the way for future exciting research to determine its effectiveness 
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Chapter 1 – Introduction 
 
1.1 Vaccines  
 
Vaccines are often hailed as one of the most important inventions in modern medicine. From 
the now famous but humble beginnings in 1796 with Edward Jenner’s Cowpox experiment 
(André, 2003), the use of vaccines is still the most effective way of combating infectious 
diseases, which is one of the leading causes of mortality worldwide. The eradication of 
smallpox in the late 1970’s (Shchelkunova, & Shchelkunov, 2017) and the control of many 
other diseases including polio, mumps, measles and diphtheria, demonstrates the great 
potential of vaccinations and their importance in protecting much of the world’s population 
from otherwise potentially fatal infections. The link between some infectious agents, for 
example Human Papilloma Virus, and cancer has also shown that it is possible to prevent 
further complications from infections using vaccines (Signorelli et al, 2017). It is also now 
evident that it may be possible to actually treat other diseases such as cancer or auto immune 
diseases using vaccines (Liu, 1999).  
The protection offered by vaccines comes from the activation of the immune system by 
exposure to a (often attenuated) pathogen or antigen, priming the immune system and 
enabling a specific and more efficient secondary response when the pathogen is next 
encountered, thus preventing infection from taking hold. In second exposure, PAMPs, or 
Pathogen Associated Molecular Patterns, which are expressed on the surface of pathogens 
are recognized by pathogen recognition receptors (PRRs) on host innate immune cells such 
as macrophages and dendritic cells. This recognition interaction leads to a release of cytokines 
and chemokines by the innate immune cells and stimulates the adaptive immune response 
by way of T and B lymphocytes. These cells have receptors for specific epitopes found on the 
antigen and can then release cytokines and specific antibodies respectively, preventing the 
infection. Immune memory, arising from this priming of the immune system with a vaccine, 
is imperative as it allows for vaccines to be used prophylactically well before any exposure to 
the actual infectious agent occurs.  
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Vaccines come in many different forms; Toxoid vaccines such as the vaccine for tetanus; Killed 
or attenuated such as those for typhoid, polio and Hepatitis A; Subunit vaccines where a 
specific antigen from a pathogen is used, such as for Hepatitis B or Influenza (Baxter, 2007). 
DNA vaccines are also being investigated as a simple way of introducing an antigen to the host 
immune system (Liu, 1999). 
Toxoid vaccines can protect against bacteria that are known to secrete toxins which are 
responsible for the disease symptoms, such as; tetanus, diphtheria, botulism and cholera 
among others (Baxter, 2007). These vaccines use inactivated (often by formaldehyde) 
bacterial toxins, which then elicit an immune response (Clem, 2011).  For example, botulism 
is a rare, yet potentially life-threatening disease caused by neurotoxins produced by various 
Clostridium species, leading to paralysis symptoms. Vaccination against the toxins themselves 
can elicit neutralising antibodies which prevent their binding to pre-synaptic neuronal cell 
receptors and allow them to be cleared and degraded by phagocytes, thus preventing the 
botulism symptoms (Smith et al, 2009; Jones et al, 2008). Tetanus toxin also binds to receptors 
located on pre-synaptic nerve cells. This results in the improper function of GABA (gamma 
Aminobutyric acid) neurons which usually act to inhibit motor neurons. Without GABA neuron 
inhibition, increased activity of motor neurons results in severe muscle spasms. A vaccine 
which uses formaldehyde treated tetanus toxoid is able to elicit an adaptive immune 
response, where the toxoid is phagocytosed by dendritic cells and its antigens displayed on 
MHCII (major histocompatibility complex II) molecules on the cell surface. The cell then 
migrates to the draining lymph node and the corresponding T cell receptor, on the surface of 
TH2 cells, binds to the MHCII-tetanus toxoid complex, activating the T cell to proliferate. The 
toxoid can also bind to a corresponding B cell receptor, also in the draining lymph node, again 
resulting in presentation of an MHC-toxoid complex. When this B cell encounters a TH2 cell 
able to recognise this specific complex, the B cell is activated and then produces antibodies 
towards the toxoid. These antibodies create a large complex when bound to the toxin and 
therefore prevent receptor binding and the typical muscle spasms as seen with tetanus 
infection (Baxter, 2007).  
Killed or inactivated vaccines are used against bacteria (e.g. typhoid) and viral pathogens (e.g. 
Hepatitis A). They are able to elicit an immune response to a wide range of antigens. The TH2 
cells recognise epitopes on these antigens and are activated to release cytokines which induce 
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B cell activation and thus proliferation and production of IgG antibodies and memory B cells, 
in preparation for future encounters with a live pathogen. This vaccination method is 
potentially less effective than others which use a more specific antigen directed approach, as 
booster immunisations are often needed due to the fact that the dead pathogen cannot 
replicate in the host, or may include antigens which can modulate the host immune system 
in a negative way and thus weaken the response (Baxter, 2007; Clem, 2011). 
Subunit vaccines elicit an immune response to only antigenic components of a pathogen. By 
including only B or T cell epitopes, these vaccines have advantages over whole cell or virus 
vaccines as there is less chance of adverse reactions and no possibility of reversion to 
virulence (Clem, 2011). These carefully selected antigens can be proteins, which elicit a T cell 
dependent immune response, such as the vaccines for Hepatitis B or Haemophilus influenzae, 
or a polysaccharide, such as capsular polysaccharides from pneumococcal bacteria, which 
elicit a T cell independent response. Polysaccharide antigens are able to activate B cells with 
a specific receptor to produce antibodies without T cell contribution, as its large size and 
repeating structure is able to bind to multiple B cell receptors on one B cell. This response 
mainly produces IgM antibodies as without T cell help, there is restricted antibody isotype 
switching, resulting in only a limited amount of IgG antibodies and memory B cells produced. 
Protection here, comes from IgM activation of the complement system, lysing the 
Streptococcus pneumoniae bacteria (Baxter, 2007).  
Live attenuated vaccines, in a similar way to killed or inactivated vaccines, use the whole 
pathogen to elicit an immune response. Viruses can be attenuated by passage in a foreign 
host, which then have a preferred virulence for the foreign host and not humans, or in 
conditions which are different to that of the human host (for example at a temperature lower 
than 37°C), resulting in mutants which are less able to thrive before the adaptive immune 
response can clear the infection (Baxter, 2007; Hanley, 2011). Bacterial pathogens can be 
genetically attenuated (see sections 1.3.1.1 and 1.3.2 for further details). There are limitations 
with these types of vaccines, for example, there is a potential to revert back to a virulent 
strain, particularly with the rapid rates of mutation of RNA viruses. It has been reported that 
some recipients of the attenuated oral polio vaccine, for example, can experience vaccine-
associated paralytic poliomyelitis as the attenuated strain reverts back to virulence. This has 
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resulted in the alternative use of an inactivated rather than live attenuated vaccine in the 
United States in particular (Hanley, 2011). 
DNA vaccines simply involve immunising with a plasmid encoding an antigen, allowing the 
host cells to produce the protein and introduce it to the immune system. There is no need for 
using live pathogens and therefore could be safer. Clinical trials for HIV, malaria and cancer 
vaccines have been carried out, but research to optimise potency are continuing (Liu, 1999). 
1.1.1 Live recombinant vaccines 
 
The use of attenuated bacteria or viruses as vectors to introduce heterologous antigen DNA 
into the host has been investigated to create recombinant vaccines. When designing vaccines 
for intracellular pathogens, including viruses, a recombinant vaccine may be a more attractive 
choice over live attenuated vaccines due to the risks of attenuation reversal and possible 
virulence in certain susceptible hosts. Recombinant vaccines, using safe attenuated vectors 
rely on an immune response directed at a particular antigen (which could be from any number 
of pathogens) which the vector has been engineered to express, and would elicit an immune 
response similar to that seen with subunit or toxoid vaccines (see above). An example of a 
successful recombinant vaccine against a virus is the Hepatitis B (Hep B) vaccine which uses 
yeast cells to express the Hep B surface antigen. The antigen can accumulate in virus like 
particles (VLPs) and elicit a protective immune response due to the high immunogenicity of 
these particles. Human papilloma Virus, which can be the cause of cervical cancer can also be 
protected against by use of VLPs made by the expression of the virus’s main capsid protein in 
insect or yeast cells. These vaccines often need co-administration with an adjuvant to increase 
the immunogenicity of the antigens (Nascimento & Leite, 2012). 
Bacterial vectors, such as has been investigated with attenuated Salmonella (as discussed in 
section 1.4), are able to express heterologous antigens by introduction of expression plasmids 
and can stimulate the immune system, also acting in an adjuvant capacity as the vector mimics 
a natural infection. To ensure a good immune response, the vector must be considered 
carefully and allow adequate expression of the antigen (Nascimento & Leite, 2012). The 
expression plasmid must also be considered to ensure it is stably retained by the vector, has 
an appropriate copy number and the promoter is strong enough for adequate expression. The 
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use of a vector also allows the generation of a multivalent vaccine towards both the vector 
and the pathogen to which the guest antigen belongs.  
 
1.1.2 Salmonella as vaccines 
 
Attenuated live Salmonella enterica serovar Typhimurium (Salmonella Typhimurium) and 
Salmonella Typhi strains have been investigated for use as vaccines against a mouse model of 
Typhoid fever and human typhoid fever respectively (Garmory et al, 2002). They can also be 
engineered to carry heterologous antigens from viruses, bacteria, protozoa, and worms to 
elicit protective immunity against these pathogens (Khan et al, 1994a; Khan et al, 1994b). 
After oral inoculation with even a relatively small dose of attenuated Salmonella, it is able to 
invade and colonise lymphoid tissue, and can then induce systemic ‘infection’, resulting in T-
cell memory and a long-lasting immune response (Curtiss et al, 2010). This will be discussed 
later in this thesis (see section 1.2.4). 
 
The mucosal surfaces of the body are major routes of pathogen entry and depending on the 
immunisation route, localised protective immune responses can be induced. Examples of 
effective mucosal vaccines, administered orally, include live-attenuated poliovirus and 
Rotavirus vaccines which are able to induce both local mucosal IgA antibodies and CD4+ and 
CD8+ T cell mediated protective immune responses respectively (Azegami et al, 2014). 
Importantly, it has been shown that an immunisation route which targets mucosal surfaces 
(such as oral administration), allows recombinant attenuated Salmonella vaccines to elicit both 
systemic and mucosal antibody responses (Clark-Curtiss & Curtiss III, 2018).  
Salmonella enterica demonstrates a natural tropism for the mucosal surfaces of the intestinal tract 
including the payer’s patches, vital components of the gut associated lymphoid tissue (GALT). 
This tropism lends itself well to an oral mucosal immunisation route (Gayet et al, 2017). Ty21a, 
a live attenuated strain of Salmonella Typhi Ty2, also taken orally, has been shown to elicit IL-
17 producing S. Typhi specific T cell responses and also induce cross reactive immune 
responses against other serovars, namely paratyphi A and B, the causative agents of 
paratyphoid fever for which there are no current effective vaccines (Azegami et al, 2014). The 
Ty21a vaccine strain is discussed in further detail later in this thesis, in section 1.3.1.1. 
 
6 
 
 Therefore, developing a recombinant multivalent vaccine for both typhoid fever and Ebola 
or Zika Viruses, as described in this thesis, may be possible in this way. Such a vaccine would 
be orally administered, thus the need for needles and cold storage facilities is no longer 
necessary. In the case of Ebola virus in particular, which is transmitted through mucosal 
contact with infected bodily fluids, a vaccine which is able to induce both systemic and 
localised mucosal protective immune responses could be very effective.  This would allow for 
a much cheaper and easier to administer vaccine, which would be most welcome, especially 
in the developing countries such as West Africa and parts of the Americas where these viruses 
have caused such devastation.  
 
 
1.2 Salmonella as human pathogens 
 
Salmonella are Gram-negative facultative anaerobes belonging to the family 
Enterobacteriaceae. A major pathogen, Salmonella can cause gastroenteritis and typhoid 
fever in humans. Two species of Salmonella are known; Salmonella bongori and Salmonella 
enterica, the latter including in excess of 2600 serotypes (Coburn et al, 2007; dos Santos et al, 
2018). Salmonella enterica are further divided into either typhoidal serovars (S. Typhi and S. 
Paratyphi) which are only able to infect humans, and non-typhoidal Salmonella (NTS), 
including S. Typhimurium, which are often zoonotic and includes some serovars with a wider 
range of hosts (Gordon, 2011). It has also been recently discovered, through genomic 
sequencing of ancient human tooth matter, that outbreaks of Salmonella enterica paratyphi 
C (which causes enteric fever) were likely a major contributing factor in the massive 
population decline of indigenous Mexican inhabitants in the 1500s and subsequently the 
collapse of the Aztec empire. It is thought that Salmonella paratyphi C was brought over 
during the European colonisation of the area by asymptomatic European carriers, which can 
be 1-6% of people infected (Vågene et al, 2017). The possibility of asymptomatic Salmonella 
Typhi carriers, was discovered in the case of Mary Mallon or “Typhoid Mary” in New York in 
the early 1900s, where she was determined to be exacerbating the spread of Typhoid fever 
in the area due to her unsanitary cooking practices (Marineli et al, 2013). 
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1.2.1 Salmonella Typhimurium as a human pathogen 
 
One of the most frequently isolated serotypes of Salmonella enterica is the NTS serovar 
Salmonella Typhimurium, which can often be found in meat for human consumption such as 
chicken, pork and beef (dos Santos et al, 2018).  
 
1.2.2 Salmonella Typhimurium infection  
 
The most common route of infection by Salmonella Typhimurium is through contaminated 
food or water. Generally, infection in a healthy human entails a self-limiting bout of 
gastroenteritis, however in some more vulnerable patients, such as those with HIV/AIDS or 
malaria, particularly in sub-Saharan Africa, there can be the danger of life threatening 
systemic bacteraemia once infected (dos Santos et al, 2018; Lathrop et al, 2015). 
 
1.2.3 Pathogenesis and invasion of Salmonella 
 
The first obstacle that ingested Salmonella must face is the low pH of the stomach. To combat 
this, it activates the acid tolerance response (ATR) which acts homeostatically to keep the 
intracellular pH higher than the extracellular pH and allows survival in this environment 
(Fabrega & Vila, 2013). The Salmonella can then cross the intestinal wall’s mucus layer, and 
with host-receptor interactions of adhesion factors on the bacterium surface, can adhere to 
the cells of the intestinal epithelium (dos Santos et al, 2018).  
Salmonella have virulence genes encoded in pathogenicity islands (SPI) which allow them to 
invade host cells. The Type 3 secretion system 1 (T3SS1), encoded in SPI-1 allows the 
Salmonella to inject effector proteins into the host intestinal epithelial or M (microfold) cells 
(found in Peyer’s patches, small areas of lymphoid tissue, in the wall of the ileum and often 
associated with macrophages) in the early stages of infection (Galan, 1999; dos Santos et al, 
2018). These effector proteins, notably; SipA, SopB, SopA and Sop E/E2, activate signal 
transduction pathways in the host cell and the actin cytoskeleton is rearranged. This leads to 
the ‘ruffling’ of the epithelial cell membrane and the Salmonella can be engulfed, similar to 
phagocytosis. The Salmonella is then contained in a Salmonella containing vacuole (SCV) in 
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the cell, where they are able to multiply (Zhang et al, 2018; Eng et al 2015; dos Santos et al, 
2018). 
The SCV is transported to the basolateral membrane of the intestinal epithelium and the 
Salmonella can enter the lymphatic system, be phagocytosed by cells such as macrophages, 
and from here develop a systemic infection (dos Santos et al, 2018). 
 
1.2.3.1 Survival of Salmonella in Macrophages 
 
Macrophages usually kill engulfed pathogens by acidifying the intracellular compartment, 
however Salmonella enterica have evolved to survive this and persist. It is thought that this 
acidification of the SCV acts as an induction signal for the expression of SPI-2 virulence 
proteins. This allows effector proteins to be delivered to the host cell and disrupt the host’s 
immune response (Chakraborty et al, 2015).  
Salmonella possess two virulence systems that allow survival after entry into macrophages 
and the SCV. These are the PhoP/Q two component regulatory system, and the SPI-2 encoded 
T3SS2. The sensor-kinase PhoQ senses when the Salmonella is in an acidified SCV such as in a 
macrophage, resulting in the phosphorylation of the response regulator PhoP. 
Phosphorylated PhoP signals to regulate proteins involved with the bacterial envelope. This 
results in the regulation of the outer membrane and increases the bacterium’s resistance to 
cationic antimicrobial peptides (CAMP) and allowing survival in this environment (Dalebroux 
& Millar, 2014). In the phagosome environment, signals leading to the expression of T3SS2 
proteins allows the secretion of effector proteins into the host cell which are needed for the 
Salmonella’s survival.  
Salmonella can cause the death of invaded macrophages by pyroptosis, by either T3SS1 
dependent (early on after phagocytosis by the macrophage) or T3SS2 dependent means 
(occurring hours after phagocytosis). The early stage pyroptosis is mediated by the T3SS1 SipB 
effector protein and allows the activation of the inflammasome leading to the targeting of 
the macrophage for programmed cell death. The later stage pyrotopsis is mediated by the 
T3SS2 SpvB effector protein which depolymerises actin and causes cell death. This then allows 
the release of the intracellular Salmonella and it is able to disseminate in infected organs such 
as the liver and spleen (Fabrega & Vila, 2013). 
9 
 
It seems however that the phenotype of the invaded macrophage can affect the Salmonella’s 
ability to replicate. (Lathrop et al, 2015). 
 
1.2.4 Immune response to Salmonella infection 
 
Mouse models of Salmonella infection are widely used to investigate the pathogenicity of 
salmonellosis and the resulting immune response (Mastroeni & Sheppard, 2004) however, it 
is unclear whether the murine model of S. Typhimurium, is a truly accurate model for human 
typhoid or non-typhoidal systemic salmonellosis (Pham & McSorley, 2015). Salmonella 
Typhimurium infection in mice appears to be similar to systemic Salmonella Typhi infection in 
humans, in that it penetrates the peyer’s patches of the intestine and quickly disseminates to 
the liver, spleen and bone marrow. It is therefore the most commonly used animal model of 
typhoid disease (Moon & Mc Sorley, 2009). 
The first line of defence against invading pathogens is the innate immune system. PAMPS on 
the bacterial surface, are recognised by pattern recognition receptors (PRRs) including Toll 
Like Receptors (TLRs) situated on the surface of resident macrophages and monocytes. For 
example, bacterial LPS is recognised by TLR 4 and flagellin recognised by TLR 5. This 
recognition initiates inflammation by the release of cytokines and the recruitment of 
neutrophils (Broz et al, 2012). 
It appears that effective immunity to Salmonella relies on CD4+ T helper cells and a Th type 1 
response. A rapid, localised CD4+ T cell response in Peyers’ patches has been shown in mice 
orally inoculated with Salmonella Typhimurium (McSorley et al, 2002). Primary Salmonella 
infection elicits antibodies against LPS, and B cell deficient mice show impaired resistance to 
oral challenge with Salmonella Typhimurium, however this does not simply appear to be due 
a diminished antibody response, it seems that B cells are required to establish a long-lasting 
T cell memory response (Mastroeni et al, 2000 (a); Mastroeni et al, 2000 (b)).  
 
1.3 Vaccines against typhoid fever 
 
It is estimated that typhoid fever, caused by systemic Salmonella Typhi infection, causes over 
21 million illnesses and 222,000 deaths annually, mainly in areas with inadequate water 
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sanitation and hygiene, such as South Asia and Sub-Saharan Africa. Vaccines for typhoid are 
important to control typhoid fever, especially in these areas where the infrastructure is not 
currently in place to improve water sanitation. It may be argued that here, prevention would 
be better than cure due to the rise in antibiotic resistance (Date et al, 2015).  
Previously, heat killed or phenol inactivated whole cell vaccines were used, however these 
have been shown to be more toxic and induce more adverse events than newer typhoid 
vaccines such as Ty21a which is taken orally (see later) and the parenteral Vi Polysaccharide 
vaccines (Engels & Lau 1998). There are also newer vaccines against typhoid, which are at 
various stages of development. These include Typhoid conjugate vaccines (TCVs), where the 
Vi antigen, an immunogenic capsular polysaccharide found in Salmonella (Virlogeux-Payant & 
Popoff, 1996) is conjugated to a carrier protein, thus enhancing immunogenicity (Date et al, 
2015). The Vi-TT (Vi-Tetanus Toxoid) conjugate vaccine for example has recently been 
recommended by the World Health Organisation (WHO) (Milligan et al, 2018). 
The latest Cochrane review on typhoid vaccines (Milligan et al, 2018), includes these new 
vaccines and comments on their efficacy (See table 1.1). It appears that the currently licenced 
Ty21a and ViPS vaccines are certainly effective in preventing typhoid fever. The effectiveness 
of new vaccines, such as Vi-TT and other TCVs however, need to be more thoroughly 
investigated to determine effectiveness for children under 2 years of age, an especially 
vulnerable population in typhoid endemic countries (Milligan et al, 2018). 
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Vaccine type Name  Route of administration Comments 
Live-attenuated Ty21a  Oral, four doses (alternate 
days) 
Approved for use in children 
over 6 years of age. Taken 
orally. E.g Vivotif (PaxVax). 
Vi Polysaccharide ViPS Single parenteral dose Approved for children 2 years 
of age and older, is not 
immunogenic in infants.  
e.g. Typherix (GSK) or Typhim 
(Sanofi Pasteur). 
Typhoid Conjugate Vi-
rEPA 
Two parenteral doses Vi conjugated to non-toxic 
recombinant Pseudomonas 
aeruginosa exotoxin A (rEPA). 
Not currently commercialised, 
only been used in children 
over 2 years of age. 
Typhoid Conjugate Vi-TT Two doses, intramuscular 
injection 6 weeks apart 
Vi conjugated to Tetanus 
Toxoid. Licensed in India as - 
Peda Typh (BioMed) and 
Typbar TCV. Has been used in 
children over 6 months of age, 
however more data is needed 
to fully determine efficacy. 
 
Table 1.1. Vaccines which have been developed against Typhoid (Milligan et al, 2018; Mitra et al 
2016). 
 
1.3.1 Live attenuated Salmonella vaccines 
 
The use of killed or inactivated whole cell vaccines against typhoid has been discontinued due 
to the increasing reports of adverse effects and limited ability to induce cell mediated 
immunity upon vaccination. Thus, new vaccines have been developed including live 
attenuated Salmonella strains such as Ty21a which have been shown to be effective in 
immunising against typhoid fever. Live attenuated Salmonella can also be used to express 
heterologous antigens for delivery to the host immune system, and have therefore also been 
investigated as a vaccine delivery platform (Mastroeni et al, 2000 (a); Garmory et al, 2002).  
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1.3.1.1 Live attenuated Salmonella Typhi vaccine Ty21a 
 
The Ty21a vaccine is an orally administered live attenuated strain of Salmonella Typhi Ty2. 
Attenuated by chemical mutagenesis using nitrosoguanidine in the 1970s, resulting in a 
mutation in the galE gene, which encodes the enzyme Uridine diphosphate (UDP)-galalctose-
4-epimerase, it was shown to be safe and trigger protective responses against Salmonella 
Typhi infection when ingested. (UDP)-galactose-4-epimerase is responsible for the conversion 
of UDP-galactose to or from UDP-glucose. UDP-galactose allows the incorporation of 
galactose into the core of LPS and O-polysaccharide (O-Antigen), therefore the galE mutation 
results in a strain with rough LPS, lacking these parts. The O-Antigen is a major epitope on the 
Salmonella surface, and therefore to ensure an immune response, during production of 
Ty21a, there needs to be a limiting source of exogenous galactose to make UDP-galactose. 
This allows the bacteria to make full LPS, in a synthesis pathway that is non-galE dependent, 
giving rise to an immune response. Further mutations in Ty21a lead to a reduction in the levels 
of enzymes that can make UDP-galactose from exogenous sources, but in vivo when the 
exogenous galactose source is supplied, a build-up of galactose-1-phoshate and UDP-
galactose inside the cell, leads to bacteriolysis and the infection is therefore not able to take 
hold.  Further attenuation in Ty21a is also attributed to mutations resulting in the lack of 
synthesis of the Vi polysaccharide capsule. (Pham & McSorley, 2015; Kolecko et al, 2009; 
Germanier & Fürer, 1975). 
 
1.3.2 Mutations resulting in attenuation of Salmonella 
 
Salmonella have many virulence genes to enable colonisation of the host and establish 
infection. It is however possible to genetically attenuate the Salmonella by introducing 
mutations into these genes. This prevents their ability to cause disease, yet as they still retain 
capability of eliciting protective immunity, they are able to be used as a live vaccine (Hoiseth 
& Stocker, 1981). 
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1.3.2.1 Aromatic pathway mutations 
 
One effective way of creating mutated strains which are attenuated, is to induce auxotrophy. 
Auxotrophic mutants require compounds essential for growth, which are not provided by the 
host, and that due to the mutation, the strain is unable to synthesise itself. A deletion in the 
aroA gene in Salmonella Typhimurium for example, results in a strain with an impairment in 
the aromatic biosynthesis pathway and is unable to synthesise aromatic amino acids (AAAs); 
tryptophan, tyrosine, phenylalanine and also the folate precursor para-aminobenzoic acid 
(PABA) and 2,3-dihydroxybenozate (DHB), the precursor for the bacterial iron acquisition 
compound; enterochelin.  
These compounds are synthesised from chorismate, the final product of the aromatic (aro) 
biosynthesis pathway (see figure 1.1). PABA and DHB are not found in mammalian cells and 
so Salmonella must synthesise them using this pathway. A mutation in genes associated with 
this pathway, such as aroA, which encodes for the enzyme 5-Enolpyruvyl-shikimate-3-
phosphate-synthase, disrupts the eventual synthesis of chorismate and therefore the 
Salmonella becomes auxotrophic for PABA, DHB and the AAAs. Thus, virulence is reduced due 
to the limit of PABA available and the Salmonella is unable to colonise the host due to its’ self-
limiting nature (Hoiseth & Stocker, 1981; Denich et al, 1993). The aroA- vaccine strain SL3261 
(parent strain – SL1344) has been used as mentioned previously to sucessfully deliver 
recombinant antigens to the host and elicit immune responses (Khan et al, 1994a; Khan et al, 
1994b; Ashby et al, 2005). 
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Figure 1.1. The aromatic (aro) synthesis pathway of Salmonella.                 
A mutation in the aroA gene, which encodes the enzyme 5-Enolpyruvyl-shikimate-3-phosphate-
synthase (circled) results in an attenuated strain, unable to synthesise PABA, DHB or aromatic amino 
acids (adapted from: Hoiseth & Stocker, 1981; Tzin & Galili, 2010). 
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1.3.2.2 HtrA mutations 
 
HtrA is a periplasmic stress induced protease found to be involved in the virulence of a 
number of bacterial pathogens. In Salmonella it allows survival in macrophages, strains with 
mutations in the htrA gene show increased sensitivity for oxidative stress (such as is found 
within the macrophage) and have been shown to be less virulent in mice (Lewis et al, 2009; 
Humphreys et al, 1999; Tacket et al, 1997). Salmonella htrA mutants have been shown to elicit 
an immune response in humans and mice and can also carry heterologous antigens for 
delivery to the immune system (Tacket et al, 1997; Chabalgoity et al, 1996). 
 
1.4 Live recombinant Salmonella vaccines 
 
As mentioned above, it has been shown that attenuated Salmonella can deliver heterologous 
antigens to the host immune system and elicit an immune response. This has been 
investigated with a number of antigens from other bacteria, viruses, protozoa and worms. 
Antigens from parasitic flatworms Schistosoma mansoni (Khan et al 1994a; Khan et al, 1994b) 
and Schistosoma haematobium (Lee et al, 2000), glycoprotein D from herpes simplex virus 
(Chabalgoity et al, 1996), and a circumsporozoite protein (CS) from a malarial parasite 
(McKelvie et al, 2008), have all been successfully used in recombinant Salmonella vaccines 
and shown to elicit protective immune responses against their respective pathogens.  
The p28 peptide of Schistosoma mansoni is the 28kDa glutathione S-transferase, and has been 
shown to induce protective immunity in a range of vaccinated hosts, containing important B 
and T cell epitopes, in particular, the immunogenic peptide aa115-131. This peptide, when 
expressed as a genetic fusion to the C-fragment of Tetanus Toxin (TetC), which will be 
discussed later in this thesis, has been shown to elicit antibody responses in vaccinated hosts 
when expressed in attenuated Salmonella (Khan et al, 1994a), in particular when the copy 
number of this short peptide is increased in tandem repeats (Khan et al, 1994b). Similarly, 
mice immunised with attenuated Salmonella Typhimurium strain C5 with a mutation in the 
stress protein gene htrA, were able to make an antibody response to tandem copies of aa 8-
23 of the Herpes simplex virus glycoprotein D expressed by this strain (Chablgoity et al, 1996).  
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A double Salmonella Typhimurium vaccine strain mutant, with lesions in both the aroA and 
waaN genes, resulting in an auxotrophic mutant expressing modified Lipid A, seemed to show 
enhanced immune responses to a guest antigen, in this case TetC fused with CS from a 
malarial parasite, in vaccinated mice compared with the single aroA mutant. This could be 
due to the reduction in LPS toxicity in the double mutant, and therefore the ability to 
immunise with higher doses of Salmonella, thus increasing the antigenic (TetC-CS) dose 
(McKelvie et al 2008).  
SL3261 expressing TetC, has also been shown to be safe when tested in rabbits and elicits a 
strong anti-TetC antibody response (Ashby et al, 2005). 
More recently, studies have shown that recombinant Salmonella Typhimurium vaccine strains 
expressing heterologous O-antigen from other serovars (e.g. Salmonella Choleraesuis) may 
be able to elicit some heterologous protection in vaccinated mice against the other serovar 
and could lead to an alternative technique for expressing heterologous antigens (Zhao et al, 
2017). 
Vaccines such as these, once the expression of the antigen has been engineered to be optimal, 
can be cost effective and relatively easy to produce, potentially providing an easy way of 
immunising people in developing or poorer countries. 
1.5 Expression of heterologous antigens in Salmonella 
 
To allow the Salmonella to express heterologous antigens, expression plasmids engineered to 
carry these antigens are transformed into the bacterial cells. The most important issue to 
ensure has been addressed, is the ability of the Salmonella to retain the plasmid in vivo; its 
stability. Stable plasmids can be retained by the bacteria even in the absence of the selection 
antibiotics that are used when conducting the in vitro expression work. This is important as 
upon immunisation, there are no antibiotics available and loss of the plasmid could result in 
a lower antigenic dose, and therefore reduced or non-existent immune response.  One way 
to improve the stability of such plasmids is by repeated passage (Chabalgoity, 1996). The copy 
number of a plasmid; how many copies are expected to be present in each cell, also can have 
an effect on its stability. A fine line must be met between the amount of antigen expressed – 
it must be sufficient for an immune response but also not too much so as to adversely affect 
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the cell, such as with toxic antigens. Using certain promoters can also help to optimise the 
vaccine. Promoters that are inducible rather than constitutively active could help to ensure 
that there is not an excessive amount of a toxic antigen being expressed, and could help direct 
expression only to the compartments where it is necessary. In vivo inducible promoters for 
example, could allow the antigen to only be expressed in response to certain signals, assisting 
with the efficiency of the vaccine. 
 
1.5.1 Expression vector pTECH2  
 
The plasmid pTECH2 (see figure 2.1 in Chapter 2, section 2.1.4) was adapted from the 
pTETnir15 vector and has been successfully used to express heterologous antigens in 
Salmonella (Chatfield et al, 1992; Khan et al, 1994a; Khan et al, 1994b; Chabalgoity et a 1996; 
Lee et al, 2000). A multiple cloning site consisting of; XbaI, BamHI, EcoRV, HindIII and SpeI, 
allows the insertion of a heterologous antigen gene which is expressed under the control of 
the anaerobically inducible promoter nirB, as a fusion to the atoxic C-fragment of tetanus 
toxin (see figure 1.2) To allow for selection of clones containing the correct plasmid, pTECH2 
has an ampicillin resistance gene (AmpR). 
 
 
 
 
 
Figure 1.2 Protein expression from pTECH2. Schematic diagram showing protein expression from the 
pTECH2 expression vector. Under the control of the anaerobically inducible promoter, nirB, the C-
fragment of tetanus toxin is expressed (TetC). A multiple cloning site (MCS) allows the insertion of a 
heterologous antigen which results in the expression of a genetic fusion with the TetC protein, 
separated by a flexible hinge motif. 
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 1.5.1.1 C-fragment of Tetanus toxin (TetC) 
 
The highly immunogenic but non-toxic C-fragment of Tetanus Toxin (TetC) has been shown to 
be easily expressed by Salmonella and can help to modulate the immune response to a fused 
antigen, increasing antibody responses (Lee et al, 2000). Followed by a flexible ‘hinge region’; 
a Gly, Pro, Gly, Pro motif, guest antigens can be cloned into the plasmid and will be expressed 
as a fusion protein to TetC. The TetC assists with solubilising and detoxifying these guest 
antigens and the hinge region allows for temporal and spatial separation between the two. 
The codons used for the Gly and Pro amino acids in the hinge are deliberately sub-optimal for 
expression in Salmonella, and therefore it is hoped that the ribosome is slowed here during 
translation, allowing time for correct folding of TetC.  
 
1.5.1.2 In vivo inducible promoters  
 
In order to maintain in vivo stability of plasmids, an in vivo inducible promoter can be used to 
direct expression of antigens. The nirB promoter, from the NADH-dependent nitrate 
reductase gene, has been shown to be activated during anaerobic growth and is regulated by 
nitrite and changes in oxygen tension. The htrA promoter, dependent on the σE transcription 
initiation factor, has been shown to increase expression of proteins in attenuated Salmonella where 
H2O2 is present, such as in the macrophage intracellular environment (Everest et al, 1995). Rather 
than using chemical induction such as with trp or lac promoters (induced by IPTG) which 
would not be possible in host tissues, in vivo inducible promoters allow protein expression to 
be turned on where it is needed in the host (Jayaraman et al, 1987; Chatfield et al, 1992).  
 
1.5.2 Expression vector pBAD24 
 
The pBAD24 vector (see figure 2.2 chapter 2, section 2.1.4) allows easy protein expression 
under the control of the L-arabinose inducible pBAD (araBAD) promoter (Guzman et al, 1995) 
The polylinker site allows cloning in of the antigen as well as signal sequences to direct 
expression to either the outer membrane or periplasm. An antibiotic resistance gene once 
again allowed for screening.  
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1.5.2.1 Arabinose inducible promoter 
 
The pBAD24 vector allows expression of proteins under the control of the arabinose inducible 
promoter. The pBAD promoter of the arabinose operon (araBAD) is switched on in the 
presence of L-arabinose (Guzman et al, 1995). This can be used to regulate protein expression 
only as needed, especially when the protein is toxic to cells. 
 
1.5.5 Salmonella Typhimurium SL5338 
 
Prior to transformation of an expression plasmid into the attenuated Salmonella vaccine 
strain, plasmids can be initially transformed into the strain SL5338 (galE r – m+).  This strain, 
which is restriction (r) negative and modification (m) positive, ensures that the transformed 
plasmid is protected as it will not be digested by certain restriction enzymes due to 
modification by methylation. 
 
1.6 Codon usage and synthetic biology 
 
The degeneracy of the genetic code means that there are multiple codons (sets of three 
nucleotides) that code for one amino acid.   
1.6.1 Codon bias 
 
It has been shown that different species tend to favour certain codons over others.  Species 
can express proteins encoded by their preferred codons more easily than if less frequently 
used codons are used (Sharp et al, 2005). Codon usage tables are used to determine the 
frequency in which codons are used in different species.  
Based on differences in codon usage in mammalian cells and Salmonella, it was decided that 
using synthetic genes coding for the Ebola Glycoprotein or Zika envelope would be 
advantageous, as they could be codon optimised for expression in Salmonella Typhimurium.  
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1.6.1.1 Codon optimisation parameters 
 
In order to optimise the Ebola GP and Zika E gene sequences, commercial gene synthesis 
facility, Eurofins was used. Using their proprietary software; ‘GENEius’ along with the codon 
usage table for Salmonella Typhimurium, codons were chosen for optimal expression based 
on the following criteria: 
 Very rare codons are avoided. 
 ‘Bad motifs’ for example, unwanted restriction sites, are identified and replaced with 
suitable alternative codons. 
 Direct and inverted repeats are changed to avoid unwanted RNA secondary structures, 
which can hinder DNA synthesis and reduce its stability. 
 GC rich areas are avoided and these nucleotides are distributed as equally as possible. 
These criteria mean that the most frequent codons for a certain species are not always the 
ones that are used in the optimised gene sequence. A balance is made to ensure good 
expression in the chosen species but avoiding certain codons which would have a negative 
effect on this (see footnote1). 
 
 
 
 
 
 
 
 
                                                     
1 Note: for details on GENEius software see: https://www.eurofinsgenomics.eu/en/gene-synthesis-molecular-
biology/geneius/ 
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1.7 Ebola Virus 
 
The Ebola Virus (EBOV) is an especially virulent pathogen and has one of the highest mortality 
rates of known human infectious diseases, causing severe haemorrhagic fever. It is also able 
to cause deadly infections in non-human primates. Part of the Filovirus family, which also 
contains Marburg Virus, EBOV includes individual species, named after the areas where they 
were discovered. In Africa, the known species are; Zaire, Sudan and Cote d’Ivoire (Feldmann 
& Geisbert, 2011). The Reston Ebola Virus was discovered in cynomolgus monkeys in a 
primate facility near Washington D.C, and traced back to the Philippines. While part of this 
group, Reston EBOV is not known to cause human disease.  (Peters & Le Duc, 1999). 
The Zaire Ebola virus was first discovered in 1976 and was named after the Ebola River in Zaire 
in what is now known as the Democratic Republic of Congo (DRC) (Emond et al, 1877; Johnson 
et al, 1977). 
 
1.7.1 Ebola Virus outbreaks 
 
The largest outbreak of Ebola virus ever seen started in West Africa in December 2013 
through to the end of 2015. It is assumed that the index case for this outbreak was a 2 year 
old boy from the small village of Meliandou, Guinea, who contracted the infection via 
zoonotic transmission from a colony of insectivorous bats, living in a hollow tree (Saéz et al, 
2015). This epidemic was particularly notable due to the dramatic symptoms of fatal 
haemorrhagic fever, and the record numbers of deaths from the virus, gaining widespread 
media coverage throughout.  
 
The R0, or basic reproductive number, of a pathogen gives an indication of how quickly an 
epidemic will spread. This is the calculated number of new cases, which an infected person 
will cause in a susceptible population. The higher the R0 value, the faster this will be and an 
R0 value less than 1 indicates that there is no epidemic. Implementation of interventions to 
control transmission of a pathogen can help to reduce the R0 (Delgado & Simon, 2016; 
Woolhouse et al, 2016).  
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When comparing Ebola Virus with the R0 of other viral pathogens, there are certainly those 
that have a higher average R0 value during epidemics. The average R0 for Ebola Virus at the 
height of the recent epidemic was 1.4 in September 2014, falling to 1.0 by that December. 
This is equivalent to the R0 of seasonal influenza but far below those of untreated HIV (R0 = 6) 
or measles (R0 = 17, which is much more easily transmissible) (Kaner & Schaack, 2016). Again, 
the severe symptoms of Ebola haemorrhagic fever compared with these other diseases, 
combined with the threat of no available cure or vaccine, may have been a factor in the 
widespread panic that ensued regarding the disease. In comparison, the H1N1 Swine flu 
pandemic which lead to many more worldwide deaths (approximately 284,000) between 
April 2009 and August 2010, with a similar R0 value of 1.4 – 1.6 (Dawood et al, 2012; Coburn 
et al, 2009; Leung & Nicoll, 2010) had similar media coverage and was also declared a public 
health emergency of international concern (PHEIC), but response to the outbreak was much 
quicker, compared to that of Ebola, where emergent cases were initially misdiagnosed as 
cholera or Lassa fever. An understanding of why delays in responding to outbreaks occur, 
could greatly help to allow much quicker responses in the future (Hoffman & Silverberg, 
2018).  
There is also a marked difference in case fatality rates (CFR) between the H1N1 and Ebola 
Viruses. Depending on the strain, Ebola virus can have a case fatality rate during an outbreak 
of between 25-50%, with some much higher into the range of 80%+. The recent West African 
outbreak, as detailed above was shown to be at about 40%, possibly due to the effectiveness 
of the Ebola Treatment Centres set up in response (De La Vega et al, 2015; Baseler et al, 2017). 
In the 2009 H1N1 pandemic, the CFR was much lower, of just 0.026% (Donaldson et al, 2009). 
Therefore, despite the much higher number of fatal H1N1 cases, the containment of the Ebola 
Virus outbreak was clearly much more effectively contained as it did not reach pandemic 
levels. 
 
A new outbreak of Ebola Virus has been documented as recently as August 2018 in The DRC, 
with over 83 possible cases and 44 deaths already reported (Claude et al, 2018), highlighting 
the constant threat of a recurrence. One positive outcome of the response to the 2013 
outbreak however, was a huge acceleration in vaccine development, and some headway has 
been made in that regard (see section 1.7.5.3). This hopefully means that an outbreak on the 
scale seen between 2013-2015 does not happen again.   
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1.7.2 The Ebola Virus genome 
 
The Ebola virus has a 19kb, linear, negative sense RNA genome which codes for seven genes, 
but allows transcription of eight proteins by way of transcriptional editing (see figure 1.4). 
These proteins are: 
Nucleoprotein (NP), Viral protein 35 (VP35), VP40, Glycoprotein (GP), secreted Glycoprotein 
(sGP), VP30, VP24 and Large protein (L).  
Proteins NP, VP30, VP35 and L are associated with the viral RNA in a ribonucleoprotein 
complex, with the L protein acting as an RNA polymerase.  
The virus’s structural proteins are GP, which appears on the virus surface, and VP24 and VP40, 
which are presumed to be located on the inner side of the viral membrane (Feldmann et al, 
1993) (see figure 1.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Known structures and location of Ebola Virus proteins. Diagram to display a cross section 
of the Ebola Virus showing the known structures and locations of viral proteins (green or blue) RNA 
(yellow), and viral membrane (purple). The Glycoprotein (GP) is shown as trimeric spikes decorating 
the membrane and is a key target for neutralising antibodies (Goodsell, 2014). 
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At both the 3’ and 5’ ends of the Ebola virus genome, there are also long non-coding ‘leader’ 
and ‘trailer’ regions of RNA (see figure 1.4). These regions have complementarity to each 
other and may form a ‘pan handle’ RNA structure. It is thought that this may be to act as a 
promoter as RNA secondary structure has been known in other virus species (Enterlein et al, 
2009). 
 
Figure 1.4. Map of Ebola virus genome. Schematic diagram of the Ebola virus negative sense genome 
showing each of its eight proteins; NP, VP35, VP40, GP (and sGP) VP30, VP24 and L. Transcriptional 
editing results in expression of two different Glycoproteins, sGP and GP1,2. The non-edited gene 
results in sGP and the addition of an extra adenosine at the editing site (dotted line) results in the 
fusion of the sGP and GP reading frames and the full-length GP is transcribed. Two long non-coding 
regions are situated at the 3’ and 5’ ends of the genome. (Adapted from Messaoudi et al, 2015). 
 
1.7.3 Pathogenesis of Ebola Virus 
 
Transmission of Ebola Virus between humans can occur either by the virus somehow entering 
the bloodstream (potentially inadvertently by injection or through wounds), or contact of the 
mucous membranes with infectious body fluids from an infected patient. It appears that the 
risk of infection is increased significantly with direct contact with infectious material (Baseler 
et al, 2017).  
The recent outbreak in West Africa, included many local outbreaks in the area. In mid-2014 
an outbreak commenced in Sierra Leone’s Pujehun district which was finally declared Ebola 
free in early 2015. In this outbreak, it was noted that the majority of transmission events were 
between family members (Ajelli et al, 2015). Overall, it appears that directly caring for 
infected persons or contact with the body of a person who has died from Ebola Virus disease, 
due to traditional funeral practices, led to the widespread person to person transmission of 
the virus (Baseler et al, 2017).  
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In the infection of humans and non-human primates, the virus targets immune cells including 
dendritic cells, monocytes and macrophages. Before the onset of symptoms, these infected 
cells then travel to the lymph nodes where the virus replicates and is disseminated 
throughout the body, (Geisbert et al, 2003). The viral load increases exponentially in the early 
stages of infection and is able to overpower the innate immune system, leading to widespread 
dissemination of the virus in the bloodstream (Lanini et al, 2015). 
 
1.7.4 Immune responses to Ebola Virus infection 
 
It has been shown that patients who have recovered from Ebola Virus infection are able to 
produce antibodies to the Glycoprotein, some of which have been shown to be protective 
(Takada et al, 1997). During infection with Ebola Virus, there is an increase in the level of pro-
inflammatory cytokines. Some of these, such as TNF-α have been shown to increase the 
permeability of human epithelial cells in vitro when released from EBOV infected monocytes 
or macrophages (Takada et al, 1997). These particular cells appear to be a target for the virus 
and the resultant over-production of these cytokines can lead to damage of the vascular 
system and result in leakage and haemorrhage (Feldmann et al, 1993). It seems apparent that 
patients who have an earlier, more controlled and balanced immune response to EBOV 
infections are generally given a better prognosis (Feldmann et al, 1993). 
 
1.7.5 Treatment and current progress in Ebola vaccine development 
 
After the scope of the most recent Ebola outbreak was realised, efforts were made to develop 
a safe and effective treatment for the many victims who contracted the infection, in an 
attempt to curb the spread of the virus. New efforts to develop an effective vaccine were also 
prompted so as to prevent such deadly epidemics in the future. 
 
 
26 
 
1.7.5.1 Small molecule drugs 
 
Some existing small molecule drugs, such as brincidofovir and favipiravir, usually used to treat 
cytomegalovirus and influenza respectively, have been re-licenced for use in patients with 
Ebola Virus (Mendoza et al, 2016). They have been shown to have anti-Ebola Virus effects in 
vitro and favipiravir has been shown to treat Ebola Virus symptoms in immune deficient mice 
(Smither et al, 2014). It could potentially be used in patients in the early stages of Ebola Virus 
Disease (EVD) with lower viral loads (Liu et al 2017). This could be a useful drug discovery 
avenue to take, however more clinical trials in humans are necessary to fully determine the 
usefulness of small molecule drugs in treating EVD. 
 
1.7.5.2 Antibody cocktails 
 
During the recent outbreak in West Africa, it was deemed appropriate to issue antibody 
cocktails against Ebola Glycoprotein in emergency compassionate treatment to people 
infected with the virus. These were shown to be effective in the protection and treatment of 
Ebola Virus disease when tested in non-human primates (Muhlberger, 2007). The antibodies 
to Ebola glycoprotein that comprise this cocktail, dubbed ZMapp, were selected from 
previous monoclonal antibody cocktails, MB-003 and ZMAb (Qiu et al, 2014). ZMapp has been 
used to treat patients with Ebola Virus disease, notably two Americans who had contacted 
Ebola (Lyon et al, 2014). Again, more human clinical trials are needed to gain a better 
understanding of the efficacy and uses of such biological treatments. 
 
1.7.5.3 Vaccines 
 
There are currently no licenced vaccines against Ebola Virus, making development of a 
successful vaccine all the more pertinent. There have however, been numerous efforts to 
produce such a drug, including some projects that have reached clinical trial stages. Most 
particularly, ChAd3-ZEBOV (GSK) and VSV-EBOV (NIAID). VSV-EBOV is a live replicating viral 
vaccine, the likes of which have been shown to provoke both cellular and humoral immune 
responses against pathogenic viruses.  Using the Vesicular Stomatitis Virus (VSV) to express 
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Ebola Virus glycoprotein, the vaccine has been shown to be effective in protecting against 
Ebola Virus challenge in non-human primates and has shown to be immunogenic in phase 1 
clinical trials (Agnandji et al 2016). 
 ChAd3-ZEBOV, uses the chimpanzee adenovirus type 3 to express Ebola glycoprotein, but is 
replication deficient. In a human clinical trial, antibody titres to Ebola Glycoprotein were seen 
comparable to the VSV-EBOV vaccine (Ewer et al, 2016b).  
Even more recently the VSV vaccine V920, expressing the Zaire Ebola Glycoprotein in lieu of 
the VSV glycoprotein, has been shown to be 100% effective in phase 3 trials and could be used 
imminently in the DRC, were a new outbreak has unfortunately been seen. It is hoped that 
the availability of this vaccine, which has been approved for use in a ring vaccination 
approach, in this new outbreak will be a great advantage and help to curb the spread before 
an epidemic on the scale of the one seen in 2013 occurs (Coller et al, 2017; Dyer et al, 2018; 
Claude et al, 2018). 
It is clear that it is possible to produce an immune response to the Glycoprotein of Ebola Virus. 
This is encouraging and allows more exploration into different expression systems and 
administration methods, which could be used, allowing for even more effective vaccines. 
 
1.7.6 Ebola Glycoprotein (GP) as a prime vaccine candidate 
 
The Ebola Virus glycoprotein enables the Virus to facilitate fusion to host cell membranes 
(Takada et al, 1997), attach to, and enter host cells (Lee & Saphire, 2009). In order for this to 
occur, the Glycoprotein must bind to the Niemann-Pick C1 (NPC1) receptor, an endosomal 
membrane protein important in trafficking cholesterol (Wang et al, 2006). Posttranslational 
cleavage of the GP protein results in two subunits. GP subunit 1 (GP1) binds to this receptor, 
and GP subunit 2 (GP2) is considered the fusion subunit allowing host cell and viral 
membranes to connect (Takada et al, 1997). On the Virus surface, the glycoprotein is arranged 
in a trimer with a chalice shaped appearance. GP1 subunits form the bowl structure, and GP2 
subunits the sides. Certain lysine residues near the centre of this bowl are believed to be 
important in attachment to host cell membranes (Lee & Saphire, 2009). Transcriptional 
editing of the Ebola Virus glycoprotein (GP) gene results in expression of different GP proteins. 
Secreted GP (sGP) is the most common product of non-edited translation of the GP gene, 
accounting for around 80% of GP translation (Feldmann et al, 2001; Tran et al, 2014). As its’ 
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name would suggest, sGP is secreted from EBOV infected cells (Muhlberger, 2007).  sGP 
shares the first 295 residues with the full-length GP, this is thought to act as a decoy as it 
competes with GP attached to the Virus for antibody binding (Cook & Lee, 2013).  At the 
editing site, a sequence of seven uridines, the addition of an extra adenosine residue by L 
protein (the viral polymerase) (Volchkova et al, 2011) results in a frame shift which fuses the 
two sGP and GP overlapping open reading frames together, leading to the continuation of 
translation of the full-length GP1,2 (De la Vega et al, 2015; Feldmann et al, 1993). 
  
While all viral components contribute to its pathogenesis, the type 1 membrane protein 
Glycoprotein (GP) is considered the most important. The singular surface protein of the Ebola 
Virus, it is currently the only known target for protective antibodies. GP is responsible for 
binding of the Virus and its entry into host cells (Lee & Saphire, 2009; Messaoudi et al, 2015) 
and acts as a catalyst to allow the Virus to attach to host cells (Lee & Saphire, 2009). It has 
been shown that GP from the Zaire Ebola strain will cause damage to endothelial cells in both 
human and non-human primate vessel models (Lee & Saphire, 2009). The ability to produce 
neutralising and protective antibodies towards this protein would allow protection against 
Ebola Virus and its haemorrhagic fever. Heavy N- and O- linked glycosylation on the surface 
of GP (see figure 1.5)  acts to deter the interaction of antibodies to vital regions such as the 
receptor binding site, however some neutralising antibodies are able to bind to a non-
glycosylated region near the base of the protein (Cook & Lee, 2013), meaning that 
glycosylation is not vital for the production of neutralising antibodies. 
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Figure 1.5. The domain organisation of the Ebola Glycoprotein. The furin cleavage site cleaves GP at 
residue 501 into the GP1 and GP2 subunits. The size (295 residues) and location of secreted GP (sGP) 
is also shown. Disulphide bonds are shown (S-S) to denote folding of the full protein. IFL – Internal 
Fusion Loop, HR 1/2 – Heptad Repeat 1 or 2, TM – Transmembrane domain which is followed by the 
cytoplasmic tail shown in grey. The Y symbol denotes N-linked glycosylation sites and the oval symbol 
O-linked glycosylation sites. sGP shares the first 295 aa of the full-length protein which is then 
transcribed after the addition of an extra adenosine residue. sGP is thought to act as a decoy for 
antibodies, while the heavy glycosylation at sites such as the mucin like domain is thought to shield 
epitopes from neutralising antibodies.  Adapted from Lee et al, 2008; Cook & Lee, 2013. 
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1.8 Zika Virus 
 
Zika virus is a Flavivirus, part of the Flaviviridae family, which also includes Dengue Virus, 
Yellow Fever and West Nile Virus. It was first isolated from a sentinel Rhesus macaque in the 
Zika forest of Uganda in 1947 (Dick et al, 1952). Thought to be a somewhat benign infection 
until an outbreak in the Federated States of Micronesia, on the Islands of Yap, and French 
Polynesia in 2007 and 2013 respectively, it then became much more well known. (Depoux et 
al, 2018; Musso & Gubler, 2016). The end of 2015 saw the rapid spread of Zika Virus 
throughout the Americas and along with it, connected incidences of foetal microcephaly 
(where a baby’s head size is much smaller than normal) and Guillain-Barré syndrome. This 
brought Zika to the attention of the World Health Organisation (WHO), who concerned by its 
spread and these severe symptoms, declared it an international public health emergency in 
2016 (Chitti et al, 2016; Tang et al, 2016). Phylogenetic analysis of different Zika Virus isolates 
has shown that there are two main lineages; African and Asian (Haddow et al, 2012).  
1.8.1 Zika Virus outbreaks  
 
Zika Virus is an arbovirus, meaning it is transmitted by arthropods, such as mosquitoes.   
After it was first discovered, the first human case of Zika Virus was detected in the early 1950s 
in Nigeria. Since then, in Africa and South-East Asia, there have been a relatively small number 
of reported cases, before the outbreak in Yap, which affected almost 75% (5000 people) of its 
population. An epidemic in French Polynesia then followed which infected around 270,000 
people in the space of approximately 6 months. In 2015, the virus was first suspected in Brazil, 
and was shown to be most closely related phylogenetically to the Asian strain from French 
Polynesia, possibly spread to Brazil from international sporting events held in Pacific countries 
around the time it was circulating there (late 2013-2014). By the end of 2017, 580,000 
suspected and 221,000 confirmed cases of Zika Virus infection were reported in South and 
Central America and the Caribbean (Depoux et al, 2018).  
The vectors of Zika Virus are dependent on the location. In The Americas, Pacific countries 
and South-East Asia, the mosquito Aedes aegypti is the most common vector, while in Africa 
it is Aedes africanus. The high competency of these vectors to disseminate the virus, means 
that it continues to spread in these areas. It has also now been shown that the virus can be 
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transmitted from person to person, such as through sexual intercourse or from mother to 
foetus (Vorou, 2016; Depoux, 2018).  
 
1.8.2 The Zika Virus genome 
 
The Zika Virus has an approximately 11Kb positive strand RNA genome which codes for a 
single polyprotein, translated in the cytoplasm of infected cells. This is then proteolytically 
cleaved by both viral and host proteases to result in 10 proteins. Three of these are structural, 
forming the virus particle; Capsid (C), Precursor-Membrane (prM) and envelope (E), and seven 
are non-structural; NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5. The non-structural proteins 
have functions related to polyprotein processing and viral genome replication and synthesis 
(Shi & Gao, 2017) (see figures 1.6 and 1.7). 
 
 
Figure 1.6. Zika Virus genome organisation. Schematic diagram showing the; Polyprotein (A) and 
processed proteins (B). A large polyprotein (A) is translated in the cytoplasm of infected cells and then 
cleaved by both host and viral (NS3) proteases to result in 10 proteins (B) (Adapted from Shi & Gao, 
2017). 
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Figure 1.7. Locations of Zika Virus proteins. Schematic diagram of the locations of main structural Zika 
Virus proteins as a cross section. The Zika Virus has an icosahedral shape and the outside of the virus 
contains 180 copies of each of the envelope and M (Membrane) proteins (Shi & Gao, 2017).  
 
1.8.3 Pathogenesis of Zika Virus 
 
During a bite from an infected female mosquito (usually the Aedes genus), which has acquired 
Zika Virus through a viremic blood meal, the saliva of the mosquito, (containing the virus) is 
injected into the host (Musso & Gubler, 2016). 
There is currently little that is known about the pathogenesis of Zika virus. It is thought that 
the virus replicates in nearby dendritic cells and can then spread to the lymph nodes and 
bloodstream. The majority of infected individuals are asymptomatic, however in those that 
do show symptoms, the virus is detectable in blood 3-4 days after their onset. In symptomatic 
patients, there is usually a mild fever, and reported rash, headache, conjunctivitis and joint 
and muscle pain (Krause et al, 2017).  
The Zika Virus targets the interferon (IFN) anti-viral response. Usually, stimulation of 
interferon receptor subunits IFNAR1 and IFNAR2 by IFN activates the Janus kinases Jak1 and 
Tyk2 (Tyrosine kinase 2) by autophosphorylation. This then allows the phosphorylation of 
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STAT1 and STAT2 (Signal Transducer and Activator of Transcription) which form a 
heterodimer, which is able to bind IFN regulatory factor 9 (IRF9). This forms the heterotrimer; 
IFN-stimulated gene factor 3 (ISGF3) which translocates to the nucleus and acts as a 
transcription factor for hundreds of IFN stimulated genes (ISGs) which have antiviral 
properties (Fleming, 2016). All human flaviviruses that have so far been tested, have shown 
that the NS5 protein specifically antagonises IFN signalling. Depending on the flavivirus, the 
mechanism by which this occurs can be different. Zika Virus NS5 binds to human STAT2, 
resulting in its proteasomal degradation and thus inhibiting the Jak/STAT pathway described 
above. Interestingly, Zika NS5 does not bind with mouse STAT2, meaning that IFNAR knockout 
mice strains are needed to use as an animal model of Zika infection (Grant et al, 2016). 
 
1.8.3.1 Microcephaly and Guillain-Barré syndrome 
 
The recent outbreak of Zika virus, beginning in Brazil in 2015, has caused alarm due to the 
reported increase (of 20 times compared to previous years) of microcephaly cases, in babies 
born at this time (Wang et al, 2016). Foetal abnormalities including not only microcephaly, 
but also central nervous system issues, restricted growth and even death, were seen using 
ultrasound analysis, in 29% of a cohort of pregnant and Zika infected women, suggesting that 
infection during pregnancy may lead to adverse outcomes for the foetus (Brasil et al, 2016). 
Zika Virus has been shown to target human cortical neural progenitor cells (hNPCs), also found 
in the developing embryo brain, and this can cause apoptosis and dysregulation of the cell 
cycle, leading to attenuation of hNPC growth and proliferation. This tropism for neural 
progenitor cells, could in part explain a potential mechanism for microcephaly (Tang et al, 
2016; Miner & Diamond, 2018). Zika virus has been shown to be present in the amniotic fluid 
of pregnant women with microcephalic foetuses, suggesting it can cross the placental barrier, 
strengthening the link between microcephaly and Zika Virus infection of pregnant women 
(Calvet et al, 2016). 
In adults, Zika Virus infection has been linked with Guillain-Barré Syndrome (GBS) of which 
symptoms include paralysis and neuropathy. This may be due to potential autoimmune 
reactions as it has been shown that there is a large overlap between peptides of the Zika 
Polyprotein and human proteins linked to myelination, demyelination and axonal neuropathy 
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(Miner & Diamond, 2018; Lucehsse & Kanduc, 2016). Another possible mechanism could also 
be the fact that Zika Virus has been shown to be particularly detrimental to myelinating 
oligodendrocytes through infection, leading to a disruption in the myelin sheath and thus 
could contribute to the GBS symptoms (Cumberworth et al, 2017). 
 
1.8.4 Immune responses to Zika Virus infection 
 
Infection with Zika Virus triggers both the innate and cellular immune responses. Innate 
responses have been shown to involve production and signalling of type 1 interferons as 
described above (section 1.8.3). The cellular immune response to Zika virus has been shown 
in mice, NHPs and humans, to include CD8+ and CD4+ T cells. Strong CD8+ T cell responses 
have been seen in Zika infected mice, along with the development of memory T cells. These 
recognise epitopes on the structural proteins prM, E and C. 
It has also been reported that in the central nervous system (CNS) there is a Zika virus specific 
CD8+ T cell response after infection of the neurons, even though this is an immune privileged 
site. While this may help to control the virus, the influx of CD8+ T cells to the CNS may 
contribute to the incidence of GBS due to the cytotoxic killing of virus infected neurons 
(Richner & Diamond, 2018; Huang et al, 2017). 
Protection against Zika Virus comes from the generation of potent neutralising antibodies, 
mainly against certain epitopes on the envelope protein (E) (Stettler et al, 2016; Sapparapu 
et al, 2016). It is however important to consider the phenomenon of antibody dependent 
enhancement of infection (ADE), which has been shown due to the antigenic cross reactivity 
of flaviviruses. In brief, phagocytes with Fc receptors (FcR) are able to clear pathogens coated 
with neutralising antibodies. Flaviviruses, in particular Dengue Virus, which this phenomenon 
has been mostly studied, can cause ADE during a subsequent infection with a similar but 
different strain or serotype. Antibodies produced in response to the first infection 
(particularly to pRM and E proteins) can bind to the second strain but are unable to act in a 
neutralising capacity. This means that FcR cells uptake the virus coated with the antibody but 
the virus can persist and replicate inside, rather than be cleared. The disease can then 
exacerbate and lead to the activation of cross reactive memory T cells and a subsequent 
cytokine storm, known as Dengue haemorrhagic fever or Dengue shock syndrome. It remains 
to be seen whether ADE is a problem in Zika Virus infections (particularly if a patient has been 
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previously infected with Dengue Virus) but it must be kept in mind in vaccine development, 
as there is a risk that disease could be exacerbated by a previous sub-optimal immune 
response (Richner & Diamond, 2018; Martin-Ascebes et al, 2018; Settler et al, 2016) 
 
1.8.5 Prevention and current progress in Zika vaccine development 
 
There is currently no commercially available prophylactic vaccines or treatment for Zika Virus, 
people in areas affected have been advised to use mosquito repellent and nets to avoid being 
bitten and pregnant women should aim to avoid Zika affected areas (Rather, 2017).  
It has been noted however, that incredible progress has been seen in the development of a 
Zika vaccine since it was declared a major worldwide public health emergency in 2016, and a 
number of vaccines have reached clinical evaluation stages. For example, two DNA vaccines 
expressing the structural Zika prM and envelope proteins, were safe, well tolerated and 
elicited antibody responses allowing advancement to phase II clinical trials (Gaudinski et al, 
2018). Other vaccine candidates have also been clinically tested, including those using 
inactivated Zika Virus, modified RNA candidates, and also a vaccine using a live measles vector 
(Barrett, 2018). This is encouraging as it will hopefully bring a safe and effective vaccine to 
market sooner rather than later. 
 
1.8.6 Zika envelope protein (ZE) as a prime vaccine candidate 
 
The Zika envelope protein (ZE) is the major virus surface protein and the main target for 
neutralising antibodies. It is a class-II fusion protein, responsible for attachment and entry 
into host cells and closely resembles the E protein of other flaviviruses (Settler et al, 2016; 
Zhang et al, 2017; Dai et al, 2016).  
On the viral membrane, 90 anti-parallel homodimers of the E protein form a “raft-like 
structure”, enveloping the virus (see figure 1.7) . Each monomer has three domains; I, II, and 
III which are connected by flexible hinges. A helical transmembrane domain connects each 
monomer to the viral membrane. (Zhang et al, 2016; Shi et al, 2018). 
It appears that some of the most potent monoclonal neutralising antibodies are directed to 
domain III (see figure 1.8) of the flavivirus envelope protein, particularly in the lateral ridge 
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region (Zhao et al, 2016). Other protective antibodies targeting the highly conserved 
hydrophobic fusion loop, situated at the tip of domain II, have also been discovered and while 
are less potent, do appear to be significantly present in the humoral immune response to 
flavivirus infection (Dai et al, 2016; Dejnirattisai et al, 2015). Furthermore, a unique 
quaternary epitope found on the dimer-dimer interface has been shown to elicit a potent 
broadly neutralising antibody (ZIKV-117) which was able to protect against vertical 
transmission of Zika Virus from mother to foetus (Sapparapu et al, 2016). An epitope for the 
broadly neutralising antibody 2A10G6 (also able to neutralise other flaviviruses), has also 
been found between residues 98 and 101 in the fusion loop area of the envelope protein (Dai 
et al, 2016) (see figure 1.8). There is clearly much evidence that many epitopes on the Zika 
envelope protein can elicit both cellular and humoral immunity, therefore suggesting that ZE 
is an attractive target for use in a vaccine.  
 
 
 
 
Figure 1.8. The domain organisation of the Zika envelope protein. Schematic diagram of domains I, 
II and III, including approximate locations for some known protective epitopes. Adapted from Dai et 
al, 2016 (Sapparapu et al, 2016; Zhao et al, 2016). 
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1.9 Outer Membrane vesicles (OMVs) as a novel vaccine platform 
 
Outer membrane vesicles (OMVs) are naturally occurring products secreted by Gram-
negative bacteria. Formed by the blebbing of the outer membrane into small spherical 
packages, they contain periplasmic contents, including bacterial virulence factors, and nucleic 
acids, and outer membrane components, including antigens such as lipopolysaccharide (LPS) 
and proteins (Ellis & Kuehn, 2010). OMVs have many functions, from interbacterial 
communication, facilitating host-bacteria interactions, delivery of virulence factors and toxins 
to host cells, procurement of nutrients, biofilm formation and modulation of the immune 
response (Ellis & Kuehn, 2010; Jan, 2017).  
1.9.1 Biogenesis of OMVs 
 
All Gram-negative bacteria have been shown to produce outer membrane vesicles 
(Schwechheimer & Kuehn, 2015). The biogenesis of OMVs likely involves the weakening of 
the cross linkage and thus creating space between the outer membrane and peptidoglycan 
wall. The membrane bulges and the curvature eventually results in the fission of the 
membrane, creating the vesicle which contains periplasmic and outer membrane 
components (Kulp & Kuhen, 2010) (see figure 1.9). This curvature could be triggered by 
certain stressors such as antibiotics, which can result in an accumulation of misfolded protein 
waste in the periplasm, and thus OMV production may be primarily a stress response 
(Schwechheimer et al, 2013; Jan, 2017). OMV production may also be a part of cell wall 
synthesis, to release turgor pressure due to an increase in peptidoglycan production. An 
increase of certain molecules including LPS and phospholipids in the outer membrane, also 
results in changes in the curvature of the outer membrane and can increase OMV production. 
It has also been shown for example in Pseudomonas aeruginosa, that a quorum sensing 
molecule, PQS, when inserted into the outer membrane acts to induce increased membrane 
curvature (Jan, 2017). 
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Figure 1.9. Biogenesis of Outer membrane vesicles (OMVs) in Gram-negative bacteria. The linkage 
between the outer membrane and peptidoglycan wall is reduced and the membrane bulges, resulting 
in the fission of a vesicle containing both outer membrane and periplasmic contents (Jan, 2017). 
 
1.9.2 OMVs as immunogenic vehicles 
 
OMVs are already a natural delivery system (Kulp & Kuehn, 2010) and have been shown to 
activate the host immune system due to the fact that they contain immunostimulatory 
molecules from the outer membrane, such as the aforementioned LPS and lipoproteins, thus 
stimulating host Toll-like receptors (TLRs). They have been shown to activate macrophages 
and stimulate dendritic cells to mature and produce cytokines such as TNF-α and IL-12. OMVs 
therefore, have been considered for use as vaccines (Alaniez et al, 2017; Rossi et al, 2016; Ellis 
& Kuehn, 2010). A vaccine against group B meningococcus, using purified OMVs from a 
Neisseria meningitidis lpxL1 mutant, with detoxified lipooligosaccharide, has already been 
shown to be safe and immunogenic in human trials (Keiser et al, 2011). 
OMVs are usually present in low quantities, so efforts have been made to genetically modify 
bacteria to increase the propensity of the cells to produce these vesicles for vaccine purposes. 
For example, in Salmonella, the deletion of the tolR gene does just this, as it disrupts the 
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linkage of the inner and outer bacterial membranes. The resulting ‘Generalised Modules for 
Membrane Antigens’, or GMMAs, could be a viable vaccine candidate with the added 
advantage of being cost effective to produce (Rossi et al, 2016; Meloni et al, 2015).  A very 
recent study comparing the immunogenicity of Salmonella GMMAs with a glycoconjugate 
vaccine for Salmonella O-antigen (a component of LPS and known target of protective 
immunity) in mice, showed that the GMMAs were able to elicit a similar if not better immune 
response to O-antigen. This highlights the fact that the approach of using OMVs as vaccines 
is certainly very promising (Micoli et al, 2018). The bacterial strains could be engineered to 
allow expression of heterologous antigens with subsequent incorporation in the OMVs, 
allowing antigen cargo to be delivered to the host immune system (Gerritzen et al 2017). This 
would also be a non-living vaccine platform which would mean that unlike the living 
attenuated Salmonella, it may be possible to use in certain vulnerable patient groups where 
living vaccine strains could prove harmful, such as the very old, very young or 
immunocompromised. 
1.9.3 Incorporating heterologous antigens into OMVs 
 
One way to include heterologous antigens as cargo in purified OMVs could be to exploit 
protein expression mechanisms of the bacteria. Engineering expression plasmids which target 
heterologous protein antigen expression to specific cellular locations, such as the periplasm 
or outer membrane, would hopefully allow these antigens to be incorporated in the OMVs 
during biosynthesis. 
 
1.9.3.1 Signal sequences for periplasmic expression of antigens 
 
As OMVs contain bacterial proteins commonly found in the periplasm, it could be possible 
that guest antigens, such as the Zika envelope protein, can be engineered to be expressed 
and transported here and therefore contained within the OMVs when they bleb off. The 
OMVs would then be purified for potential use as an alternative delivery system than the 
living attenuated Salmonella. 
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 1.9.3.1.1 The DsbA Signal sequence 
 
It has been shown that cytoplasmically expressed bacterial proteins can be exported to the 
periplasm by the incorporation of the signal sequence of DsbA (Disulphide bond formation 
protein A), a bacterial thiol disulphide oxidoreductase. This directs the fused protein partner 
to the SRP pathway (Schierele et al, 2003). 
 
1.9.3.2 Signal sequences for outer membrane expression of antigens 
 
As the OMVs incorporate proteins situated on the bacterial outer membrane, it would be 
sensible to suggest that directing antigen expression there, would result in it being included 
when the OMVs bleb off.  
 
 1.9.3.2.1 The OmpA signal sequence  
 
The OmpA protein (Outer membrane protein A) is a major Gram-negative outer membrane 
protein. It has been shown that by fusing an antigen to the OmpA leader sequence, it is 
possible to direct their expression to the bacterial outer membrane and also include them in 
OMVs (Ruppert et al, 1994; Fantappie et al, 2014).  
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1.10 Overall aims and scope of this thesis 
 
This thesis aims to test Salmonella vaccine delivery platforms for developing effective 
vaccines against Ebola and Zika viruses.  
A panel of variant constructs expressing the Ebola Glycoprotein, Zika envelope protein and 
sub-fragments thereof, will be designed and evaluated for antigen expression and plasmid 
stability. 
The best Salmonella vaccine constructs, those which are able to express antigen at levels 
expected to be immunogenic, and which have been shown to be segregationally and 
genetically stable both in vitro and in vivo, will be used to immunise mice. The immune 
responses to these antigens will then be evaluated to assess the potential of this platform to 
develop effective vaccines to either Ebola aor Zika viruses. 
An alternative non-living vaccine towards Zika virus will also be constructed. This will involve 
creating genetically modified Salmonella strains with a higher propensity to make 
immunogenic Outer Membrane Vesicles (OMVs). We aim to see if it is possible to direct the 
expression of the Zika envelope protein to these vesicles, which can then be purified, and 
hopefully used as a non-living vaccine. 
It is hoped these prototype vaccines will elicit protective immune responses in mice and can 
therefore be a ‘proof of concept’ of a potentially cheap method by which to protect against 
such devastating viruses. 
 
 
 
 
 
 
 
42 
 
Chapter 2 – Materials and methods 
 
2.1 Materials 
 
All materials used in this study are documented below. 
2.1.1 Chemicals 
 
General laboratory chemicals and antibiotics were purchased from Sigma-Aldrich® (Dorset, 
UK) or Thermo Fisher Scientific (Loughborough, UK).  Ingredients for bacterial growth media 
were purchased from BD (Oxford, UK). 
 
2.1.2 Kits and Reagents 
 
The Qiagen mini-prep kit, Qiagen PCR purification kit and Qiagen Gel extraction kit used to 
prepare DNA for cloning were purchased form Qiagen (Manchester, UK). 
T4 DNA ligase, Quick-Load® 1 kb DNA Ladder, Restriction endonuclease enzymes and 
Phusion® High-Fidelity DNA polymerase PCR kit were purchased from New England Biolabs 
(NEB UK, Herts, UK).  EmeraldAmp® GT PCR Master Mix was purchased from Clontech (Takara 
Bio Europe SAS, Saint-Germain-en-Laye, France).  
Gel Red TM (Biotium, Fremont, CA, USA) was used to detect DNA under UV light in agarose 
gels.  
GeneRuler™1kb DNA Ladder and PageRuler™ Prestained Protein Ladder molecular weight 
markers were purchased from Thermo Fisher Scientific (Loughborough, UK).  
Q5 Site Directed Mutagenesis kit was purchased from New England Biolabs (NEB UK, Herts, 
UK).   
In-Fusion® HD cloning kit, used for ligation independent cloning was purchased from Clontech 
(Takara Bio Europe SAS, Saint-Germain-en-Laye, France). 
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2.1.3 Antibodies and recombinant proteins 
 
Monoclonal antibodies 
Antibody Source 
Mouse monoclonal anti-Ebola GP – 5E6 Professor Gary Kobinger, Public Health Agency of Canada 
Mouse monoclonal anti-Ebola GP – 7G4 Professor Gary Kobinger, Public Health Agency of Canada 
Mouse monoclonal anti-Ebola GP – 1H3 Professor Gary Kobinger, Public Health Agency of Canada 
Mouse monoclonal anti-Ebola GP – 4G7 Professor Gary Kobinger, Public Health Agency of Canada 
Mouse monoclonal anti Zika E Aalto-Bioreagents (Dublin, Ireland) 
 
Table 2.1. Details and sources of monoclonal antibodies used in this study. 
 
Polyclonal antisera and secondary antibodies 
Antibody Source 
Mouse anti-EBOV 
Serum from C57BL/6 mouse surviving Ebola 
challenge after treatment with mAb 5E6 
Professor Gary Kobinger, Public Health 
Agency of Canada 
Rabbit anti-Tet C Polyclonal sera Professor Neil Fairweather, Imperial 
College London, UK 
Rabbit anti-Zika envelope – R34 
Serum from rabbit immunised with a peptide 
corresponding to residues 147-166 of Zika envelope 
(HGSQHSGMIVNDTGHETDENRAK) 
Professor Alain Kohl, Glasgow University 
Rabbit anti-Mouse HRPO Abcam (Cambridge, UK) 
Goat anti-Rabbit HRPO Abcam (Cambridge, UK) 
 
Table 2.2. Details and sources of polyclonal anti-sera and secondary antibodies used in this study. 
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Recombinant proteins 
 
 
Table 2.3. Sources of recombinant proteins used in this study. 
 
2.1.4 Plasmids 
 
Plasmid Genotype 
pTECH2 Used to express Ebola and Zika virus antigens fused to Tet C, under control of nirB 
promoter, AmpR, TetC. 
pBAD24 Arabinose-inducible expression vector. PBAD promoter, Amp r. 
pKD46 Red helper plasmid. Derivative of pINT-ts, araC-ParaB and γ β exo, tL3 terminator 
downstream of exo. λ Red Recombinase gene, AmpR. Sensitive to temperature above 
30°C. 
pKD4 Derivative of pANTSγ with Kanamycin resistance (KanR) gene flanked by FLP 
recognition target (FRT) sites, AmpR 
pCP20 FLP+, λ cI857+, λ PR Repts, AmpR, CmR. Sensitive to temperature above 30°C. 
 
Table 2.4. Details of plasmids used in this study. 
 
 
 
 
Protein Strain Source 
Ebola 
Glycoprotein 
Zaire Ebolavirus (strain Mayinga-76)  Professor Katie Ewer, Oxford University, UK 
(Ewer et al, 2016a) 
(Via Yper Hall, Public Health England) 
Zika envelope  Derived from unspecified African 
strain, however all strains share high 
identity in this region. 
Fitzgerald (Acton, MA, USA) 
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Figure 2.1.  Plasmid map of the pTECH2 expression vector. Under the control of the nirB promoter, 
the atoxic C-fragment of Tetanus toxin TetC is expressed. A short Gly Pro Gly Pro hinge motif allows 
temporal and spatial separation between TetC and a guest antigen which can be cloned in at the 
polylinker site with a choice of five restriction enzyme sites. An ampicillin resistance gene allows for 
selection of colonies harbouring the plasmid. Plasmid map was made using the commercial software 
Snapgene. 
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Figure 2.2.  Plasmid map of the pBAD24 expression vector. Under the control of the pBAD (araBAD) 
promoter, in the presence of L-arabinose, the protein whose gene is cloned in the polylinker site can 
be expressed. An ampicillin resistance gene allows for selection of colonies harboring the plasmid and 
the vector also includes the pBR322 origin of replication. Plasmid map was made using the commercial 
software Snapgene. 
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2.1.5 Bacterial growth media 
 
LB-Lennox broth 
5g Tryptone, 2.5g Yeast extract, 5g NaCl, made up to 500ml with dH20. 
 
LB-Lennox Agar media 
5g Tryptone, 2.5g Yeast extract, 5g NaCl, 7.5g Agar, made up to 500ml with dH20. 
 
EBU plates  
LB-lennox agar (see above) plus 1.25g glucose, then when molten agar cooled to 55°C - 20ml 
12.5% K2HPO4, 625µl 1% Evans Blue, 125µl 10% Sodium fluorescein (Uranine). 
 
2.1.6 Buffers and Stock solutions 
 
Antibiotic stock solutions 
Ampicillin (1000x) - 50mg ampicillin sodium salt dissolved per 1 ml dH20. 
Working concentration: 50 µg/ml. 
 
Kanamycin (1000x) - 50 mg kanamycin sulphate salt dissolved per 1 ml dH20.  
Working concentration: 50 µg/ml. 
 
Chloro-naphthol (Western blot developer) 
30mg 4-chloro-1-naphthol, 10ml methanol, 40ml PBS, 30µl hydrogen peroxide (30% w/w). 
Freshly prepared using cold ingredients immediately prior to use. 
 
0.5M EDTA 
93.06g EDTA made up to 500ml with dH20. Adjusted to pH 8.0. 
 
ELISA coating buffer 
Phosphate buffered Saline (PBS) (see below). 
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LPS ELISA coating buffer (Reggiardo’s buffer) 
1.88g glycine (0.05M), 2.92g NaCl (0.1M), 0.19g EDTA (1mM), 1.05g NaF (0.05M), made up to 
100ml in dH20. Stored at 4°C, protected from light. 
For use, dilute 1:5 in dH20 plus DOC (Sodium Deoxycholate) to final concentration of 0.1%. 
Adjusted to pH 8 with NaOH. 
 
ELISA block buffer 
BlockerTM Casein in PBS (Thermo ScientificTM). 
  
Phosphate Buffered Saline (PBS)  
PBS tablets (SIGMA), 1 tablet dissolved in 200ml dH20. 
 
SDS-PAGE running buffer 
30.3 g Trizma® base (250 mM), 187.7 g glycine (2.5 M), 10 g sodium dodecyl sulphate (SDS) 
(1%), made up to 1 litre with dH20. 
 
TAE buffer (50X) 
242 g Trizma® base, 57.1 ml acetic acid, 100 ml 0.5 M EDTA, made up to 1 litre with dH20. 
Adjusted to pH 8.0. 
 
TE buffer 
10mM Tris-HCl pH 8.0, 10mM EDTA  
 
Western blot transfer buffer 
14.4 g glycine, 3.06 g Trizma® base, 200 ml methanol, made up to 1 litre with dH20.  
Freshly prepared and cooled to 4°C prior to use. 
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2.1.7 Bacterial strains 
  
Strain Genotype Source 
S. enterica serovar 
Typhimurium SL5338 
galE, r – m + (Rough LPS mutant) Khan lab strain 
S. enterica serovar 
Typhimurium SL1344 
Wild-type, derivative of LT2 Khan lab strain 
S. enterica serovar 
Typhimurium SL3261 
SL1344 aroA Derek Pickard, Wellcome 
Trust Sanger Institute 
(London) 
BRD 807 aroA and htrA double mutant of Salmonella 
Typhimurium SL1344 
Derek Pickard, Wellcome 
Trust Sanger Institute 
(London) 
BRD 509 aroA and aroD double mutant of Salmonella 
Typhimurium SL1344 
Derek Pickard, Wellcome 
Trust Sanger Institute 
(London) 
C5htrA htrA::TnphoA insertion mutant of Salmonella 
Typhimurium C5 
Derek Pickard, Wellcome 
Trust Sanger Institute 
(London) 
E. coli NEB5α  
Chemically competent 
cells 
fhuA2 (argF-lacZ)U169 phoA glnV44 80 
(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 
hsdR17 
New England Biolabs, 
Massachusetts, USA  
E. coli Stellar TM 
Competent cells 
F–, endA1, supE44, thi-1, recA1, relA1, gyrA96, 
phoA, Φ80d lacZΔ M15, Δ (lacZYA - argF) U169, 
Δ (mrr - hsdRMS - mcrBC), ΔmcrA, λ– 
Clontech Laboratories, 
Inc. Califonia, USA 
 
Table 2.5. Details and sources of bacterial strains used in this study. 
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2.1.8 Primers and Oligonucleotides 
 
Synthetic oligonucleotide primers were designed and then purchased from Eurofins genomics 
and delivered as lyophilised samples. They were subsequently reconstituted in nuclease-free 
dH2O to a final concentration of 100µM and stored at -20°C until use.  
 
 
Antigen genes 
Gene Strain Source 
Synthetic Ebola GP (V1) Zaire Ebolavirus (strain 
Mayinga-76) 
Eurofins Genomics (Ebersberg, 
Germany) 
Synthetic Ebola GP (V2) Zaire Ebolavirus (strain 
Mayinga-76) 
Eurofins Genomics (Ebersberg, 
Germany) 
WT Zika E PE243 (Donald et al, 2016) Dr Claire Donald (Glasgow 
University, UK) 
Synthetic Zika E PE243 (Donald et al, 2016) DC Biosciences (Dundee, UK) 
 
Table 2.6.  Sources of antigen genes used in this study. 
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Cloning primers 
 
Construct Primer name 5’  3’ Sequence Usage 
Ebola Glycoprotein expression constructs 
pTECH2-
GP (v1) 
 
 
Synthetic GP 
FWD 
 
CGC TCT AGA ATC CCG TTA GGC GTC ATT CA XbaI cloning of synthetic 
GP(v1) into pTECH2 
(minus signal peptide) 
Synthetic GP 
REV 
 
ACT AAG CTT CTG TCG CCA GCC TGT CCA 
 
HindIII cloning of 
synthetic GP(v1) into 
pTECH2 
(minus transmembrane 
region) 
pTECH2-
GP (v1) 
section 1 
Section 1 GP 
REV  
TGC AAG CTT CGC AGG GGA TGG CTA CTA AA 
Used with Synthetic GP FWD   
HindIII cloning of 
synthetic GP(v1) section 1 
into pTECH2 
pTECH2-
GP (v1) 
section 2 
Section 2 GP 
FWD 
CGC TCT AGA CCT CAG GCT AAG AAA GAC TT XbaI cloning of synthetic 
section 2 GP(v1) into 
pTECH2 
Section 2 GP 
REV 
GCT AAG CTT TGG ACT TGT ACC ATC GCG GA HindIII cloning of 
synthetic GP(v1) section 2 
into pTECH2 
pTECH2-
GP (v1) 
section 3 
Section 3 GP 
FWD 
ACA TCT AGA GCC TCC GAA AAT TCC TCC GC XbaI cloning of synthetic 
section 3 GP(v1) into 
pTECH2 
Section 3 GP 
REV 
CAG AAG CTT TGA GCA TTG ACG ATC GCT TC HindIII cloning of 
synthetic GP(v1) section 3 
into pTECH2 
pTECH2-
GP (v1) 
section 4 
Section 4 GP 
FWD 
ATA TCT AGA CGG ACG CGT CGT GAA GCG AT 
Use with Synthetic GP REV 
 
XbaI cloning of synthetic 
section 4 GP(v1) into 
pTECH2 
52 
 
Construct Primer name 5’  3’ Sequence Usage 
pTECH2-
GP (v2) 
GP FWD GAT ATC ATT CCG CTG GGC GTG A EcoRV cloning of 
Synthetic GP (v2) full-
length into pTECH2 
GP REV AAG CTT TTG ACG CCA GCC GGT C HindIII cloning of 
Synthetic GP (v2) full-
length into pTECH2 
pTECH2-
GP MFL 
GP MFL FWD CAG ATG GAT CCA CGC CGG TCT ATA AGC TG 
Use with D-MFL REV to amplify sub-fragment 
‘MFL’ 
BamHI cloning of 
Synthetic GP (v2) sub-
fragment MFL into 
pTECH2 
pTECH2-
GP D-MFL 
GP D-MFL FWD CAG ATG GAT CCC ACA AGG AAG GCG CAT TTTT
C 
BamHI cloning of 
Synthetic GP (v2) sub-
fragment D-MFL into 
pTECH2 
pTECH2-
GP D-MFL 
 
pTECH2-
MFL 
GP D-MFL REV CTG ATA AGC TTG CCA TCC TGA TTG TGC AT HindIII cloning of 
Synthetic GP (v2) sub-
fragments MFL or D-MFL 
into pTECH2 
pTECH2-
GP D 
GP D REV TAC TGA AGC TTT GCG AAA CAG CT 
Use with D-MFL FWD to amplify sub-fragment 
‘D’ 
HindIII cloning of 
Synthetic GP (v2) sub-
fragment D into pTECH2 
pTECH2-
GP LH 
GP LH FWD CAG ATG GAT CCC CGC AGG CGA AGA AAG AT BamHI cloning of 
Synthetic GP (v2) sub-
fragment LH into pTECH2 
GP LH REV TAC TGA AGC TTT TGC CCG ATG ACG CGC TTT C HindIII cloning of 
Synthetic GP (v2) sub-
fragment LH into pTECH2 
pTECH10-
GP 
pTECH10 REV CAG AAA GTC TCC TGT GGA Used together with 
pTECH2-GP as a template 
to remove TetC gene with 
inverse PCR (Q5 site 
directed mutagenesis – 
NEB) 
pTECH10 FWD ATG GAT ATC ATT CCG CTG GGC 
pTECH11-
GP 
 
 
pTECH11 REV GTT GTC GAC CCA ACA ATC AAG Used together with 
pTECH2-GP as a template 
to remove all but the first 
30bases of the TetC gene 
with inverse PCR (Q5 site 
directed mutagenesis – 
NEB) 
 
 
 
 
 
 
 
 
pTECH11 GP 
FWD 
 
 
GAT ATC ATT CCG CTG GGC GTG 
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Table 2.7. Cloning primers. All primers used to PCR amplify Ebola GP or Zika E genes or gene fragments 
for cloning into expression vectors pTECH2 or pBAD24 as described. All primers were synthesised by 
Eurofins Genomics. 
 
Construct Primer name 5’  3’ Sequence Usage 
pTECH11-
GP (155) 
GP 155 FWD CCG CAG GCG AAG AAA GAT TTC Used with pTECH11 REV 
(pTECH2-GP template) - 
inverse PCR (Q5 site 
directed mutagenesis – 
NEB 
Zika envelope Expression constructs 
pTECH2-
synthetic 
ZE 
ZEs FWD TAG CCG GAT CCA TTC GTT GTA TCG GCG TA BamHI cloning of 
Synthetic Zika E into 
pTECH2 
ZEs REV AAG CTT TTT GCC GAT GGT GGA GCC 
 
HindIII cloning of 
Synthetic Zika E into 
pTECH2 
pTECH2-
ZE(s193) 
ZEs 193 REV CTG ATA AGC TTA CGC GGT TCG CAA TCC AG HindIII cloning of 
Synthetic Zika E (193) into 
pTECH2 
pTECH2-
ZE(WT) 
ZE WT FWD GGA TCC ATC AGG TGC ATA GGA GTC BamHI cloning of WT Ze 
into pTECH2 
ZE WT REV CGC AAG CTT TTA AGT GGC TTC AAA TGC HindIII cloning of WT Ze 
into pTECH2 
pTECH10-
ZE(s) 
pTECH10-ZE(s) 
FWD 
ATG GGA TCC ATT CGT TGT ATC GGC 
Used with pTECH10 FWD 
Used together with 
pTECH10 REV with 
pTECH2-ZE as a template 
to remove TetC gene with 
inverse PCR (Q5 site 
directed mutagenesis – 
NEB) 
pTECH11-
ZE(s) 
pTECH11-ZE(s) 
FWD 
GGA TCC ATT CGT TGT ATC GGC 
used with ZEs FWD 
 
Used together with 
ptECH11 REV with 
pTECH2-ZE as a template 
to remove all but the first 
30bases of the TetC gene 
with inverse PCR (Q5 site 
directed mutagenesis – 
NEB) 
pTECH-ZE-
DMFL 
ZE-DMFL FWD GCT TAA AGC TTG GTC CTG GTC CTC ACA AGG 
AAG GCG CAT TTT TC 
HindIII cloning of Ebola GP 
DMFL into pTECH10-ZE(s) 
ZE-DMFL REV CGC GTA CTA GTG CCA TCC TGA TTG TGC ATC A SpeI cloning of Ebola GP 
DMFL into pTECH10-ZE(s) 
pBAD24-
ZE 
pBAD24 ZE In-
Fusion® FWD 
CCG GGG ATC CTC TAG AAT GTC CAT TCG 
TTGTAT CGG CG 
In-Fusion® Ligation 
independent cloning of ZE 
into pBAD24 
pBAD24 ZE In-
Fusion® REV 
CAA AAC AGC CAA GCT TTT ATT TGC CGA T
GG TGG AGC C 
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Signal sequence Oligonucleotides and In-Fusion® primers 
 
 
Table 2.8.  Signal sequence Oligonucleotides and In-Fusion® primers.                  
Oligonucleotides used to construct OmpA and DsbA DNA signal sequences and In-Fusion® primers to 
allow the addition of the OmpA membrane spanning region (MSR). All primers were synthesised by 
Eurofins Genomics. 
 
 
 
 
 
 
 
 
Construct Oligo/primer 
name 
5’  3’ sequence Usage 
pBAD24 
OmpA ss ZE 
OmpA ss 
Sense 
[PHO] AAT TCA TGA AAA AGA CAG CTA TCG CGA 
TTG CAG TGG CAC TGG CTG GTT TCG CTA CCG 
TAG CGC AGG CCT 
 
Annealed oligo (sense and 
anti-sense strands) of 
OmpA signal sequence 
containing ‘pre-digested’ 
EcoRI and XbaI restriction 
sites, for cloning into 
pBAD24-ZE 
OmpA ss 
Anti-sense 
[PHO] CTA GAG GCC TGC GCT ACG GTA GCG AAA 
CCA GCC AGT GCC ACT GCA ATC GCG ATA GCT 
GTC TTT TTC ATG 
 
pBAD24 
OmpA ss 
MSR ZE 
OmpA ss 
MSR In-
Fusion® REV 
ACA ACG AAT GGA CAT TTT AGC ACC AGC GTA 
CCA GGT GTT ATC TTT CGG AGC GGC CTG CGC 
TAC GGT AGC 
In-Fusion® ligation 
independent cloning of 
OmpA Membrane spanning 
Region (MSR) into pBAD24-
OmpA ss ZE, using pBAD24-
OmpA-ZE as a template. 
OmpA ss 
MSR In-
Fusion® FWD 
ATG TCC ATT CGT TGT ATC GGC G 
 
pBAD24 
DsbA ss ZE 
DsbA ss 
Sense 
[PHO] AAT TCA TGA AAA AGA TTT GGC TGG CGC 
TGG CTG GTA TGG TTT TAG CTT TTA GCG CCT 
CGG CAG CAT 
Annealed oligo (sense and 
anti-sense strands) of DsbA 
signal sequence containing 
‘pre-digested’ EcoRI and 
XbaI restriction sites, for 
cloning into pBAD24-ZE 
DsbA ss 
Anti-sense 
[PHO] CTA GAT GCT GCC GAG GCG CTA AAA GCT 
AAA ACC ATA CCA GCC AGC GCC AGC CAA ATC 
TTT TTC ATG 
 
55 
 
Construct screening primers 
 
Table 2.9. Construct screening primers. All primers used to screen putative clones as described, both 
with colony PCR and DNA sequencing (Eurofins). All primers were synthesised by Eurofins Genomics. 
 
Knockout oligonucleotides 
Strain oligo name 5’  3’ sequence Usage 
SL1344 ΔtolR tolR KO FWD CCA GGC GTT TAC CGT AAG CGA AAG CAA CA 
AGGG GTA AGC CGT GTA GGC TGG AGC TGC TTC 
 
Used in one-step 
gene disruption 
technique to 
knockout tolR in 
Salmonella SL1344 
SL1344 ΔtolR tolR KO REV  CCT GTT ACT CGC CGT CTT TCA AGC CAA CGG 
GAC GCA GAC TAT GGG AAT TAG CCA TGG TCC 
 
SL1344 ΔmlaA mlaA KO 
FWD 
ATG GCA ATC AGC GAT AGC CAT AAT TCA CAG 
GGA GAC ATC TGT GTA GGC TGG AGC TGC TTC 
 
Used in one-step 
gene disruption 
technique to 
knockout mlaA in 
Salmonella SL1344 
SL1344 ΔmlaA mlaA KO REV AAA AGG TGA GCA TTG CGC TCA CCT TTT TAT 
TTA CTG CCG TAT GGG AAT TAG CCA TGG TCC 
 
 
Table 2.10. Knockout oligonucleotides. All oligonucleotides (primers) used to PCR amplify the KanR 
gene from the pKD4 template to carry out the Lambda-red recombinase technique to knockout genes 
tolR or mlaA from Salmonella Typhimurium strain SL1344. 
 
 
Construct Primer name 5’  3’ sequence Usage 
Any pTECH2 pTETnir15 FWD GAC CTG AAA ACC TAC TCT GT pTECH2 screening  
pTETnir15 REV CAG CGA GTC AGT GAG CGA G 
pTECH10/11 pTECH10/11 screen 
FWD 
CGT CTT CAG AAT TCA GGT A pTECH10/11 
screening 
Any pBAD24 pBAD screen FWD TCT CGC TAA CCA AAC CGG TAA C pBAD24 screening 
pBAD screen REV CAG GAG AGC GTT CAC CGA CAA 
pTECH ZE-DMFL  pTECH ZE-DMFL 
screen FWD 
CGTCTTCAGAATTCAGGTA Used for DNA 
sequencing pTECH-ZE-
DMFL construct 
pBAD24-OmpA ss 
ZE 
 
pBAD24-OmpA MSR 
ss ZE 
OmpA ss screen 
FWD 
CAT GAA AAA GAC AGC TAT CGC G Used for DNA 
sequencing to confirm 
insertion of OmpA 
signal sequence (with 
or without MSR) into 
pBAD24-ZE 
pBAD24-DsbA ss ZE DsbA ss screen FWD CAT GAA AAA GAT TTG GCT GGC GC 
 
Used for DNA 
sequencing to confirm 
insertion of DsbA 
signal sequence into 
pBAD24-ZE 
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Knockout screening primers 
Strain Primer name 5’  3’ sequence Usage 
SL1344 ΔtolR tolR check FWD CGC CAG GCG TTT ACC GTA Screening for successful 
tolR knockout SL1344 ΔtolR tolR check REV GTT CGC CTG TTA CTC GCC G 
SL1344 ΔmlaA mlaA check FWD GGA TGG CAA TCA GCG AT Screening for successful 
mlaA knockout SL1344 ΔmlaA mlaA REV CTT TCT GAA ACG GAT CA 
 
Table 2.11. Knockout screening primers. List of all primers and oligonucleotides used in this study. All 
primers were synthesised by Eurofins Genomics. 
 
 
2.1.9 SDS-PAGE gel 
 
3.5% stacking gel 
3.01ml dH20, 1.2ml 1M Tris pH 6.8, 590µl 30% bis-acrylamide, 100µl 10% Sodium Dodecyl 
Sulphate (SDS), 150µl 10% Ammonium persulfate, 15µl N,N,N’N’-
Tetramethylethylenediamine (TEMED). 
 
10% separating gel 
6.3ml dH20, 3.75ml 1.5M Tris pH 8.8, 5.025ml 30% bis-acrylamide, 300 µl 10% Sodium Dodecyl 
Sulphate (SDS), 150µl 10% Ammonium persulfate, 15µl N,N,N’N’-
Tetramethylethylenediamine (TEMED). 
 
2.1.10 SDS PAGE Molecular weight marker 
 
PageRulerTM 10kDa-180kDa prestained protein ladder (ThermoScientific) was used as a 
molecular weight marker in SDS-PAGE gels and western blots to indicate the size of separated 
proteins (kDa) after fractionation by electrophoresis.  
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Figure 2.3. Protein molecular weight marker. Indicators of protein size (kDa) for PageRulerTM 10kDa-
180kDa prestained protein ladder (ThermoScientific). Used in SDS-PAGE and western blots to 
determine size of fractionated proteins. 
 
 
2.1.11 Agarose with Gel Red TM 
 
 0.7% agarose in TAE buffer, with 10000x Gel Red TM (Biotium) to final 1x concentration, was 
used to fractionate DNA samples with electrophoresis and allowed the ability to view DNA 
bands under UV light with a UVP BioDoc-ItTM imaging system. 
 
2.1.12 Agarose Gel DNA Molecular weight marker 
 
GeneRuler™ 1 kb DNA Ladder (ThermoScientific) or Quick-Load® 1 kb DNA Ladder (New 
England Biolabs) were used as DNA molecular size markers for fractionation of DNA in agarose 
gels. 
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Figure 2.4.  DNA molecular weight markers. Indicators of DNA fragment sizes for GeneRuler™ 1 kb 
DNA Ladder (ThermoScientific) or Quick-Load® 1 kb DNA Ladder (New England Biolabs). Used in 
agarose gel electrophoresis of DNA to determine size of DNA fragments.  
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2.2 Methods 
 
All methods and protocols used in this study are documented below. 
2.2.1 Growth conditions for Bacteria 
 
Bacteria was grown in liquid LB broth or plated on LB agar with appropriate antibiotics if 
necessary. Ampicillin and Kanamycin were both added at 50µg/ml. 
 
2.2.2 Plasmid DNA purification 
 
Plasmid DNA was extracted from overnight bacterial cultures using the Qiagen mini-prep kit. 
5ml overnight cultures were pelleted by centrifugation at 3220 x g for 10 minutes. Pellets 
were resuspended in 250µl Qiagen buffer P1 containing RNase, and 250µl Qiagen alkaline cell 
lysis buffer P2 was added. This was then mixed by inversion, prior to adding 350µl Qiagen 
neutralisation buffer N3. Samples were centrifuged at 16060 x g for 10 minutes and 
supernatant added to the provided QIAprep spin columns.  The columns were centrifuged at 
3220 x g for 1 minute and flow through discarded. The bound DNA remaining in the column 
was washed with 500µl Qiagen binding buffer, PB, followed by 750µl Qiagen wash buffer, PE 
with 1-minute spins in between at 3220 x g. Remaining wash buffer was removed with an 
extra 30 second spin at 3220 x g. The columns were then placed in clean 1.5ml 
microcentrifuge tube and the DNA was eluted with either 50µl of Qiagen Elution buffer, EB, 
or 50µl distilled DNase/RNase free water, depending on subsequent use. The purified plasmid 
was stored at -20°C. 
 
2.2.3 Restriction enzyme digestion of DNA 
 
Restriction endonuclease enzymes from New England Biolabs (NEB) were used according to 
the manufacturer’s instructions using the provided NEB 10X CutSmart ® buffer.  
Generally, 1µg of DNA was cut with 10 units of restriction enzyme and digested at 37°C for 1 
hour. Following digestion, samples were purified using the QIAquick PCR purification kit 
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(Qiagen) according to manufacturer’s instructions and visualised under UV light after agarose 
gel electrophoresis a UVP BioDoc-ItTM imaging system. 
 
2.2.4 PCR amplification and purification of DNA for cloning 
 
DNA encoding the Ebola Glycoprotein and Zika envelope genes and sub-fragments were 
prepared for cloning into pTECH2 or pBAD24 using polymerase chain reaction (PCR) with NEB 
Phusion® High-Fidelity DNA polymerase PCR kit on a Biometra T1 thermocycler. 
Regents were mixed on ice according to the manufacturer’s instructions and the following 
cycling conditions were followed: 
 
 
 
 
 
 
 
 
 
Table 2.12.  PCR amplification and purification of DNA for cloning. Thermal cycling conditions for 
polymerase chain reaction to amplify antigen gene fragments for cloning into expression vectors. 
 
The PCR product, which included the restriction endonuclease sites from each primer, was 
then purified using the Qiagen PCR purification kit according to manufacturer’s instructions.  
 
2.2.5 Ligation  
 
Ligation of DNA fragments and vector was carried out using T4 DNA Ligase (NEB). Following 
the creation of sticky ends by restriction enzyme digestion the following ligation mix was 
combined: 2µl 10X T4 DNA Ligase buffer (NEB), 1µl (400 units) T4 DNA ligase (NEB), calculated 
amounts of digested vector and insert DNA (approximately 150ng vector with a molar ratio 
of 3:1 vector to insert) Nuclease-free dH2O up to 20µl.  
Cycle step No. of cycles Temp Duration 
Initial denaturation 1 98°C 30 seconds 
Denaturation 
Annealing 
Extension 
 
30 
98°C 
50°C 
72°C 
10 seconds 
30 seconds 
30 seconds per kb 
Final extension 1 72°C 10 minutes 
Hold 1 4°C ∞ 
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Volumes of digested insert and vector DNA was calculated using the following equation: 
 
൬
𝑛𝑔 𝑣𝑒𝑐𝑡𝑜𝑟 × 𝑘𝑏 𝑖𝑛𝑠𝑒𝑟𝑡
𝑘𝑏 𝑣𝑒𝑐𝑡𝑜𝑟
൰ ×
3
1
= 𝑛𝑔 𝑖𝑛𝑠𝑒𝑟𝑡 
 
Ligation reactions were mixed on ice and incubated at 16°C overnight using a Biometra T1 
thermocycler. The following day, ligation reaction mixes were heat inactivated at 65°C for 10 
minutes and transformed into chemically competent SL5338 Salmonella Typhimurium. Cells 
were spread onto LB agar at a range of dilutions with 50µg/ml ampicillin and incubated 
overnight at 37°C. 
 
2.2.6 Colony PCR 
 
To determine bacterial clones which had been successfully transformed with effectively 
ligated plasmids, single colonies from transformed cells were picked and transferred into 50µl 
TE buffer with 1% TritonX100. Samples were incubated at 95°C for 10 minutes and centrifuged 
at 16060 x g for 10 minutes. 1µl of this supernatant was then added to a master mix consisting 
of: 5µl Emerald master mix (Clontech), 1µl forward screening primer (10µM), 1µl reverse 
screening primer (10µM), 2µl nuclease-free dH2O. Regents were mixed on ice according to 
the manufacturer’s instructions and the following cycling conditions using a Biometra T1 
thermocycler were followed: 
 
 
 
 
 
 
 
 
 
Table 2.13. Colony PCR. Thermal cycling conditions for polymerase chain reaction to amplify DNA from 
lysed bacteria to confirm the identity of putative clones. 1µl of the PCR mix was run on a 0.7% agarose 
gel and visualised under UV light with a UVP BioDoc-ItTM imaging system. 
Cycle step No. of cycles Temp Duration 
Initial denaturation 1 98°C 10 seconds 
Denaturation 
Annealing 
Extension 
 
30 
98°C 
52°C 
72°C 
10 seconds 
30 seconds 
60 seconds per kb 
Final extension 1 72°C 5 minutes 
Hold 1 4°C ∞ 
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2.2.7 Q5 Site-directed mutagenesis 
 
To remove the TetC gene and create the pTECH-10 constructs, inverse PCR was carried out, 
using a Q5 Site-Directed Mutagenesis Kit (New England Biolabs). Primers were designed on 
either side of the TetC gene, so that the 5’ ends annealed back to back on the new construct. 
The construct was then amplified using PCR. The reaction was mixed as follows: 12.5µl Hot 
Start High-Fidelity 2X Master Mix, 1.25µl of each primer (forward and reverse, to a final 
concentration of 0.5µM), 25ng template DNA (here, the pTECH2-GP or ZE plasmid), and 9µl 
nuclease-free dH2O. The following cycling conditions using a Biometra T1 thermocycler were 
followed: 
 
Cycle step No. of cycles Temp Duration 
Initial denaturation 1 98°C 30 seconds 
Denaturation 
Annealing 
Extension 
 
30 
98°C 
50-72°C 
72°C 
10 seconds 
30 seconds 
30 seconds per kb 
Final extension 1 72°C 2 minutes 
Hold 1 4°C ∞ 
 
Table 2.14. Q5 Site-directed mutagenesis. Thermal cycling conditions for inverse polymerase chain 
reaction using a Q5 Site-Directed Mutagenesis Kit (New England Biolabs). 
 
The PCR product from the above reaction was then used in a KLD reaction, using the same kit. 
1µl of PCR product was mixed with 5µl 2X KLD reaction buffer, 1µl KLD enzyme mix and 3µl 
nuclease free dH2O. This reaction was incubated for 5 minutes at room temperature and 5µl 
used to transform NEB5α chemically competent E. coli cells (New England Biolabs) using the 
manufacturer’s heat-shock protocol. Cells were spread onto LB agar at a range of dilutions 
with 50µg/ml ampicillin and incubated overnight at 37°C. Putative clones were screened using 
colony PCR (see section 2.2.6) and DNA sequencing (Eurofins).  
 
63 
 
2.2.8 In-Fusion® ligation independent cloning 
 
The template vector was linearised by appropriate restriction enzyme digestion (see section 
2.2.3) and the insert gene fragment was amplified by PCR using primers designed to have 
15bp extensions complementary to the ends of the linearised vector, where the gene will be 
inserted. 
100ng of template DNA was added to 1.2µl CloneAmpTM HiFi PCR premix, forward and reverse 
primers to a final concentration of 0.2µM and nuclease free dH2O to a final volume of 25µl. 
The following cycling conditions using a Biometra T1 thermocycler were then followed: 
 
 
Cycle step No. of cycles Temp Duration 
Denaturation 
Annealing 
Extension 
 
35 
98°C 
55°C 
72°C 
10 seconds 
15 seconds 
5 seconds per kb 
Hold 1 4°C ∞ 
 
Table 2.15. In-Fusion® ligation independent cloning. Thermal cycling conditions for polymerase chain 
reaction to amplify DNA for In-Fusion® cloning. 
 
The resulting PCR product was then spin column purified using Nucleospin® PCR cleanup kit 
(Macherey-Nagal) according to manufacturer’s instructions and the In-Fusion® cloning 
reaction was subsequently set up as follows: 100ng of purified DNA insert, 100ng purified 
linearised plasmid, 2µl 5X In-Fusion® HD Enzyme premix, and nuclease free dH2O to a final 
volume of 10µl. The reaction was mixed and incubated for 15 minutes at 50°C using a 
Biometra T1 thermocycler, then placed on ice. 5ng of the reaction mixture was then 
immediately transformed into StellarTM competent E. coli (Clontech) according to the 
manufacturer’s instructions. Cells were spread onto LB agar at a range of dilutions with 
50µg/ml ampicillin and incubated overnight at 37°C. 
Putative clones were screened using colony PCR (see section 2.2.6) and DNA sequencing 
(Eurofins).  
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2.2.9 Annealing of oligonucleotide strands 
 
The oligonucleotides encoding the OmpA and DsbA signal sequences were synthesised in 
sense and anti-sense strands and reconstituted in nuclease free and nuclease free dH2O to a 
concentration of 100µM. To anneal the strands, 10µl of each reconstituted strand (making a 
final concentration of 10µM) was added to 80µl nuclease free dH2O resulting in a final volume 
of 100µl. This mixture was heated to 95°C for 5 minutes using a Biometra T1 thermocycler 
and cooled at a rate of 1°C per minute. 
 
2.2.10 Production of chemically competent Salmonella Typhimurium SL5338 and 
transformation 
 
Salmonella Typhimurium strain SL5338 was cultured overnight at 37°C, with shaking at 200 
RPM. The following morning the culture was diluted 1:100 in 100ml LB broth and placed at 
37°C with shaking at 180 RPM until OD600 0.4 – 0.6. Cells were chilled on ice for 20 minutes 
and then pelleted at 3220 x g at 4°C for 10 minutes.  
Cells were resuspended in 50ml 0.1M MgCl2 and pelleted at 3220 x g at 4°C for 10 minutes. 
The pellet was then resuspended in 50ml 0.1M CaCl2 and pelleted as above. The pellet was 
finally resuspended in in 5ml 0.1M CaCl2 and 250µl TES added.  
Cells were chilled on ice for 30 minutes and the plasmid or ligation mix added to 200µl cells 
prior to chilling on ice for a further 30 minutes. Each 200µl reaction was heat shocked at 42°C 
for 2 minutes and left on ice to cool.  
2ml warm LB broth was added and cells were placed at 37°C with shaking at 80 RPM for 30 
minutes then 200 RPM for 1 hour. 100µl cells was plated on LB agar plates at a range of 
dilutions (1X to 1:100) with appropriate selective antibiotics. 
 
2.2.11 Production of electro-competent Salmonella vaccine strains and electroporation 
 
Salmonella Typhimurium vaccine strains were cultured overnight at 37°C, with shaking at 200 
RPM. The following morning the culture was diluted 1:100 in 100ml LB broth and placed at 
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37°C with shaking at 180 RPM until OD600 0.5. Cells were then washed in ice cold sterile dH20 
4 times in increasingly smaller volumes (25ml, 10ml, and 5ml until a final volume of 400µl). 
Cells were aliquoted, and plasmid was added to 100µl cells. Cells were left on ice for 30 
minutes prior to electroporation at 2500V. 600µl warm SOC was added to each sample and 
incubated at 37°C for 1 hour. 100µl cells was plated on LB agar plates at a range of dilutions 
with appropriate selective antibiotics  
 
2.2.12 Analysis of protein expression  
 
Expression of the recombinant proteins in Salmonella Typhimurium strains SL5338, SL1344 or 
the various attenuated vaccine strains were examined by SDS-PAGE and western blot.  
 
 2.2.12.1 Cell Lysate preparation for analysis of recombinant proteins 
 
5ml LB broth with 50µg/ml ampicillin was inoculated with the appropriate strain from a sterile 
loop and grown overnight at 37°C, with shaking at 200RPM.  The following day, a reading was 
taken at OD600 to determine growth and the culture was pelleted by centrifugation at  3220 x 
g. Each pellet was resuspended in varying amounts of PBS-TX100 (resuspension buffer), 
depending on OD600 to allow for cell-number equilibration of samples.  
 
The volume of resuspension buffer was calculated using the following method:  
First, the OD600 of a 1:10 dilution of each of the samples was taken.  
This value was converted to its antilog and the sample with the lowest value was identified. 
This would be the sample containing the smallest number of bacteria and would be 
resuspended in 150µl of the PBS-TX100 resuspension buffer. The resuspension volumes of 
the other samples were calculated as follows: 
 
ቀ௔௡௧௜௟௢௚ ௌ௔௠௣௟௘ ை஽లబబ
௔௡௧௜௟௢௚ ௟௢௪௘௦௧ ை஽లబబ
ቁ × 150𝜇𝑙 =  𝜇𝑙 𝑅𝑒𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 𝑏𝑢𝑓𝑓𝑒𝑟 𝑓𝑜𝑟 𝑠𝑎𝑚𝑝𝑙𝑒  
 
This ensured that if an equal volume of each resuspended sample was used for loading onto 
SDS-PAGE, there should be protein from an equivalent number of cells.  
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Once resuspended, 15µl of each sample was added to 5µl 4X Sample buffer (Expedeon) (for 
precast gels) or 15ul 2X NovexTM tris glycine buffer (Invitrogen) (for hand-made gels) with 5% 
beta-mercaptoethanol as a reducing agent. 
Samples were boiled for 5 minutes and subsequently centrifuged at 16060 x g.  
 
 2.2.12.2 SDS-PAGE 
 
The samples as prepared above were fractionated on either hand-made (see section 2.1.9) or 
NuPAGETM 12% Bis-Tris protein gels (Expedeon), and run accordingly until the dye front 
reached the bottom of the gel. Following this, gels were stained with InstantBlueTM protein 
stain (Expedeon) to allow visualisation of protein bands.  
 
 2.2.12.3 Western blotting 
 
Samples were prepared in the same way as for SDS-PAGE, however after running the gel, 
protein bands were transferred to nitrocellulose membrane (Amersham, GE healthcare) at 
100V for 1 hour 30 minutes. The blot was then blocked with 5% milk powder (Sigma) in PBS 
0.01% Tween (Sigma) for 1 hour at room temperature with constant rocking. The appropriate 
primary antibody was added, diluted in the milk blocking buffer and incubated overnight at 
4°C. The blot was washed in PBS 0.01% Tween three times, for 5 minutes before the 
appropriate secondary antibody (with HRPO), again diluted in the milk buffer was added. The 
blot was incubated at room temperature for 2 hours before washing as above with PBS 0.01% 
Tween and developing with 4-chloro-1-naphthol to visualise bands.  
 
2.2.13 In vitro stability of plasmids 
 
The pTECH2 expression plasmid includes an ampicillin resistance gene to allow for easy 
selection of colonies. In order to carry out in vivo immunisation experiments, stability testing 
was carried out to ensure that the Salmonella vaccine strain would retain the plasmid, despite 
the fact that there was no advantage to the cell (no need to overcome antibiotic selection 
pressure) when antibiotics were not present.  
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SL3261 cells containing each plasmid were grown overnight in a 5ml LB liquid culture 
containing 50µg/ml ampicillin at 37°C shaking at 200RPM. These cultures were then diluted 
1:100 in LB with either no ampicillin or 50µg/ml ampicillin and again grown overnight as 
above. The next day, a 10-6 dilution of each culture was made and 10µl was dropped (in 
triplicate) onto agar plates both with and without ampicillin. These were incubated overnight 
at 37°C and the CFU/ml calculated from each spot. From these, the plasmid stability was 
calculated from the CFU/ml of each sample from the overnight culture with no ampicillin (see 
red box in figure 2.5). As a control, the stability from the overnight culture with ampicillin was 
also calculated, but had no impact on the results. 
To determine % stability, the following calculation was used: 
% 𝑃𝑙𝑎𝑠𝑚𝑖𝑑 𝑠𝑡𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = ൬ 
𝐶𝐹𝑈/𝑚𝑙 𝑎𝑚𝑝 +
𝐶𝐹𝑈/𝑚𝑙 𝑎𝑚𝑝 − 
൰  𝑋 100 
 
This work was carried out in collaboration with Bethany Gollan, MRes student under my 
supervision in the Khan lab, Newcastle University.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. Method to determine recombinant plasmid stability in vitro.  
 
 
 
68 
 
2.2.14 In vivo stability of vaccine strains 
 
After confirmation that the expression plasmids were stable without antibiotic selection in 
vitro, a pilot immunisation experiment was carried out to determine in vivo stability and to 
ensure that the Salmonella vaccine strain was still able to express the Ebola GP or Zika E 
proteins after passage in vivo when recovered from the livers and spleens of immunised mice. 
The work covered in 2.2.14.1 and 2.1.14.2 was very kindly carried out by Dr Omar Rossi, 
University of Cambridge.  
 
2.2.14.1 Intravenous inoculation of mice with Salmonella vaccine strain 
 
6-week-old BALB/c mice used in immunisation experiments were housed in standard facilities at the 
department of veterinary medicine, Cambridge University. They were allowed to acclimatise for 2 
weeks and immunised at 8 weeks old. Mice were immunised intravenously (I.V) with Salmonella 
vaccine strains (see chapter 3, tables 3.3 and 3.4; and chapter 4 tables 4.2 and 4.3) and sacrificed 8 
weeks post immunisation. Each plasmid was allocated 4 mice. Immunisations of the mice and bleeds 
were kindly carried out by Dr Omar Rossi, Cambridge University. 
 
2.2.14.2 Determination of organ colonisation by Salmonella vaccine strains and plasmid 
stability  
 
11 days post immunisation, the mice were sacrificed, and livers and spleens were dissected 
for analysis of colonisation. These organs were homogenised and resuspended in 5ml PBS. 
This was then diluted 1:100 and 50µl of this was spread onto LB agar plates both with and 
without ampicillin in triplicate. After incubation overnight at 37°C, the CFU/ml was calculated 
using the following calculation: 
 
𝐶𝐹𝑈/𝑚𝑙 = (𝑚𝑒𝑎𝑛 𝑛𝑜. 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 × 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟) × (1000 ÷ 50µ𝑙) 
 
From this, the total number of bacteria per organ could be determined by multiplying the 
CFU/ml by 5 (the total resuspension volume in ml for each organ). 
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From the total number per organ, the plasmid stability could be determined as before, using 
the colonies recovered from the organs grown on LB agar plates both with and without 
ampicillin, with the calculation: 
 
% 𝑃𝑙𝑎𝑠𝑚𝑖𝑑 𝑠𝑡𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = ൬
𝑂𝑟𝑔𝑎𝑛 𝑡𝑜𝑡𝑎𝑙 𝑜𝑛 𝑎𝑚𝑝 + 𝑝𝑙𝑎𝑡𝑒
𝑂𝑟𝑔𝑎𝑛 𝑡𝑜𝑡𝑎𝑙 𝑜𝑛 𝑎𝑚𝑝 − 𝑝𝑙𝑎𝑡𝑒
൰ × 100 
 
2.2.14.3 Determination of recombinant protein expression after in vivo passage 
 
10 colonies from each organ sample were collected on a loop and stored as stab agar culture 
in order to send to Newcastle for expression testing. Once arrived, streak plates were made 
from these stab agar cultures and following growth overnight on LB agar with 50µl/ml 
ampicillin, were used to make a 5ml LB broth liquid culture also with 50µl/ml ampicillin. Cells 
from this liquid culture were then processed as above for a western blot, probed with 
polyclonal Rabbit anti-Tet C sera followed by Goat anti Rabbit (HRPO) to determine expression 
of Tet C and Tet C fusion proteins from cells recovered from each mouse organ.  
 
2.2.15 Investigation of immune response  
 
IgG response to Ebola GP, Zika E or Tet C, constituents of the pTECH2 expression plasmids 
were assessed by ELISA. 
 
2.2.15.1 ELISA to determine immune response to recombinant antigens or Tet C  
 
Recombinant Ebola Glycoprotein, kindly provided by Oxford University and Public Health 
England (Ewer et al, 2016a), was coated 1µg/ml, Zika envelope protein (Fitzgerald) at 5µg/ml, 
and Tet C, kindly provided by Professor Neil Fairweather (Imperial College London) was coated 
at 1µg/ml onto 96 well Nunc MaxiSorp™ plates at in sterile PBS.  
Plates were incubated at 4°C overnight before washing 6 times with 200µl/well wash buffer 
(PBS 0.05% Tween). Each well was blocked with 100µl Casein (Fisher) and the plate incubated 
at room temperature for 1 hour. Mouse sera dilutions were prepared to a volume of 50µl in 
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casein block buffer and placed in a SterilinTM 96 well plate. Blocking buffer was washed from 
the experimental plate as above and sera samples transferred from the sample plate before 
incubating at room temperature for 2 hours. Plates were again washed as above and 50µl per 
well Rabbit anti-mouse HRPO secondary antibody (Abcam) diluted in casein was added. Plates 
were incubated for 1 hour at room temperature before washing as above. Assays were 
developed with 50µl per well TMB substrate (Sigma) and stopped with 50µl per well 0.5M 
H2SO4. Assays were read at 450nm with a BioTek plate reader. 
 
 2.2.15.2 ELISA to determine immune response to Salmonella Typhimurium LPS 
 
Salmonella Typhimurium LPS (Sigma) was prepared by mixing in equal volumes with 0.5% 
Sodium Deoxycholate (DOC), making a solution of 0.5mg/ml LPS with 0.25% DOC. This was 
incubated for 15 minutes at 37°C and subsequently stored at -20°C until needed.  
LPS in DOC was thawed and diluted to a final concentration of 5µg/ml in Reggiardo’s buffer 
with 0.1% DOC, 50µl was added per well of a Nunc MaxiSorp™ 96 well plate and incubated at 
37°C overnight. Wells were then emptied and washed with PBS 0.05% Tween (200µl/well, 2 
quick rinses and then 3 times for 3 minutes each) and subsequently blocked with PBS 2% BSA, 
then incubated at 37°C for 1 hour.  
Wells were emptied and washed as above, and serum diluted in PBS 0.05% Tween plus 1% 
BSA was added at 50µl per well. Plates were then incubated at 37°C for 2 hours before 
emptying and washing as above. 50µl per well Rabbit anti-mouse HRPO secondary antibody 
(Abcam) diluted in PBS 0.05% Tween plus 1% BSA was added and incubated for 1 hour at 37°C. 
Wells were emptied and washed as above before the assay was developed with 50µl per well 
TMB substrate (Sigma) and stopped with 50µl per well 0.5M H2SO4. Assays were read at 
450nm with a BioTek plate reader. 
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2.2.15.3 Determination of neutralisation of Zika Virus by immunised mouse serum 
 
The following assay was kindly carried out by Professor Arvind Patel and Ricardo Sachez-
Velasquez, Glasgow University. 
7x103 cells/well Vero cells were used to seed a 96 well plate in DMEM 10% FBS overnight. 
The following day, three-fold dilutions of the experimental sera (1:20 – 1:43740) were mixed 
with 100 pfu of ZIKV Brazilian strain PE243 (Donald et al 2016) for 1 hour. The Vero cell 
medium was removed, and the sera/ZIKV mixture added onto the cells. The cells were topped 
up with 100µl of DMEM 2%FBS and incubated for 72 hours.  
Cell supernatant was removed, and cells lysed with LB2 lysis buffer (20mM Tris-HCL (pH 7), 20 
mM iodoacetamide, 150 mM NaCl, 1 mM EDTA, 0.5% Triton X-100, Complete TM protease 
inhibitors).  
A 96 well plate (Immulon, 2HB – ThermoScientific) was coated with 3µg/well 4G2 anti 
Flavivirus antibody (Merk Millipore) and incubated overnight at room temperature. The 
following day, the antibody was removed and wells were blocked for 2 hours at room 
temperature with 2% skimmed milk powder in PBS-0.02% Tween-20.  
100µl cell lysate added and incubated for 1 hour at room temperature. The plate was washed 
with PBS-0.02% Tween-20 and Rabbit anti-Zika envelope – R34 sera was added at 1:4500 and 
incubated for 1 hour at room temperature. The plate was washed as above and 1:10000 anti-
rabbit IgG H&L (HRP) (Abcam) was added and again incubated for 1 hour at room 
temperature. The plate was washed as above and the assay was developed with TMB 
substrate (Sigma) for approximately 10 minutes before the reaction was stopped with 0.5 M 
H2SO4. Assays were read at 450nm with a Varioskan plate reader. 
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2.2.16 Salmonella mutagenesis 
 
Knockouts of specific Salmonella Typhimurium genes were carried out to increase the 
propensity of the SL1344 strain to produce outer membrane vesicles.  
 
2.2.16.1 One Step gene disruption technique, Lambda-red system 
 
To create gene specific Salmonella knockout mutants, the Lambda-red recombinase 
technique was used (Datsenko & Wanner, 2000).  
A DNA cassette containing a kanamycin-resistance gene (KanR) was amplified by PCR from 
the pKD4 plasmid. Primers were designed to include 40 bases from either the 5’ or 3’ end of 
the target gene (tolR or mlaA) on the SL1344 genome as well as 20 bases from the pKD4 
plasmid, flanking the KanR gene and flippase recognition target (FRT) sites at the priming 
sites, P1 and P2.  
73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6.  Plasmid map of pKD4. PKD4 contains the kanamycin resistance gene – KanR, found on 
bacterial transposon Tn5, encoding neomycin transphospherase, which is situated between two 
flanking FRT sites. Primers were made which included part of the Salmonella Typhimurium SL1344 
genome, flanking the tolR or mlaA genes which were to be knocked out and also the P1 and P2 priming 
sites of pKD4. When amplified by PCR, the resulting cassette was transformed into parent SL1344 
strains harbouring the pKD46, lambda-red recombinase enzyme expressing plasmid. Plasmid map was 
made using the commercial software Snapgene. 
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Figure 2.7. Gene sequences for tolR and mlaA genes in the Salmonella Typhimurium genome and 
corresponding primer oligonucleotide sequences. Oligonucleotides were used to amplify the KanR 
gene from the pKD4 plasmid (see figure 2.6). The genes are shown in blue with the flanking genome 
in black. The oligos contain 40 bases complementary to the flanking genome and 20 bases 
corresponding to priming sites 1 and 2 (P1, P2) on the pKD4 plasmid (shown in green). The resulting 
amplified PCR product is a cassette including the KanR gene, flanked by flippase recognition target 
(FRT) sites to allow for the subsequent lambda-red recombination reaction.  
 
 
A) 
B) 
5’ 
3’ 
5’ 
3’ 
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2.2.13.2 P22 Lysate production 
 
Once the KanR gene and FRT site cassette had been amplified it was transformed into electro-
competent Salmonella Typhimurium strain SL1344 which had previously been transformed 
with the pKD46 plasmid, expressing the Lambda-red recombinase enzyme. Homologous 
recombination allowed the KanR cassette to be inserted specifically at the tolR or mlaA gene 
sites. Knockout strains were then checked using colony PCR and successful knockouts 
transduced to a fresh WT SL1344 strain using P22 (see section 2.2.16.2).  
 
2.2.16.2 P22 Transduction 
 
Confirmed knockout mutants were transduced into a fresh wild type SL1344 background 
using P22 phage transduction. 
2.2.16.2.1 P22 Lysate production 
 
To prepare lysates of SL1344 ΔtolR or ΔmlaA, 10µl of P22 phage lysate was added to a 10ml 
LB with 50µg/ml kanamycin, of each of the knockout strains and grown overnight at 37°C with 
shaking at 200RPM. The following day, a few drops of chloroform were added and the culture 
forcefully shaken in order to release the phage from the now lysed cells. The solution was 
then divided into microcentrifuge tubes and centrifuged at 16060 x g for 3 minutes. The 
resulting supernatant was then removed and a few drops of chloroform added before filter 
sterilisation with 0.22µm syringe filters (Sartorius). The lysate was stored in sterile glass 
universal tubes at 4°C until required for transduction. 
 
2.2.16.2.2 Transduction 
 
The fresh wild type SL1344 strain was grown overnight in 5ml LB at 37°C with shaking at 
200RPM. The following day, 1ml of this culture was removed and centrifuged at 16060 x g for 
1 minute. The pellet was resuspended in 100µl of LB broth and 10µl of the P22 lysate (see 
section 2.2.16.2.1) was added and the mixture incubated at room temperature for 30 
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minutes. As a control a sample of wild type SL1344 was subject to the same conditions but 
without the addition of P22. 1ml of warm LB broth was then added to each sample before 
incubation at 37°C for 30 minutes. The cells were then once again centrifuged at 16060 x g 
for 1 minute and the pellet resuspended in 100µl of LB broth. This was then spread onto LB 
agar plates with 50µg/ml kanamycin and incubated overnight at 37°C. 
 
2.2.16.2.3 Evans-Blue-Uranine (EBU) plates to remove P22 phage 
 
A number of kanamycin resistant colonies of transduced SL1344 were picked from the LB agar 
plates and streaked onto EBU plates containing 50µg/ml kanamycin. The following day, 
cultures were checked for their colour; dark colonies still had phage present and light colonies 
were phage-free. The phage-free colonies were then screened with colony PCR to determine 
successful knockouts. 
 
2.2.16.3 FLP recombination with pCP20 
 
Phage-free SL1344 ΔtolR or ΔmlaA strains were then made electro-competent to allow 
transformation of the pCP20 plasmid, expressing FLP-recombinase. This resulted in 
recombination between the two FRT sites and the subsequent removal of the KanR gene.  
The strains containing pCP20 were grown overnight with 50µg/ml ampicillin at 30°C with 
shaking at 200RPM. The following day, the culture was diluted 1:100 in 100ml LB and grown 
to OD600 0.1, still at 30°C. The culture was then shifted to 42°C and grown until OD600 0.8 – 1, 
to cure the strain of the heat-sensitive pCP20 plasmid. This culture was then streaked onto 
an LB agar plate and grown overnight at 37°C.  
To confirm that the strain has been cured of the pCP20 plasmid, single colonies from the 
above plate were patched onto three separate LB agar plates; one with 50µg/ml ampicillin, 
one with 50µg/ml kanamycin and one with no antibiotics. The strains which are sensitive to 
both ampicillin and kanamycin should be successful knockout strains, cured of pCP20. 
 These colonies were then once again checked using colony PCR and DNA sequencing 
(Eurofins) to confirm successful knockout of tolR or mlaA genes. 
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2.2.17 Fractionation of Outer Membrane Vesicles  
Cells were grown overnight with shaking at 37°C in 5ml LB broth with appropriate antibiotics. 
The following day, cells were diluted 1:100 in LB broth with appropriate antibiotics, and grown 
at 37°C with shaking to OD600 0.2. Cells containing either of the pBAD plasmids were then 
induced with L-arabinose to a final concentration of 0.2%. The cells were then left to continue 
growing to OD600 1. Cells were centrifuged twice at 3220x g at 4°C and the supernatant filtered 
with 0.22µm Stericup-GV Sterile Vacuum Filtration System (Merk Millipore). The cell pellet 
was retained and used for SDS-PAGE and western blot analysis.  
The supernatants were then ultracentrifuged at 100,000 X g for 2 hours at 4°C and the 
resultant pellet was resuspended in 1ml sterile PBS before filter sterilising with 0.22µm 
syringe filters (Sartorius). 
The OMV fraction in PBS was then prepared with appropriate loading buffer for SDS-PAGE 
and western blot. 
2.2.18 Negative staining Transmission Electron Microscopy of Salmonella Outer Membrane 
Vesicles   
5µl of purified OMV sample in PBS was adsorbed onto 300 mesh copper Formvar/carbon 
coated grids for 5 minutes. The grids were washed with drops of distilled water and dried with 
filter paper (Whatman). Grids were then treated 2% uranyl acetate in distilled water for 1 
minute then blotted as above with filter paper and air dried. OMVs were observed with a 
Philips CM100 Transmission Electron Microscope operating at 100kV, recording electron 
micrographs at magnifications of 46000X and 92000X. EM images were acquired by Tracey 
Davey (Newcastle University Electron Microscopy Research services). 
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Chapter 3 - Expression of Ebola GP in Salmonella and evaluation of immune 
response in vaccinated hosts 
 
The Ebola Virus is a deadly and highly virulent pathogen which has become well known in 
recent years due to large scale catastrophic outbreaks which highlighted the urgent need for 
an effective vaccine. Mostly problematic in poor African countries, a vaccine to protect 
against Ebola Virus would need to be cost effective as well as widely accessible in remote 
areas. The Glycoprotein (GP) is situated on the virus surface and is a major target for 
protective and neutralising antibodies. Using attenuated Salmonella vaccine strains to 
express and deliver the GP protein to the host immune system, could elicit these protective 
antibodies and be an affordable and easy to administer vaccine to prevent outbreaks on such 
a scale from occurring in the future. 
 
3.1 Generating a panel of GP expression constructs 
 
The Ebola virus glycoprotein (GP) is the major component of the viral surface and has been 
shown elicit protective neutralising antibodies (Lee & Saphire, 2009). This makes it an 
attractive target for use in a vaccine. It is hoped that using attenuated Salmonella 
Typhimurium to express GP or sub fragments of GP, this may elicit this protective response 
after these antigens are delivered to the immune system by the Salmonella. These gene 
fragments were first amplified by PCR and subsequently cloned into an expression vector 
using restriction enzymes and T4 ligation. 
3.1.1 Synthetic codon optimised Ebola GP gene 
 
A Synthetic Ebola GP gene was codon optimised for expression in Salmonella Typhimurium. 
By generating a synthetic Ebola gene sequence, using ‘GENEius’, the propriatory gene 
optimisation software of Eurofins Genomics, codons which are most frequently used by 
Salmonella Typhimurium were picked and unwanted sequences avoided. It was hoped that 
this would give the best chance of good levels of Ebola GP expression in the attenuated 
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vaccine strains. The wild type gene sequence was sent to Eurofins and was subsequently used 
to create the synthetic gene. The parameters for codon optimisation used by Eurofins are 
described in chapter 1, section 1.6.1.1. 
 
 
 
Figure 3.1. Map of the synthetic Ebola GP gene, including overlapping sub sections 1-4. Primers were 
designed to amplify the full-length Ebola GP, but devoid of the hydrophobic signal and transmembrane 
sequence and also 4 evenly sized sub fragments (sections 1-4). These PCR products were then cloned 
into the pTECH2 expression vector and once confirmed, checked for GP expression. Size of synthetic 
GP – 1854bp. Size of sub fragments - 1 (504 bp) 2 (504bp),3 (498bp), and 4 (459bp). 
 
3.1.2 PCR amplification of Ebola GP and sub-fragments 
 
Primers were designed to PCR amplify specifically demarcated regions of the Ebola GP gene 
(see figure 3.1), to determine whether smaller fragments (approximately equal sized) would 
be expressed better than the full-length GP. The PCR products from these reactions were then 
fractionated on a 0.7% agarose gel and visualised using UV light. Primers contained specific 
restriction sites allowing for cloning into the pTECH2 expression vector following digestion. 
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Figure 3.2. Plasmid map of the pTECH2-GP expression vector. Under the control of the nirB promoter, 
a TetC-GP fusion protein is expressed. The GP gene was cloned in using restriction enzymes XbaI and 
HindIII. Colony PCR was carried out on Salmonella Typhimurium SL5338 colonies after transformation 
using the pTETnir15 screening primers as shown to confirm putative clones containing the plasmid 
prior to expression analysis. Each of the smaller gene sections 1-4, as shown in figure 3.1 above (not 
pictured here), were cloned in place of the full GP gene to allow expression of shorter TetC-GP fusions. 
Plasmid map was made using the commercial software Snapgene. 
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3.1.2.1 PCR amplification of full synthetic Ebola GP 
 
First, the full synthetic GP gene was amplified, giving a PCR product as expected of 1854bp 
(figure 3.3). This was the sequence of the full wild type Ebola GP, but devoid of the 
hydrophobic signal and transmembrane sequences at the N and C termini respectively. 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. PCR amplification of synthetic GP. 0.7% agarose gel showing the PCR product of the 
synthetic GP gene, devoid of the hydrophobic signal and transmembrane sequences (lane 2) when 
amplified with corresponding primers containing restriction cloning sites for XbaI and HindIII (denoted 
by arrow). Lane 1 shows the pTECH2 vector, digested with XbaI and HindIII in preparation for ligation. 
 
The 1854bp GP PCR product was then subsequently digested with XbaI and HindIII, spin 
column purified, and cloned into digested pTECH2 plasmid. 
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3.1.2.2 PCR amplification of Synthetic Ebola GP sub fragments 1-4 
 
Since it has proved difficult for many groups to express the full-length Ebola GP in bacterial 
cells (Das et al, 2007; Zai et al, 2016) as an alternative strategy, it was then decided to generate 
constructs to attempt to express smaller sub-fragments of the Ebola GP gene, as this may 
facilitate expression of smaller defined proteins which may lack toxicity for the host cells. 
First, the gene was split into four roughly even approximately 500bp sections, 1 (504 bp) 2 
(504bp), 3 (498bp), and 4 (459bp) (figure 3.4).  
 
 
Figure 3.4. PCR amplification of synthetic GP sections 1-4. 0.7% agarose gel showing the PCR products 
of the synthetic GP gene split into 4 approximately equal sections. A1 - Synthetic GP section 1 (504bp), 
A2 - Synthetic GP section 2 (504bp), B1 – Synthetic GP section 3 (498bp), B2 – Synthetic GP section 4 
(459bp). These products were subsequently digested with XbaI and HindIII, spin column purified, and 
cloned into digested pTECH2 plasmid. 
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3.1.3 Generation of pTECH2-GP constructs  
 
The pTECH2 expression vector is derived from the pTETnir15 vector (Khan et al 1994 a; Khan 
et al 1994b). Under the control of the anaerobically inducible nirB promoter, the C-fragment 
of Tetanus toxin (TetC) is expressed. Guest antigen genes, such as Ebola GP can be cloned into 
the multiple cloning site following a flexible hinge region to allow expression of a TetC-antigen 
fusion protein. The Ebola GP gene and sub-fragments were successfully cloned into this vector 
with restriction cloning and T4 DNA ligation.   
The mix from the ligation reaction was then transformed into the intermediate Salmonella 
Typhimurium strain SL5338 (r- m+). Colony PCR was performed on selected colonies to screen 
for putative recombinants. Screening primers flanking the cloning site of pTECH2 were 
designed to allow visualisation of successful insert cloning as this would result in a larger 
colony PCR product than if it were not present, a negative colony with no insert gives a PCR 
product of 543bp and those with the insert included are 543bp plus the insert size. The 
plasmid DNA from putative positive clones were then purified and digested with the cloning 
restriction enzymes to further confirm the presence of an insert of the correct size. Plasmids 
from putative clones determined by both of these methods were then sent for DNA 
sequencing (Eurofins), using the same oligonucleotide primers as in the colony PCR screen. 
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3.1.3.1 Construction of pTECH2-GP expression plasmid 
 
The 1854 bp Ebola GP PCR product was cloned into the multiple cloning site of the pTECH2 
vector using restriction enzymes XbaI and HindIII and ligation with T4 ligase. Colony PCR using 
pTECH2 vector screening primers (see table 2.9, chapter 2) and restriction enzyme digests and 
agarose gel fractionation of the resultant plasmid after transformation into SL5338 cells 
confirmed successful cloning (figure 3.5).  
 
Figure 3.5. Colony PCR and restriction digest screens of putative pTECH2-GP clones. A) 0.7% agarose 
gel showing PCR products from colony PCR using pTECH2 screening primers to determine successful 
construction and transformation of the pTECH2 vector containing the 1854bp Synthetic GP into 
SL5338 Salmonella strain. Following transformation, colonies 1-19 (as shown on gel) were boiled 
before PCR amplification of the plasmid between each screening primer. Positive colonies which have 
successfully taken up the plasmid pTECH2 GP show a band at approximately 2.3kb (denoted by 
arrows). Colonies which have only taken up pTECH2 show a band at approximately 543bp. The agarose 
gel here is overloaded with sample, causing a rippling effect, however the differences in size between 
the samples are clearly apparent. 
B) 0.7% agarose gel showing purified plasmid from positive colonies (see arrows on figure 3.5 A) 
digested with XbaI and HindIII, showing an insert band of 1854bp which corresponds to the size of the 
PCR product for the Ebola GP gene. Positive plasmids were then sent for DNA sequencing using 
pTETnir15 (pTECH2) screening primers. 
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3.1.3.2 Construction of pTECH2-GP sub sections 1-4 expression plasmids 
Smaller fragments of the GP gene were cloned into the pTECH2 vector in the same way as the 
full-length GP. Successful cloning was determined again by colony PCR with the pTECH2 
screening primers and restriction enzyme digestion. Here, also with the cloning enzymes XbaI 
and HindIII (figure 3.6). 
Figure 3.6. Colony PCR and restriction digest screens of putative pTECH2-GP 1-4 clones.               
A) 0.7% agarose gel showing PCR products from colony PCR using pTECH2 screening primers to 
determine successful construction and transformation of the pTECH2 vector containing the 500bp 
Synthetic GP sections 1, 2, 3 and 4 into SL5338 Salmonella strain. Following transformation, colonies 
1-19 (as shown on gel) were boiled before PCR amplification of the plasmid between each screening 
primer. Positive colonies which have successfully taken up the plasmid pTECH2 GP show a band at 
1000bp. Colonies which have only taken up pTECH2 show a band at approximately 543bp. The agarose 
gels here are overloaded with sample, causing a rippling effect, however the differences in size 
between the samples are clearly apparent. B) 0.7% agarose gel showing purified plasmid from positive 
colonies (see figure 3.6 A) digested with XbaI and HindIII, showing an insert band of 500bp which 
corresponds to the size of the PCR product for each of these four Ebola GP sections. P is an uncut 
plasmid control. Positive plasmids were then sent for sequencing using the same screening primers as 
above. 
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3.1.4 Expression of TetC-GP fusion proteins in Salmonella intermediate strain SL5338 (r– m+) 
 
Once the plasmid constructs of pTECH2-GP (or pTECH2-GP sub fragments 1-4) had been 
confirmed by colony PCR and informative digest (see figures 3.5 and 3.6), it then needed to 
be determined whether these could be used to express the TetC Ebola GP fusion protein in 
Salmonella. Chemical transformation of the plasmid into intermediate Salmonella strain 
SL5338 resulted in expression of these fusion proteins in bacterial culture. 
To ensure that each sample contained an equivalent amount of cells, a dilution calculation 
was carried out using the OD600 of overnight cultures. Cell lysates were resuspended in 
varying amounts of PBS TX-100, depending on the OD600 value, and the same volume was 
taken from each of these diluted samples for preparation for SDS-PAGE. For the relevant 
calculations, please refer to Chapter 2, section 2.2.9.1. 
 
3.1.4.1 Expression of TetC-GP fusion protein  
 
The TetC-GP fusion protein expressed from the plasmid pTECH2-GP can be detected by 
polyclonal anti-TetC sera. The TetC protein is approximately 52 kDa in size and the GP protein 
(minus the hydrophobic N and C termini) is approximately 67 kDa. The resultant fusion protein 
is therefore approximately 121 kDa (figure 3.7). Other bands seen below the fusion protein, 
indicate either breakdown products or premature termination of translation, particularly 
where a band appears which is the same size as the TetC protein. This is not necessarily 
concerning as these may still contain important immunological epitopes of the GP protein 
(see figure 3.7). The full TetC-GP fusion band, appears to be relatively faint however, so this 
needs to be addressed to allow for adequate antigen availability during immunisation. 
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Figure 3.7. Expression of TetC-GP fusion protein. Western blot showing expression of TetC-GP fusion 
protein in cell lysates of 4 clones of Salmonella Typhimurium SL5338. The fusion is present as a band 
at approximately 121 kDa (shown by arrow). Bands below this indicate either fusion protein 
breakdown products or premature termination of translation, giving a ‘ladder effect’. Blots were 
probed with polyclonal rabbit anti-TetC serum (1:1000) and Goat anti-rabbit HRPO (1:2000). As a 
positive control, SL5338 cells harbouring only the PTECH2 plasmid were used. This gives a single TetC 
band at approximately 52 kDa (denoted by lane marker +). The blot was developed with 4-chloro-1-
napthol. 
 
 
3.1.4.2 Expression of TetC-GP sub fragments 1-4 fusion proteins 
 
After expression of the TetC-GP fusion protein was confirmed by western blot, the smaller 
sub fragments (each encoded by an approximately 500bp DNA cassette) were tested to 
determine if a smaller sized DNA cassette improved the expression levels of the fusion 
protein. Each sub-fragment was approximately 18 kDa, so the fusion with the 52 kDa TetC 
shows a band at approximately 70 kDa (see figure 3.8) It appears that while each of the four 
fusion proteins are expressed, there is variation between the sub fragments. The full fusion 
proteins are nowhere near as highly expressed as the TetC. There is an additional unexpected 
band the size of TetC which may be due to the premature termination of translation 
immediately after the TetC has been translated, possibly due to the toxicity of the GP protein. 
 
 
 
88 
 
 
Figure 3.8. Expression of TetC-GP 1-4 fusion proteins. Western blot showing expression of TetC-GP 
sub fragments fusion proteins 1-4 in cell lysates of 4 clones of Salmonella Typhimurium SL5338. The 
fusions are present as a band in each blot at approximately 70kDa (shown by arrow).  
Blots were probed with polyclonal rabbit anti-TetC serum (1:1000) and Goat anti-rabbit HRPO 
(1:2000). As a positive control, SL5338 cells harbouring only the PTECH2 plasmid were used. This 
gives a single TetC band at approximately 52 kDa (denoted by +). Blots were developed with 4-
chloro-1-napthol. 
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3.2 Generating a panel of GP expression constructs with important immunological features 
– ‘GP version 2’ 
 
Due to the fact that the expression levels of the TetC-GP fusion proteins appeared to be less 
than what is hoped for, especially in relation to the levels at which TetC is expressed, it was 
decided to get a new synthetic GP gene synthesised to see if a sequence using codons 
determined by an alternative algorithm, Genscript’s OptimumGeneTM, would facilitate better 
expression. OptimumGeneTM appears to use a wider variety of parameters than the Eurofins 
GENEius software, optimising transcription, translation and protein folding (see footnote 2). 
It was also decided that instead of evenly sized GP sub fragments, which did not seem to have 
improved expression compared to the full-length protein, the GP gene would be demarcated 
into sub fragments which were known to contain important immunological features (figure 
3.9). These included known protective epitopes, sections which had been successfully 
expressed in bacterial cells (see section ‘D’) (Das et al, 2007), contained highly immunogenic 
regions (see section 3.2.1.3, MFL) (Wang et al, 2014), and also the area with the lowest 
concentration of hydrophobic residues (see section 3.2.1.4, LH). 
These new sub fragments and the full GP were successfully cloned into the pTECH2 expression 
vector and subsequently expressed in Salmonella. Hereafter, only this ‘version 2’ GP sequence 
was used and therefore will be referred to simply as GP. For primers see Chapter 2 section 
2.1.8 table 2.7 where the previous GP sequence is referred to as GP (v1), and this as GP.  
 
 
 
 
                                                     
2 Note: for details on OptimumGeneTM, see https://www.genscript.com/codon-opt.html 
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Figure 3.9. Map of the Ebola glycoprotein gene and sub fragments containing important 
immunological epitopes. The full-length synthetic GP is 1854bp long as is devoid of the wild type’s 
hydrophobic signal and transmembrane sequences. The locations of the four sub fragments are 
shown, D, MFL, LH and a ‘mini-gene’ which incorporates both the D and MFL sub fragments. Locations 
of known protective epitopes are shown in yellow (Qiu et al, 2011) (see section 3.3.1.1 Conservation 
of known protective epitopes in Ebola GP). Made using the commercial software Snapgene. 
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3.2.1 PCR amplification of Ebola GP and sub-fragments 
 
In the same way as above, the new synthetic GP gene was used and with primers specific to 
the full GP or various sub fragments, was PCR amplified and digested for subsequent 
restriction cloning into the pTECH2 expression vector (figure 3.10). A panel of constructs was 
created to enable evaluation of which expressed the GP protein best and would then be taken 
forward into in vivo testing (figure 3.11). 
 
 
Figure 3.10. Plasmid map of the pTECH2-GP expression vector. Under the control of the nirB 
promoter, a TetC-GP fusion protein is expressed. The GP gene was cloned in using restriction enzymes 
EcoRV and HindIII. Colony PCR was carried out on Salmonella Typhimurium SL5338 colonies after 
transformation using the pTETnir15 screening primers as shown to confirm putative clones containing 
the plasmid prior to expression analysis. Each of the gene sub fragments (not pictured here) as shown 
in figure 3.11 below were cloned in place of the full GP gene to allow expression of shorter TetC-GP 
fusions. Plasmid map was made using the commercial software Snapgene. 
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Figure 3.11. TetC-Ebola GP fusion protein constructs. Schematic presentation of the panel of Ebola 
GP fusion protein constructs generated in this study. Under the control of the nirB promoter, the full-
length Ebola GP (devoid of hydrophobic signal and transmembrane sequences) and sub fragments 
thereof were expressed either as a fusion to the C-fragment of Tetanus Toxin (TetC), alone, or as a 
fusion to the full TetC ribosome binding site (RBS) in the pTECH2 expression vector in Salmonella 
Typhimurium. The TetC and Ebola GP fragments are separated by a flexible hinge, Gly Pro Gly Pro 
motif, which allows temporal and spatial separation between the two components to allow time for 
correct folding. 
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3.2.1.1 Synthetic Ebola GP (V2) 
 
The new synthetic GP gene was amplified as above, using primers to remove the hydrophobic 
signal and transmembrane sequences at the N and C termini, giving a PCR product as expected 
of 1854bp. This PCR reaction also resulted in a smaller band showing at approximately 300bp. 
This could be due to the primers binding elsewhere on the gene sequence. This was rectified 
using gel extraction of DNA, where the correct top 1854bp band was excised and purified 
after digestion with the cloning restriction enzymes (see figure 3.12). 
 
 
 
 
 
 
 
Figure 3.12. PCR amplification of synthetic GP (V2). 0.7% agarose gel showing the 1854bp PCR 
product of the ‘version 2’ full synthetic Ebola GP gene (1) when amplified with corresponding primers 
containing restriction cloning sites. This product was subsequently gel purified due to the presence of 
an extra band shown at approximately 300bp. It was then digested with the appropriate restriction 
enzymes, EcoRV and HindIII, spin column purified, and cloned into digested pTECH2 plasmid. 
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3.2.1.2 PCR amplification of GP Sub-fragment ‘D’  
 
The full-length Ebola GP has proved challenging for many groups to express in bacterial cells, 
particularly E. coli (Das et al, 2007; Zai et al, 2016) A sub fragment of the full-length wild type 
GP protein however, has been expressed at high levels in E. coli (Das et al, 2007). The ‘D’ gene 
sub fragment is 633bp (figure 3.13) and contains residues 157-368 of the GP protein, including 
some known protective epitopes.  
 
 
 
 
 
 
 
 
 
Figure 3.13. PCR amplification of synthetic GP sub fragment D. 0.7% agarose gel showing the 633bp 
PCR product ‘D’ Sub fragment of the synthetic Ebola GP gene (1) when amplified with corresponding 
primers containing restriction cloning sites. This product was subsequently digested with BamHI and 
HindIII, spin column purified, and cloned into into the digested pTECH2 plasmid (see figure 3.10) 
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3.2.1.3 PCR amplification of GP Sub-fragment ‘MFL’  
 
Sub fragment MFL is a highly immunogenic region, containing the mucin like domain (M) and 
fusion loop (FL) of the full GP. The wild type version has been shown to induce humoral and 
cellular immune responses and elicit neutralising antibodies towards this sub fragment (Wang 
et al, 2014). The ‘MFL’ gene sub fragment is 489bp (figure 3.14). 
 
 
 
 
 
 
 
 
 
 
Figure 3.14. PCR amplification of synthetic GP sub fragment MFL. 0.7% agarose gel showing the 
489bp PCR product ‘MFL’ Sub fragment of the synthetic Ebola GP gene (1) when amplified with 
corresponding primers containing restriction cloning sites. This product was subsequently digested 
with BamHI and HindIII, spin column purified, and cloned into the digested pTECH2 plasmid (see figure 
3.10). This construct was made in collaboration with Bethany Gollan, a Masters student supervised by 
myself in the Khan laboratory.  
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3.2.1.4 PCR amplification of GP Sub-fragment ‘LH’  
 
There are potential difficulties encountered when expressing hydrophobic proteins, due to 
their tendency to aggregate, lower solubility and toxicity (Montigny et al, 2004). Therefore, a 
low hydrophobicity sub-fragment of Ebola GP was chosen using a Kyte-Doolittle Hydropathy 
plot (figure 3.15). It was thought that this sub-fragment which still contained some known 
epitopes may have improved expression, compared to its more hydrophobic counterparts. 
Gene sub fragment LH is 873bp (figure 3.16). 
 
 
 
 
 
 
 
 
 
Figure 3.15 Kyte-Doolittle Hydrophobicity plot of the synthetic GP gene. The LH (low hydrophobicity) 
sub-fragment, containing the lowest concentration of hydrophobic residues is situated between 
residues 155 and 444.  
 
 
155 444 
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Figure 3.16. PCR amplification of synthetic GP sub fragment LH. 0.7% agarose gel showing the 873bp 
PCR product ‘LH Sub fragment of the synthetic Ebola GP gene (1) when amplified with corresponding 
primers containing restriction cloning sites. This product was subsequently digested with BamHI and 
HindIII, spin column purified, and cloned into the digested pTECH2 plasmid. 
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3.2.1.5 PCR amplification of GP Sub-fragment ‘D-MFL’  
 
Since the wild type D and MFL sub fragments have been shown to be expressed in E. coli (Das 
et al, 2007; Wang et al, 2014), it was then decided to make a ‘mini gene’ combining ‘D’ sub 
fragment, which had been shown to express in bacterial cells (Das et al, 2007) and the 
adjacent highly immunogenic sub fragment ‘MFL’, which contains important immunological 
epitopes. It is hoped that that this mini gene allows for high expression of the protein and 
elicits a protective immune response in vaccinated hosts, due to the epitopes it contains. The 
D-MFL sub fragment is 1201bp (figure 3.17). 
 
 
 
 
 
 
 
 
Figure 3.17. PCR amplification of synthetic GP sub fragment D-MFL.  0.7% agarose gel showing the 
1201bp PCR product ‘D-MFL’ Sub fragment of the synthetic Ebola GP gene (1) when amplified with 
corresponding primers containing restriction cloning sites. This product was subsequently digested 
with BamHI and HindIII, spin column purified, and cloned into the digested pTECH2 plasmid. Although 
the agarose gel here is overloaded with sample the approximate 1201bp size of the band is apparent. 
This construct was made in collaboration with Bethany Gollan, a Masters student supervised by myself 
in the Khan laboratory. 
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3.2.2 Generation and expression of Ebola GP constructs, without TetC 
 
In an attempt to evaluate the contribution of TetC to expression levels, a construct with the 
TetC gene deleted was made; pTECH10-GP (see figure 3.18).  
 
3.2.2.1 Construction of pTECH10-GP expression plasmid 
 
Primers were designed to allow inverse PCR, using Q5 site directed mutagenesis (NEB), to 
remove the TetC region of the pTECH2-Synthetic GP and insert a start codon at the beginning 
of the GP gene. This vector is designed to only express the synthetic GP as opposed to a TetC-
GP fusion. Following chemical transformation into NEB5α E. coli cells (NEB), plasmid DNA from 
putative clones were purified and digested with the cloning restriction enzymes to visualise 
the GP insert on an agarose gel (see figure 3.19). Once the identity of the construct was 
confirmed, plasmid DNA was chemically transformed into Salmonella Typhimurium SL5338 
cells. The construct was then further verified with DNA sequencing (Eurofins Genomics). 
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Figure 3.18. Plasmid map of the pTECH10-GP expression vector. This vector was constructed using 
Q5 Site Directed Mutagenesis (NEB) using the forward (FWD) and reverse (REV) primers shown. 
Inverse PCR allowed the removal of the TetC gene from the pTECH2-GP plasmid. Expression of Ebola 
GP is under the control of the nirB promoter and is expressed alone, without TetC as a fusion partner. 
Plasmid map was made using the commercial software Snapgene. 
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Plasmid DNA was purified from SL5338 cells after transformation of pTECH10-GP and digested 
with EcoRI and HindIII to ensure that the GP gene was present but the TetC was not. A band 
co-migrating with the synthetic GP PCR product shows that a band of the expected size for 
GP was present (see figure 3.19). A restriction fragment DNA band corresponding to the 
remainder of the plasmid itself is also present as expected, and is smaller in size than that of 
pTECH2-GP, suggesting that the TetC gene has been successfully deleted. Purified plasmid 
was then sent for DNA sequencing (Eurofins) for verification. 
 
  
 
 
 
 
 
 
 
Figure 3.19. Restriction digest screens of putative pTECH10-GP clones. 0.7% agarose gel showing 
purified plasmid from 5 colonies of NEB5α E. coli suspected to contain the pTECH10-GP plasmid. The 
plasmid was digested with EcoRI and HindIII showing an insert band of 1854bp which co-migrated with 
the PCR product for the Ebola GP gene (labelled GP). The correct plasmid was then sent for sequencing 
(Eurofins) and once confirmed, transformed into Salmonella Typhimurium SL5338 cells for expression 
analysis. 
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3.2.2.2 Expression of Ebola GP alone in Salmonella strain SL5338 
 
With confirmation that the plasmid pTECH10-GP had been constructed, it was then necessary 
to determine whether the Ebola GP could be expressed alone, without the TetC fusion 
partner. It appeared however that when probed with an anti-Ebola GP antibody there was no 
evidence of GP expression from SL5338 cell lysates containing the pTECH10-GP construct (see 
figure 3.20). Therefore, it seems that it is not possible to express Ebola GP alone in this system 
with no fusion partner. This could be due to the toxicity of the GP protein and thus the TetC 
may allow some detoxification when used as a fusion partner, and at least some of this is 
necessary for GP expression. 
 
 
 
 
 
 
 
 
Figure 3.20. Expression of Ebola GP alone in Salmonella Typhimurium. Western blot to determine 
whether the plasmid pTECH10-GP is able to express Ebola GP in SL5338 cells with no fusion partner. 
Each lane contains cell lysates of Salmonella Typhimurium SL5338 with no plasmid (1), pTECH2 only 
(2), pTECH2-GP as a positive control (+) and pTECH10-GP. Blots were probed with polyclonal mouse 
anti-EBOV sera (From a C57BL/6 mouse which had survived Ebola virus challenge after treatment with 
monoclonal antibody 5E6) and Rabbit anti-mouse HRPO secondary antibody (Abcam). It is evident that 
there is no expression of GP from the pTECH10-GP plasmid which would show a band at approximately 
69kDa. pTECH2-GP on the other hand, allows clear expression of a TetC-GP fusion protein, showing a 
band as expected at approximately 121kDa (+), denoted by arrow. The blot was developed with 4-
chloro-1-napthol. 
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3.2.2.3 Construction of pTECH11-GP expression plasmid – Retention of the TetC ribosome 
binding site (RBS)  
 
With the lack of Ebola GP expression from the pTECH10-GP construct, it was decided that 
retaining a small part of the TetC gene which could include the full ribosome binding site (RBS) 
may help with expression. The RBS is a region in the mRNA transcript, including the Shine-
Dalgarno sequence situated upstream of the start codon (AUG), and encompasses some of 
the mRNA coding sequence downstream of the start codon between bases 1 and 18 (codons 
1-6), this could be responsible for stabilisation of the Salmonella ribosomal RNA and 
translated mRNA complex during translation (Etchegaray & Inouye, 1999). This construct – 
pTECH11-GP was made in the same way as above, using Q5 site directed mutagenesis, 
however the first 10 amino acids (30 bases) of TetC were retained. This included the whole 
RBS of TetC, including the 5’ UTR and Shine-Dalgarno sequence, necessary for regulation of 
protein synthesis. It has been postulated that when an mRNA sequence, named the 
‘Downstream box’, situated downstream of the initiation or start codon, has some 
complementarity to bases 1534-1542 at the 3’ end of the 16S ribosomal RNA (rRNA), it could 
act to enhance translation, with greater enhancement relating to greater complementarity 
with that section of the 16S rRNA. It is thought that the formation of the translation initiation 
complex could be brought about first by interaction between the 16S rRNA and the Shine-
Dalgarno sequence, and then the ribosome-mRNA interaction is further stabilised by the 
pairing between the downstream box and its complementary 16S ribosomal RNA sequence 
(Etchegaray & Inouye, 1999). Therefore, this improved expression of the GP protein could be 
due to an increase in complementarity between the TetC mRNA just downstream of the start 
codon, and the Salmonella 16S rRNA. 
Another smaller construct was also made which instead of the whole GP gene, a truncated 
version starting at residue 155 was used. From examining the hydrophobicity plot of the Ebola 
GP (see figure 3.15) it was evident that the middle portion of the protein contained the area 
of lowest hydrophobicity. Starting at P155, it is possible that this truncated version of 
Synthetic GP may be more easily expressed due to the lack of a large area of hydrophobic 
residues. Using Q5 site directed mutagenesis as above, all but the first 10 residues of TetC and 
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the remainder of GP after P155, resulted in the plasmid pTECH11-GP (155) confirmed once 
again by restriction digest using EcoRI and HindIII (figures 3.21 and 3.22). 
 
Figure 3.21. Plasmid map of the pTECH11-GP/GP (155) expression vector. This vector was 
constructed using Q5 Site Directed Mutagenesis (NEB) using the forward (FWD) and reverse (REV) 
primers shown. Inverse PCR allowed the almost complete removal of the TetC gene, apart from the 
first 10 amino acids, from the pTECH2-GP plasmid. Expression of Ebola GP is under the control of the 
nirB promoter and is expressed with the RBS of TetC as a small fusion partner. Plasmid map was made 
using the commercial software Snapgene. 
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Figure 3.22. Restriction digest screens of putative pTECH11-GP/GP (155) clones. 0.7% agarose gel 
showing purified plasmid from 5 colonies of NEB5α E. coli suspected to contain the pTECH11-GP or 
pTECH11-GP (155) plasmid. The plasmid was digested with EcoRI and HindIII showing an insert band 
of 1854bp (full GP, lanes 1, 2 and 3) or 1389bp (GP 155, lanes 4, 5 and 6) as denoted by arrows. Bands 
corresponding to the size of the remainder of the plasmid are seen above as expected. The correct 
plasmids were then sent for sequencing (Eurofins) and once confirmed, transformed into Salmonella 
Typhimurium SL5338 cells for expression analysis. 
 
3.2.2.4 Expression of Ebola GP with TetC RBS in Salmonella strain SL5338 
 
With confirmation that the plasmids pTECH11-GP and pTECH11-GP (155) had been 
constructed (figure 3.22), it was then necessary to determine whether the Ebola GP could be 
expressed when only a small part of the TetC gene (the 10-amino acid or 30 base RBS) was 
present. Here, it appeared that SL5338 cell lysates containing these pTECH11-GP constructs 
probed with an anti-Ebola GP antibody, the addition of this RBS rescued expression of the GP 
protein, both full-length and truncated (see figure 3.23). Therefore, it seems that it is 
necessary to include the full TetC Ribosome Binding Site including the 30 bases downstream 
of the start codon to ensure that proper recruitment of all ribosome components and 
enzymes necessary for translation. It may be that the start of the synthetic GP gene sequence 
(which here is devoid of the hydrophobic and potentially toxic signal sequence) is suboptimal 
in maintaining stability of the ribosome and mRNA complex, as there could be less 
complementarity between the nucleotides downstream of the GP start codon, with the 
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Salmonella Typhimurium 16S ribosome. This could mean that the interaction between the 
mRNA and 16S rRNA is less stable and therefore the protein is unable to be expressed. 
 
 
 
 
 
 
 
 
Figure 3.23. Expression of Ebola GP with TetC RBS in Salmonella Typhimurium. Western blot to 
determine whether the plasmid pTECH11-GP and pTECH11 GP (155) are able to express Ebola GP in 
SL5338 cells with only the RBS of TetC retained. Each lane contains cell lysates of Salmonella 
Typhimurium SL5338 with no plasmid (1), pTECH2 only (2), pTECH2-GP as a positive control (3) 
pTECH11-GP (4) and pTECH11-GP (155) (5). Blots were probed with polyclonal mouse anti-EBOV sera 
(From a C57BL/6 mouse which had survived Ebola virus challenge after treatment with monoclonal 
antibody 5E6) (1:2000) and Rabbit anti-mouse HRPO secondary antibody (Abcam) (1:4000).  It is 
evident that there is expression of GP from both of the pTECH11 GP plasmids, but this is not as strong 
as the bands seen when GP is expressed with the full TetC protein (lane 3). The full GP plus the RBS of 
TetC is approximately 71Kda and the truncated GP protein which starts at p155, plus the TetC RBS, is 
approximately 54Kda (see arrows). The blot was developed with 4-chloro-1-napthol. 
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3.2.3 Screening putative clones after generation of pTECH2-GP expression plasmids (Colony 
PCR) 
 
It appears that the Ebola GP protein cannot be expressed in this system without at least a 
small fusion partner of the TetC RBS. It is clear that expression is increased when the full TetC 
is present, and therefore to maximise protein expression and thus antigen delivery, it was 
decided that the full TetC would be kept as a fusion partner. It could also act as built in 
adjuvant to enhance the immune response to the vaccine. The constructs described in section 
3.2 were therefore generated and expression was analysed by western blot to determine the 
best prospects to take forward for in vivo analysis of immune response.  
 
3.2.3.1 Construction of pTECH2-GP (v2) expression plasmid  
 
As with the previous pTECH2-GP construct, the expression plasmid containing the new, 
alternatively codon optimised GP (v2) was cloned into the pTECH2 plasmid by restriction 
cloning and ligation with T4 DNA ligase, followed by transformation into Salmonella SL5338. 
Single colonies were then picked, and colony PCR carried out using screening primers which 
were complimentary to inert flanking regions on pTECH2 (figure 3.24). This allowed 
visualisation of successful insertion of GP, as the PCR product shows a band at approximately 
2354bp, rather than 543bp as would be amplified by the screening primers with the ‘empty’ 
pTECH2 vector as a template. Restriction digest using the cloning enzymes and DNA 
sequencing on putative clones acted to further confirm the successful generation of the 
desired pTECH2-GP construct.  
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Figure 3.24. Colony PCR and restriction digest screens of putative pTECH2-GP (v2) clones.   A) 0.7% 
agarose gel showing PCR products from colony PCR using pTECH2 screening primers to determine 
successful construction and transformation of the pTECH2 vector containing the 1854bp Synthetic GP 
into SL5338 Salmonella strain. Following transformation, colonies 1-19 (as shown on gel) were boiled 
before PCR amplification of the plasmid between each screening primer. Positive colonies which have 
successfully taken up the plasmid pTECH2 GP (notably colony 2) show a band at 2354bp (denoted by 
arrow). Colonies which have only taken up pTECH2 show a band at approximately 543bp.  
B) 0.7% agarose gel showing purified plasmid from colony 2 (see figure 3.24 A) digested with EcoRV 
and HindIII, showing an insert band of 1854bp (lane 2, see arrow) which corresponds to the size of the 
PCR product for the Ebola GP gene (lane 1). This plasmid was then sent for sequencing using the same 
screening primers as described above 
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3.2.3.2 Construction of pTECH2-GP ‘D’ expression plasmid 
 
Again, following transformation of Salmonella SL5338 with the ligation reactions inserting the 
‘D’ fragment of the new optimised GP gene, colony PCR was used to screen for putative clones 
using screening primers as described above. Successful insertion of sub-fragment ‘D’, results 
in a band at approximately 1176bp (figure 3.25). 
 
 
 
 
 
 
Figure 3.25. Colony PCR screen of putative pTECH2-GP D clones.          
0.7% agarose gel showing PCR products from colony PCR using pTECH2 screening primers to 
determine successful construction and transformation of the pTECH2 vector containing the 633bp 
Synthetic GP section D into SL5338 Salmonella strain. Following transformation, colonies 1-8 (as 
shown on gel) were boiled before PCR amplification of the plasmid between each screening primer. 
Positive colonies which have successfully taken up the plasmid pTECH2 GP-D show a band at 
approximately 1176bp, as shown by arrow.  
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3.2.3.3 Construction of pTECH2-GP ‘MFL’ expression plasmid  
 
Transformation of Salmonella SL5338 with the ligation reactions inserting the ‘MFL’ fragment 
of the new optimised GP gene was followed by colony PCR to screen for putative clones using 
the screening primers as described above. Successful insertion of sub-fragment ‘MFL’, results 
in a band at approximately 1032bp (figure 3.26) 
 
 
 
 
 
 
 
Figure 3.26. Colony PCR screen of putative pTECH2-GP MFL clones.     
0.7% agarose gel showing PCR products from colony PCR using pTECH2 screening primers to 
determine successful construction and transformation of the pTECH2 vector containing the 489bp 
Synthetic GP section MFL into SL5338 Salmonella strain. Following transformation, colonies were 
boiled before PCR amplification of the plasmid between each screening primer. Positive colonies 
which have successfully taken up the plasmid pTECH2 GP-MFL show a band at approximately 1032bp, 
notably in lanes 2, 11 and 16 (denoted by arrows). The agarose gel here is overloaded with sample, 
causing a rippling effect, however the differences in size between the samples are clearly apparent 
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3.2.3.4 Construction of pTECH2-GP ‘LH’ expression plasmid 
 
Colony PCR was used to screen for putative clones using screening primers as described above 
following the transformation of Salmonella SL5338 with the ligation reactions inserting the 
‘LH’ fragment of the new optimised GP gene. Successful insertion of sub-fragment ‘LH’, results 
in a band at approximately 1416bp (figure 3.27) 
 
 
 
 
 
 
 
Figure 3.27. Figure 3.26. Colony PCR screen of putative pTECH2-GP LH clones.           
0.7% agarose gel showing PCR products from colony PCR using pTECH2 screening primers to 
determine successful construction and transformation of the pTECH2 vector containing the 873bp 
Synthetic GP section LH into SL5338 Salmonella strain. Following transformation, colonies were boiled 
before PCR amplification of the plasmid between each screening primer. Positive colonies which have 
successfully taken up the plasmid pTECH2 GP-LH show a band at approximately 1416bp, as shown by 
arrow. The agarose gel here is overloaded with sample, causing a rippling effect, however the 
differences in size between the samples are clearly apparent. 
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3.2.3.5 Construction of pTECH2-GP ‘D-MFL’ expression plasmid 
 
Salmonella SL5338 was transformed with the ligation reactions inserting the ‘D-MFL’ 
fragment of the new optimised GP gene, and colony PCR was used to screen for putative 
clones using screening primers as described above. Successful insertion of sub-fragment ‘D-
MFL’, results in a band at approximately 1743bp (figure 3.28) 
 
 
 
 
 
 
Figure 3.28. Figure 3.26. Colony PCR screen of putative pTECH2-GP DMFL clones.        
0.7% agarose gel showing PCR products from colony PCR using pTECH2 screening primers to 
determine successful construction and transformation of the pTECH2 vector containing the 1200bp 
Synthetic GP section DMFL into SL5338 Salmonella strain. Following transformation, colonies were 
boiled before PCR amplification of the plasmid between each screening primer. Positive colonies 
which have successfully taken up the plasmid pTECH2 GP-DMFL show a band at approximately 
1743bp, as shown by arrow. The agarose gel here is overloaded with sample, causing a rippling effect, 
however the differences in size between the samples are clearly apparent. 
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3.2.3.6 Informative digests of putative recombinant clones  
 
Following the selection of colonies which through colony PCR had shown to have successfully 
taken up the recombinant plasmids, containing the sub fragments of the Ebola GP gene, the 
plasmid DNA from these colonies was purified and digested with the appropriate cloning 
restriction enzymes to allow visualisation of an insert at the expected size for each sub 
fragment (figure 3.29). From this, plasmid DNA from clones which were deemed to contain 
the correct insert was sent for sequencing using the pTET screening primers as used in the 
colony PCR tests to confirm that each of the sub fragments had been inserted in frame and 
downstream of the nirB promoter to allow their expression.  
 
Figure 3.29. Restriction digest screens of putative recombinant pTECH2-GP sub fragment clones. 
0.7% agarose gel showing purified plasmid from SL5338 colonies deemed (through colony PCR) to 
contain the Ebola GP sub fragment inserts. Plasmid DNA from these colonies were digested with the 
restriction enzymes used to clone these inserts (BamHI and HindIII). Successful cloning of the inserts 
into the pTECH2 plasmid resulted in a band of equivalent size to drop out when digested and visualised 
on an agarose gel. A) Plasmid DNA from clones containing the LH (873 bp) or DMFL (1200bp) inserts 
with the corresponding PCR products shown alongside the digested plasmid inserts to confirm size. B) 
As with A, however using plasmid DNA from clones containing the D (633bp, labelled 1) or MFL (489bp 
labelled 2) inserts. PD – pTECH2 digested with BamHI and HindIII. PU – un-digested pTECH2 plasmid. 
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3.3 Expression of TetC-GP fusion proteins 
 
After a panel of constructs had been generated, expression analysis was carried out using 
western blot. Ensuring that each sample contained the same number of cells, calculated from 
the OD600 of overnight cultures, the expression levels of each construct could be determined 
and it could then be decided which to take forward, transform into vaccine strains and use in 
in vivo immunisations to determine immune response to Ebola GP.  
 
3.3.1 Expression of TetC-GP fusion proteins in Salmonella intermediate strain SL5338 
 
Firstly, to determine expression of the new Ebola GP a western blot was carried out on SL5338 
cell lysates harbouring either pTECH2 alone, pTECH2-GP or no plasmid. When probed with 
polyclonal anti-TetC serum it was evident that the TetC-GP fusion protein was being 
expressed as with the previous GP sequence. Again, the fusion protein was expressed at a 
lower level than TetC and there was still evidence of breakdown products or premature 
termination of translation as seen in the lower bands (TetC-GP is shown at approximately 
121kDa, see figure 3.30). It appears that with this alternatively optimised GP sequence, there 
are less of these lower bands present than as above with the first. This could suggest that 
there is less breakdown occurring. 
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Figure 3.30.  Expression of TetC-GP (v2) fusion protein Western blot showing expression of the TetC-
GP fusion protein or TetC alone, in cell lysates of clones of Salmonella Typhimurium SL5338. The top 
band is the TetC-GP fusion protein at approximately 121kDa (see arrow.) The blot was probed with 
polyclonal rabbit anti-TetC serum (1:1000) and Goat anti-rabbit HRPO (1:2000). The blot 
was developed with 4-chloro-1-napthol. 
 
After showing that the full new GP sequence was successfully expressed by Salmonella, it was 
then determined that the smaller constructs containing Ebola GP gene sub fragments should 
be tested for expression. A panel of various sub-fragment constructs was created to allow 
comparison of the expression levels, and therefore only take those which expressed the best 
through to the next stage of in vivo testing. Each sub-fragment was chosen for certain 
characteristics, either containing important immunological epitopes, has shown to be 
expressed previously in bacteria, or has a lower concentration of hydrophobic residues (figure 
3.31). 
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Figure 3.31. Expression of TetC-GP sub fragment fusion proteins.                
Western blot showing all TetC-GP fusion proteins expressed in Salmonella Typhimurium SL5388. Cell 
lysates were fractionated on SDS-PAGE gel, cell numbers were corrected to the OD600 of the 
overnight cultures to ensure equivalent amounts are in each sample. Both blots were probed with 
mouse polyclonal anti EBOV sera (1:2000) and a secondary Rabbit anti mouse HRPO (1:4000). A) 
SL5338 cells only and SL5338 harbouring pTECH2 only were used as negative controls (lanes 1, 2). 3) 
TetC-full GP fusion at approximately 121kDa. 4) TetC-GP DMFL fusion at approximately 97kDa. 5) TetC-
GP LH fusion at approximately 85kDa. 6) GP alone (no fusion) which did not express. 7) RBS of TetC 
fusion with GP at approximately 71kDa. 8) RBS of TetC fusion with truncated GP (155) at approximately 
54kDa (as shown by arrows. B) Comparison of GP D and MFL fragments with full GP and GP DMFL. 1) 
TetC-DMFL fusion at approximately 97kDa. 2) TetC-GP MFL fusion at approximately 70kDa (see arrow). 
3) TetC-GP D fusion at approximately 77kDa (see arrow). 4) TetC-full GP fusion at approximately 
121kDa. Blots were developed with 4-chloro-1-napthol. Constructs pTECH2-GP DMFL and pTECH2-
MFL were made in collaboration with Bethany Gollan, a Masters student supervised by myself in the 
Khan laboratory. 
 
 
B) 
A) 
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From these results it appears that when an equivalent number of cells are fractionated on an 
SDS-PAGE gel, and the expressed protein visualised by western blotting, the construct which 
allows greatest expression of the TetC-GP fusion protein, is that of pTECH2-GP DMFL. Sub 
fragment DMFL is a ‘mini-gene’ consisting of two sub fragments ‘D’ and ‘MFL’ which have 
been shown to express in E. coli and also contain important immunological epitopes (Das et 
a, 2007; Wang et al, 2014). It appears that this sub fragment expresses better than any of the 
others as a fusion to TetC. The two constituent parts of DMFL, sub fragments D and MFL, do 
express as a fusion to TetC, but at very low levels (see figure 3.31 B lanes 2 and 3). 
Expressing the GP protein alone, with no fusion partner, does not appear to be possible in 
this system. No expression of GP was seen from the cells harbouring the pTECH10-GP 
construct. Adding a small 10 amino acid fragment of TetC (the RBS), rescued this expression, 
although not to the levels seen with the full TetC fusion proteins.  
Antigen expression from Salmonella vaccine strains, must be optimised to ensure that a 
suitable antigenic dose is administered which can elicit a protective immune response. 
Therefore, the constructs which have shown to express the TetC-GP fusion proteins more 
efficiently, will be taken further for expression analysis in Salmonella vaccine strains and then 
in vivo, to allow the best chance of success.  
 
3.3.1.1 Conservation of known protective epitopes in TetC-Ebola GP fusion proteins 
 
Prior to testing these constructs for expression in Salmonella vaccine strains, further analysis 
was carried out to determine whether known protective epitopes were present in these 
fusion proteins. The ‘ladder’ effect of multiple bands seen in the western blot, suggests that 
there could be some breakdown of the fusion proteins.  Monoclonal antibodies directed to 
these epitopes (kindly provided by Professor Gary Kobinger, see table 3.1) were used in a 
western blot to show that these are still present even in these breakdown or shortened 
protein products. 
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Antibody Epitope Category Notes 
5E6 (IgG2a) 401 ATQVEQHHRRTDND 415 
Towards the start of the MFL sub 
fragment 
Linear Protective 
7G4 (IgG1) Between residues 157-369 
Includes the D sub-fragment 
Conformational Protective 
4G7 (IgG2b) 501 REAIVNAQPKCNPNL 515 
Towards the end of the MFL sub fragment 
Linear Neutralising 
1H3 (IgG2a) 267 SNTTGKLIWKVNPEI 280 
Towards the middle of the D sub 
fragment. 
Conformational Neutralising 
 
Table 3.1. Monoclonal antibodies to Ebola GP. Provided by Professor Gary Kobinger (Université Laval, 
Quebec, Canada), these were used to determine whether the TetC-GP fusion proteins expressed in 
Salmonella contained these protective epitopes. The conformational epitopes could allow us to 
determine if the GP protein is folding correctly (Qiu et al, 2011; Gonzalez-Gonzalez, 2015). Also refer 
to figures 3.9 and 3.3.2 for epitope locations on Ebola GP.  
 
 
The use of a selection of antibodies which recognised a variety of linear or conformational 
epitopes would also help to determine if the GP protein has folded correctly. Conformational 
epitopes are non-continuous along the protein and require a certain (folded) tertiary 
conformation in order to be recognised by their specific antibody. 
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Figure 3.32. Conservation of known epitopes in TetC-Ebola GP fusion proteins.       
A) Schematic diagram showing epitope locations (in yellow) for relevant mouse monoclonal antibodies 
in relation to sub-fragments of Ebola GP and the full-length protein (Qiu et al, 2011; Gonzalez-
Gonzalez, 2015). Also refer to table 3.1. B)  Western blot showing expression of 4 different TetC-GP 
fusion proteins in cell lysates of Salmonella Typhimurium SL5338 probed with a selection of 4 different 
monoclonal antibodies to Ebola GP, the epitopes of which are described above in table 3.1. In each 
sample, the top band is the size expected for the full-length fusion protein. 1) Tet RBS plus GP – 
approximately 70kDa. 2) TetC-GP LH – approximately 85kDa. 3) TetC-GP DMFL – approximately 97kDa. 
4) TetC-full GP – approximately 121kDa. With breakdown products forming a ‘ladder’ underneath. 
Blots were probed with 1:5000 monoclonal Mouse anti Ebola GP antibodies (kindly provided by 
Professor Gary Kobinger) as labelled, and 1:4000 Rabbit anti-mouse HRPO. 
Blots were developed with 4-chloro-1-napthol. 
 
Bands were seen at the expected size for each of the TetC-GP and sub-fragment fusions (see 
figure 3.32) when blotted with 3 of the 4 monoclonal antibodies and importantly, the 
conformational epitope recognising antibody, 7G4, detected bands in each of the samples. 
This suggests that the GP protein here is still folded in a way that this antibody can bind. 
Importantly, the smaller bands seen in each blot are still detectable by antibodies to specific 
epitopes on Ebola GP, suggesting that despite potential protein degradation, these smaller 
fragments may still be able to elicit antibodies in vivo. The antibody 4G7 recognises a linear 
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epitope at the end of the MFL sub fragment, so the fusion proteins without this will not be 
recognised.  The conformational epitope recognising antibody 1H3 did not appear to bind to 
any of the fusion proteins, this could be due to either protein mis-folding around this epitope, 
or that the antibody itself was defective. None the less, protective epitopes on Ebola GP are 
clearly present in the TetC-GP fusion proteins as shown using the small panel of antibodies 
which were available. 
 
3.3.2 Expression of TetC-GP fusion proteins in Salmonella vaccine strains 
 
TetC-GP fusion proteins successfully expressed in Salmonella strain SL5338 contained 
protective linear and conformational epitopes of Ebola GP. SL5338 is non-attenuated, so to 
develop these constructs into a vaccine, they must be transformed into attenuated 
Salmonella vaccine strains.  
In order to determine which vaccine strain to use in in vivo experiments, the constructs which 
appeared to express the TetC-GP fusion proteins best were then electroporated into a small 
panel of attenuated Salmonella vaccine strains and evaluated by western blot to determine 
which expressed the fusion proteins best (figure 3.33). The plasmids chosen to take forward 
to this stage were: pTECH2 (as a TetC control), pTECH2-full GP, pTECH2-GP DMFL and pTECH2-
LH.  
The attenuated strains used for this testing were as follows: 
Strain Mutation 
SL3261 aroA mutant of Salmonella Typhimurium SL1344 
BRD 807 aroA and htrA double mutant of Salmonella Typhimurium SL1344 
BRD 509 aroA and aroD double mutant of Salmonella Typhimurium SL1344 
C5htrA htrA::TnphoA insertion mutant of Salmonella Typhimurium C5 
 
Table 3.2 Attenuated Salmonella vaccine strains used in this study (Roberts et al, 2000; Chabalgoity 
et al, 1996). 
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It appears that the strain SL3261 expresses the fusion proteins best and therefore this will be 
used in the in vivo immunisation studies to determine immune response to Ebola GP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.33. Expression of TetC-GP fusion proteins in Salmonella vaccine strains.              
Western blot showing expression of TetC-GP fusion proteins in four different Salmonella Typhimurium 
attenuated vaccine strains; SL3261, BRD 509, BRD 807 and C5htrA. Cell lysates were fractionated on 
SDS-PAGE and transferred to nitrocellulose. Blots were probed with polyclonal mouse anti Ebola 
serum (1:2500) and Rabbit anti mouse HRPO (1:4000). The lanes are as follows: 1) TetC-GP showing a 
band at approximately 121kDa, 2) TetC-GP DMFL showing a band at approximately 97kDa, 3) TetC-GP 
LH showing a band at approximately 85kDa all denoted by arrows. It appears that the strain which 
expresses the GP fusions best is SL3261 due to the stronger bands seen in these samples. It was 
ensured that a equivalent numbers of cells were used in each sample, so the variation in band strength 
is therefore due to variation in expression levels between each strain. TetC-GP 121kDa, TetC-DMFL 
97kDa, TetC-LH 85kDa. 
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3.4 In vitro stability of pTECH2-GP plasmids in Salmonella Typhimurium vaccine strain 
SL3261 
 
In order to go forward with in vivo immunisation experiments to determine to the immune 
response to Ebola GP, it was vital to first determine the stability of the pTECH2 expression 
plasmids. When used in vivo, there are no antibiotics present to allow for selection and the 
ampicillin resistance gene present on the pTECH2 vector is not necessary. Therefore, the 
Salmonella vaccine strain must be able to stably retain the expression plasmid with no 
antibiotic selection pressure. This was first carried out in vitro using culture with and without 
ampicillin and the resultant CFU/ml which was determined allowed the calculation of plasmid 
stability. The results show that pTECH2-GP is 100% stable and pTECH2-GP DMFL 91.5% stable 
when grown in the absence of ampicillin and can therefore be taken forward for in vivo 
analysis. The pTECH2 control vector is 100% stable as expected.  
Constructs Overnight 
Growth media 
Plate growth 
media 
CFU/ml % Stability 
pTECH2 LB LB  8 X 108  
100% LB + AMP 8 X 108 
pTECH2-GP LB LB 1.37 X 109  
100% LB + AMP 1.37 X 109 
pTECH2-GP 
DMFL 
LB LB 1.4 X 109  
91.5% LB + AMP 1.53 X 109 
 
Table 3.3. In vitro Stability of pTECH2 constructs expressing Ebola GP. Calculated to show stable 
retention of the pTECH2 plasmids expressing Ebola GP or the sub fragment DMFL in the absence of 
selective pressure from ampicillin. This work was carried out in collaboration with Bethany Gollan, a 
Masters student supervised by myself in the Khan laboratory. 
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3.5 In vivo stability of pTECH2-GP plasmids in Salmonella Typhimurium vaccine strain 
SL3261 
 
After confirmation that the pTECH2-GP expression plasmids were stable without antibiotic 
selection in vitro, a pilot immunisation experiment was carried out to determine in vivo 
plasmid stability and to ensure that the Salmonella vaccine strain was still able to express the 
Ebola GP or Zika E proteins after passage in vivo when recovered from the livers and spleens 
of immunised mice. The work covered in 3.5.1 and 3.5.2 was very kindly carried out by Dr 
Omar Rossi, University of Cambridge.  
 
3.5.1 Initial inoculation of mice with Salmonella vaccine strain SL3261 expressing TetC-GP 
fusion proteins  
 
BALB/c mice were split into groups of 4 and immunised with Salmonella Typhimurium vaccine 
strains harbouring the pTECH2 expression plasmids. These are; pTECH2, the TetC only 
expressing control and pTECH2-GP and pTECH2-GP DMFL which express the Ebola GP and GP 
sub fragment DMFL. Each mouse was immunised intravenously with 5 X 105 CFU SL3261 in 
0.2ml PBS. 
 
Table 3.4. Mice used in GP plasmid stability inoculation experiment. Mice immunised in initial 
inoculation experiment to determine plasmid stability and TetC-GP fusion protein expression after in 
vivo passage.  
 
 
 
 
Group Immunisation n BALB/c = 
TETC SL3261 pTECH2 4 
TETC-GP SL3261 pTECH2-synthetic EBOV GP 4 
TETC-DMFL SL3261 pTECH2-synthetic EBOV GP DMFL 4 
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3.5.2 Plasmid stability after in vivo passage in Salmonella Typhimurium vaccine strain 
SL3261 
 
11 days post immunisation, the inoculated mice were sacrificed, and the livers and spleens 
analysed for colonisation by Salmonella Typhimurium SL3261 vaccine strain harbouring the 
pTECH2, pTECH2-GP and pTECH2-GP DMFL plasmids. These vaccine strain cells were 
recovered from the organs and plated on LB agar both with and without ampicillin and a count 
for SL3261 numbers in each organ was calculated. The percentage difference in these totals 
between those grown in the presence of ampicillin and those without, allowed a % value for 
plasmid stability (cells which retained the plasmid without ampicillin selection pressure) was 
calculated. Mice were immunised with pTECH2 only as a control and these results show that 
after in vivo passage, the cells harbouring this plasmid were able to stably retain it despite the 
absence of ampicillin as expected. It seems that the pTECH2-GP plasmid is somewhat less 
stable as a smaller percentage of cells recovered from the livers and spleens were able to 
retain the plasmid with no antibiotic selection. The pTECH2-GP DMFL plasmid on the other 
hand, appears almost as stable as the pTECH2 control plasmid (figure 3.34) 
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Figure 3.34. Plasmid stability of recombinant Ebola GP constructs in vivo.               
Graph to show plasmid stability % of pTECH2 constructs expressing GP or the GP DMFL sub fragment 
after in vivo passage and recovery from the livers and spleens of inoculated mice.  Results are 
presented as the mean percentage of all mice in each group plus SD. 
 
 
 
 
 
In vivo plasmid stability of GP constructs 
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3.5.3 Expression of TetC- GP fusion proteins after in vivo passage 
 
Following confirmation that the plasmids are retained stably in SL3261 cells when recovered 
from inoculated mice livers and spleens after in vitro passage, it was then necessary to 
determine whether these cells were still able to express the TetC or the TetC-GP fusion 
proteins. Cells recovered from these organs were plated onto LB agar with ampicillin and a 
loop of colonies of each were picked for transport to Newcastle as agar stabs by Dr Omar 
Rossi, Cambridge University. Upon arrival these samples were streaked out onto agar plates 
containing ampicillin and after growth overnight, a sample of these cells were taken for 
processing for SDS-PAGE and western blot (figure 3.35).  
Cells recovered from the livers and spleens were all able to express either TetC (SL3261 
harbouring pTECH2) or the TetC-GP or TetC-GP DMFL (pTECH2-GP or pTECH2-GP DMFL) 
fusion proteins and showed an equivalent pattern of bands as SL3261 cells from stock agar 
plates harbouring  the same plasmids, which had not been subject to in vivo passage. 
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Figure 3.35. Expression of TetC-GP fusion proteins after in vivo passage.                
Western blot showing expression of TetC and TetC-Ebola GP fusion proteins from Salmonella 
Typhimurium SL3261 cell lysates after recovery from immunised mouse livers and spleens. Cell lysates 
were fractionated on SDS-PAGE before transfer to nitrocellulose. Blots were probed with Blots were 
probed with polyclonal rabbit anti-TetC serum (1:1000) and Goat anti-rabbit HRPO (1:3000). The TetC 
protein is clearly seen at approximately 50 kDa (A) and the TetC-GP (B) and TetC-GP DMFL (C) fusion 
proteins at 121kDa and 97kDa respectively, as shown in line with arrows. Cells from a stock plate which 
had not been subject to in vivo passage were used as a positive control (shown in the first lane of each 
blot). 
 
 
 
 
 
 
 
 
A
B C) 
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3.6 Immune responses to Salmonella based Ebola Virus vaccine 
 
Stability of the pTECH2 expression plasmids both in vitro and in vivo was confirmed and 
expression of the TetC-GP fusion proteins has been shown in SL3261 vaccine strains when 
recovered from livers and spleens of immunised mice 11 days post inoculation. It could then 
be determined whether these vaccine strains expressing the TetC-GP fusion proteins would 
elicit a protective immune response in mice. 
 
3.6.1 Inoculation of mice with Salmonella vaccine strain SL3261 expressing TetC-GP fusion 
proteins 
 
As with the initial pilot immunisation to determine in vivo plasmid stability, mice were once 
again inoculated by intravenous injection with the SL3261 Salmonella Typhimurium vaccine 
strain expressing TetC or the TetC-GP fusion proteins.  
 
 
 
 
 
 
 
Table 3.5. Mice used in GP immunisation experiment. Inoculation experiment to determine immune 
response to TetC-GP fusion proteins. 6 mice were immunised with the SL3261 vaccine strain 
expressing either TetC or the TetC-GP fusion proteins. 4 mice were not immunised so as to allow a 
baseline reading for normal mouse serum. * One mouse died before the conclusion of the experiment, 
due to a UTI, not related to immunisation.  
 
 
Group Immunisation n BALB/c = 
TETC SL3261 pTECH2 
6.41 log10 CFU in 0.2ml PBS 
6 
TetC-GP SL3261 pTECH2-GP 
6.32 log10 CFU in 0.2ml PBS 
6* 
TetC-GP DMFL SL3261 pTECH2-GP DMFL 
6.24 log10 CFU in 0.2ml PBS 
6 
NEG Not immunised  4 
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8 weeks post immunisation, the mice were sacrificed, and blood was collected from each 
mouse. This was allowed to coagulate before centrifugation to allow collection of serum only. 
Sera was kindly collected and processed by staff at Cambridge University and sent to 
Newcastle to be tested for immune response.  
Once received, sera was aliquoted and stored at -80 °C prior to use in ELISA assays.  
 
3.6.2 IgG antibody response to Ebola GP 
 
Firstly, the IgG response of immunised mouse serum to Ebola GP was determined by ELISA. 
ELISA plates were coated with 2µg/ml recombinant Ebola GP kindly provided by PHE, Oxford. 
Sera was diluted 1:25 and the IgG response was measured at 450nm with Rabbit anti-mouse 
HRPO (Abcam) as the secondary antibody. The ELISA was developed with TMB and stopped 
with H2SO4 prior to reading.  Disappointingly, it does not seem from these results (see figure 
3.36) that there is an apparent IgG antibody response to Ebola GP above the background 
controls. There is perhaps one outlier in the TetC-DMFL group with a higher reading than all 
others, but in general, the response is still quite low. 
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Figure 3.36. IgG antibody response to Ebola GP in GP immunised mice.               
Graph showing IgG response in immunised mouse sera as measured by ELISA with plates coated with 
2µg/ml recombinant Ebola GP. Readings are presented as an average of triplicate wells + SD. Statistical 
significances compared to normal mouse sera (NEG) were analysed by unpaired t test. P values <0.05 
were considered significant. Here, none of the means of any of the immunised groups (TETC-GP, TETC-
DMFL and TETC) were significantly different from normal mouse sera (ns = not significant). 
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3.6.3 IgG antibody response to TetC 
 
It was then determined that the IgG response to TetC should be determined as a control for 
IgG response in general of all immunised mice. As each of the fusion proteins contain TetC, 
and this is a potent immunogen, it would be assumed that all mice immunised would elicit 
antibodies towards TetC. ELISA plates were coated with 1µg/ml TetC (kindly provided by 
Professor Neil Fairweather, Imperial College London), sera once again diluted to 1:25 and 
Rabbit anti-mouse HRPO used as a secondary antibody. Here (see figure 3.37) it is obvious 
that the mice immunised with SL3261 expressing TetC only have a clear IgG response to the 
TetC protein and no response is seen from the non-immunised mice (NEG) as expected. 
Interestingly, there is a much lower response seen in mice immunised with SL3261 expressing 
the TetC-GP or TetC-DMFL fusion proteins. It would be expected that a strong IgG response 
to TetC would also be seen in these mice as it is present in the fusion proteins. This reduced 
response to TetC in these mice could be indicative of an overall dampened immune response, 
and this may also indicate why there was no IgG response to Ebola GP. 
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Figure 3.37. IgG antibody response to TetC in GP immunised mice.               
Graph showing IgG response in immunised mouse sera as measured by ELISA with plates coated with 
1/ml TetC protein. Readings are presented as an average of triplicate wells + SD. Statistical 
significances compared to normal mouse sera (NEG) were analysed by unpaired t test. P values <0.05 
were considered significant. Here, neither of the means of the groups immunised with SL3261 cells 
expressing the TetC-GP fusion proteins (TETC-GP, TETC-DMFL) were significantly different from normal 
mouse sera (ns = not significant). Mice immunised with SL3261 cells expressing TetC only however 
showed a significant IgG response to TetC compared with non-immunised mice (P = <0.0001 - ***). 
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3.6.4 IgG antibody response to Salmonella Typhimurium LPS 
 
It appeared that there was a dampened IgG response to TetC from the mice immunised with 
SL3261 cells expressing the TetC-GP fusion proteins. This was unexpected as the mice 
immunised with the TetC only expressing cells showed a strong IgG response to TetC. It was 
postulated that this may be due to a potential immunosuppressive effect of the vaccines (Lee 
et al, 1985). To determine if this was the case, the IgG response to Salmonella Typhimurium 
LPS was measured again using ELISA (figure 3.38). Salmonella Typhimurium LPS (Sigma) was 
coated onto ELISA plates at 5µg/ml and pooled sera from each of the groups was titrated from 
a 1:50 to a 1:6400 dilution. The secondary antibody was once again Rabbit anti-mouse HRPO 
and the assay was developed as before with TMB and H2SO4. It appears that from these 
results that there is not a clear difference between the anti LPS IgG titre in mice immunised 
with SL3261 cells expressing only TetC compared to those immunised with SL3261 expressing 
the fusion proteins. Compared to the non-immunised mice, which as expected did not show 
an IgG response to LPS as expected, this suggests that the overall immune response is not 
suppressed and therefore there may be alternative reasons as to why the IgG response to 
Ebola GP was so low.  
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Figure 3.38. IgG antibody response to Salmonella Typhimurium LPS in GP immunised mice.          
Graph showing titration of IgG response against Salmonella Typhimurium LPS, from 1:50 to 1:6400 
dilution, of pooled sera from mice immunised with Salmonella Typhimurium SL3261 vaccine strain 
expressing TetC or TetC-GP fusion proteins. Non- immunised mice (NEG) were used as a control. 
Readings are presented as an average of triplicate wells + SD. Statistical significances compared to 
TetC immunised sera (TETC) were analysed by unpaired t test. P values <0.05 were considered 
significant and at all dilutions, none were significantly different. 
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3.7 Discussion 
 
A panel of constructs were generated to allow expression of the Ebola Glycoprotein by 
attenuated Salmonella vaccine strains. From this panel, constructs which had shown to be 
expressed best were selected for use in in vivo immunisation experiments to determine 
immune response in mice to Ebola GP. The constructs expressing the fusion proteins of the 
C-fragment of tetanus toxin (TetC) and Ebola GP were based on the pTECH2 expression 
plasmid.  
 TetC-GP (the full-length GP protein) and TetC-GP DMFL (containing known epitopes for 
protective antibodies) were deemed to be qualitatively expressed best, using western 
blotting, in SL3261, an aroA mutant of Salmonella Typhimurium. Attempts were also made to 
express the Ebola GP protein without the addition of the TetC fusion partner (figure 3.20). 
This was more difficult than expected and no GP expression was seen in Salmonella 
Typhimurium harbouring the pTECH10-GP expression vector, which did not contain any of the 
TetC sequence. Expression of GP was rescued by the addition of the first 30 bases (10 
residues) of the Tet C sequence upstream of the GP gene (figure 3.23), possibly due to an 
increase in the stability of the mRNA and 16S ribosomal RNA interaction, which has potentially 
been improved with increasing complementarity to a sequence in the 16S ribosomal RNA 
downstream of the Shine-Dalgarno recognising sequence. By creating a large panel of variant 
constructs, the differences in expression between each construct could be assessed and the 
ones allowing the best levels of GP expression then brought forward for further testing. 
The pTECH2-GP and pTECH2-GP DMFL plasmids were shown to be stably retained in the 
absence of selective ampicillin both in vitro and following in vivo passage in mice (figures 3.34 
and 3.35). Recovery of strains from livers and spleens, showed that the strains were still 
expressing the TetC-GP fusion proteins (figure 3.35). This allowed an immunisation 
experiment to determine mouse immune responses to Ebola GP to be carried out. Mice were 
immunised with intravenous SL3261 harbouring the pTECH2, pTECH2-GP and pTECH2-GP 
DMFL plasmids and after 8 weeks, sera analysed by ELISA to determine IgG responses (figures 
3.36, 3.37, 3.38). Unfortunately, there was no significant IgG response to Ebola GP from either 
of the groups immunised with the Salmonella expressing the TetC-GP fusion proteins.  In 
addition, the mice immunised with Salmonella harbouring the pTECH2 only plasmid, as 
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expected, had a strong IgG response to TetC, however the mice immunised with the vaccine 
strains expressing the TetC-GP fusion proteins elicited a lower response to TetC. It was 
thought that potentially, this may have been due to an immunomodulatory effect which has 
been reported with attenuated Salmonella vaccine strains, potentially resulting in an overall 
lower IgG response (Lee et al, 1985). To test this theory, ELISA assays were carried out to 
determine the IgG responses from the immunised mice against Salmonella Typhimurium LPS. 
There was not a significant difference in the responses seen in mice immunised with SL3261-
TetC control and the other SL3261-TetC-GP fusion experimental groups. This suggests that 
the overall immune response from the mice was not lowered in the TetC-GP fusion 
experimental groups. 
This lack of response could be due to a variety of reasons, including in vivo expression levels 
of the fusion proteins. This is discussed in more detail in chapter 6, section 6.4. 
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Chapter 4 - Expression of Zika Envelope in Salmonella and evaluation of 
immune response in vaccinated hosts 
 
The Zika virus, carried by Aedes species mosquitoes, has recently seen rapid spread 
throughout the Americas. It has also been determined to be the cause of a large increase in 
incidences of foetal microcephaly and central nervous system issues when the pregnant 
mother is infected. In adults, infection with Zika Virus has been connected with Guillain-Barré 
Syndrome (GBS), which can cause neuropathy and paralysis. These alarming complications 
resulting from an infection that otherwise causes relatively mild symptoms, has highlighted 
the need for a safe and effective vaccine against Zika Virus, to reduce the impact it can have 
on vulnerable populations. The envelope glycoprotein (ZE) is situated on the virus surface and 
has epitopes that are able to elicit cellular and humoral immune responses and is therefore 
an attractive target for use in a vaccine. Using attenuated Salmonella vaccine strains to 
express and deliver the ZE protein to the host immune system, could elicit protective 
antibodies and be a cost effective easy to administer vaccine hopefully preventing such 
devastating complications from this rapidly spreading virus in the future.  
 
4.1 Generating a panel of Zika envelope expression constructs 
 
The Zika Virus envelope protein (ZE) is the major protein situated on the viral surface and has 
been shown elicit protective neutralising antibodies (Dai et al, 2016). This makes it an 
attractive target for use in a vaccine. It is hoped that using attenuated Salmonella 
Typhimurium to express ZE may elicit a protective immune response to Zika infection. Zika E 
genes were first amplified by PCR in the same way as with Ebola GP in chapter 3, and 
subsequently cloned using restriction enzymes and T4 ligation.  
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4.11 Synthetic codon optimised and wild type Zika envelope genes 
 
A Zika envelope gene was codon optimised for expression in Salmonella Typhimurium. The 
gene sequence was generated using Eurofins Genomics’ proprietary software ‘GENEius’, 
utilising codons most frequently used by Salmonella Typhimurium and avoiding unwanted 
motifs. It was hoped that this would allow optimum expression of the Zika envelope protein. 
The synthetic gene sequence was then sent to DC Biosciences (Dundee, UK) for synthesis.  
With this synthetic Zika E gene sequence which has been codon optimised for expression in 
Salmonella Typhimurium we can compare its expression and immunogenicity, with a wild 
type (WT) (non-optimised) ZE, which was kindly provided by Dr Claire Donald and Professor 
Alain Kohl, Glasgow University.  
The gene sequence used (both WT and synthetic) was from the Zika Virus Isolate KX197192, 
strain PE243 (Donald et al, 2016). 
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4.1.2 PCR amplification of Zika envelope and sub-fragments 
 
Both the synthetic, codon optimised and wild type Zika Envelope genes were PCR amplified 
with primers specific to the full ZE or a truncated version consisting of the first 193 amino 
acids.  These amplified gene products were then digested for subsequent restriction cloning 
into the pTECH2 expression vector (figure 4.1). A panel of constructs was created to enable 
evaluation of which expressed the ZE protein best and would then be taken forward into in 
vivo testing (figure 4.2). 
 
 
 
Figure 4.1. Plasmid map of the pTECH2-ZE expression vector. Under the control of the nirB promoter, 
a TetC-GP fusion protein is expressed. The GP gene was cloned in using restriction enzymes BamHI 
and HindIII. Colony PCR was carried out on Salmonella Typhimurium SL5338 colonies after 
transformation using the pTETnir15 screening primers as shown to confirm putative clones containing 
the plasmid prior to expression analysis. The full-length ZE shown in pink represents either the codon 
optimised synthetic gene (ZEs) or the WT gene sequence (ZE WT). The location of the smaller synthetic 
gene fragment (ZE 193) is shown and was cloned in place of the full ZE gene to allow expression a 
shorter TetC-ZE fusion. Plasmid map was made using the commercial software Snapgene. 
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Figure 4.2. TetC-Zika envelope fusion protein constructs.             
Zika envelope Fusion protein constructs. Schematic presentation of the panel of Zika envelope fusion 
protein constructs generated in this study. Under the control of the nirB promoter, the full-length Zika 
envelope was expressed either as a fusion to the C-fragment of Tetanus Toxin (TetC), alone, or as a 
fusion to the full TetC ribosome binding site (RBS) in the pTECH2 expression vector in Salmonella 
Typhimurium. The TetC and Zika E fragments are separated by a flexible hinge, Gly Pro Gly Pro motif, 
which allows temporal and spatial separation between the two components to allow time for correct 
folding. A short fragment of the synthetic Zika E gene (the first 193 residues) was also expressed as a 
fusion to TetC to determine if length may have an effect on expression levels. The wild type ZE 
sequence (Zika E WT) was also incorporated into a pTECH2 construct to determine the difference in 
expression between this sequence and the synthetic sequence codon optimised for expression in 
Salmonella Typhimurium (Zika E synth). 
 
First, each of the Zika envelope genes (Synthetic optimised – ZE(s) or Wild type – ZE(WT)) and 
the truncated version of the synthetic ZE (the first 193 aa – ZE(s193)) were amplified by PCR, 
with the cloning restriction enzyme sites included on each end (BamHI and HindIII). Each PCR 
product was the expected size; ZE(s) 1242bp, ZE(s193) 579bp and ZE(WT) 1218bp (figure 4.3). 
In the case of ZE(WT), a smaller band (under 250bp) was seen when the PCR product was 
visualised on an agarose gel, potentially due to the presence of primer dimers. This was easily 
rectified by the use of the QIAquick ® Gel Extraction kit (Qiagen), where the correct band 
(1218bp) was excised and purified prior to further processing to prevent contamination with 
the smaller unwanted piece of amplified DNA. 
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Figure 4.3. PCR amplification of Zika envelope.             
0.7% agarose gel showing PCR products of the Zika envelope gene when amplified with corresponding 
primers containing restriction cloning sites for BamHI and HindIII. Lane 1 is the truncated synthetic 
Zika E (193), consisting of the first 193aa of the envelope protein at 579bp. Lane 2 is the full-length 
synthetic, codon optimised Zika E gene at 1242bp and lane 3 is the WT Zika E gene (non-codon 
optimised) at 1218bp, all denoted by arrows. In lane 3, an extra smaller band is also seen possibly due 
to the presence of primer dimers, in this case, the top correct band (1218bp, denoted by arrow) was 
excised and purified using the Qiagen Gel purification kit.  
 
These PCR products were subsequently digested with BamHI and HindIII, spin column 
purified, and cloned into digested pTECH2 plasmid. 
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4.1.3 Generation of pTECH2-ZE constructs 
 
As mentioned previously, guest antigens can be cloned into the multiple cloning site of 
pTECH2. This allows the expression of a protein consisting of the C-fragment of Tetanus Toxin 
(TetC) and the guest antigen as a genetic fusion, under the control of the nirB promoter. Here, 
the PCR products for the Zika envelope constructs were digested with restriction enzymes 
BamHI and HindIII and cloned into the digested pTECH2 vector using T4 ligase. The ligation 
mix from this reaction was then transformed into chemically competent Salmonella 
Typhimurium SL5338 cells. Colonies were screened using pTETnir15 screening primers to 
determine putative clones containing one of the pTECH2-ZE plasmids. The screening primers 
amplify a 543bp region on the pTECH2 plasmid which includes the multiple cloning site (See 
figure 4.1). When the correct gene is inserted into the cloning site, the resultant PCR product 
from a colony PCR is the insert plus 543bp in total. Negative colonies that do not include the 
ZE insert give a product of only 543bp. Plasmid DNA from positive clones from this screen was 
then purified and digested with the cloning enzymes to visualise the insert band and further 
confirm successful cloning (figure 4.4) 
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4.1.3.1 Construction of pTECH2-Full synthetic ZE expression plasmid 
 
The 1242bp synthetic Zika envelope PCR product was cloned into the multiple cloning site of 
the pTECH2 vector using restriction enzymes BamHI and HindIII and ligation with T4 ligase. 
Colony PCR using vector screening primers showing a band at 1785bp and informative digests 
of the resultant plasmid after transformation into SL5338 cells confirmed successful cloning 
(figure 4.4).  
 
 
 
 
 
 
 
Figure 4.4. Colony PCR Colony PCR and restriction digest screens of putative pTECH2-ZE (s) clones. 
A) 0.7% agarose gel showing PCR products from colony PCR using pTETnir15 screening primers to 
determine successful construction and transformation of the pTECH2 vector containing the 1242bp 
Synthetic ZE gene into SL5338 Salmonella strain. Following transformation, colonies 1-19 (as shown 
on gel) were boiled before PCR amplification of the plasmid between each screening primer. Positive 
colonies which have successfully taken up the plasmid pTECH2-ZE(s) (notably colony 12 – denoted by 
arrow) show a band at 1785bp. Colonies which have only taken up pTECH2 show a band at 
approximately 543bp.  
B) 0.7% agarose gel showing purified plasmid from colony 12 (see figure 4.4 A) digested with BamHI 
and HindIII, showing an insert band of 1242bp (lane 2) which corresponds to the size of the PCR 
product for the Zika envelope gene (lane 1). PD is plasmid pTECH2 digested with the same restriction 
enzymes as a negative control. This putative plasmid from colony 12 was then sent for sequencing 
using the same screening primers as above This construct was made in collaboration with Bethany 
Hunter, a Masters student supervised by myself in the Khan laboratory. 
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4.1.3.2 Construction of pTECH2-Truncated (193aa) Synthetic ZE (pTECH2-ZE193) expression 
plasmid 
 
The 579bp truncated synthetic Zika envelope (193) PCR product was cloned into the multiple 
cloning site of the pTECH2 vector using restriction enzymes BamHI and HindIII and ligation 
with T4 ligase. Colony PCR using vector screening primers, showing a band at 1122bp, and 
informative digests of the resultant plasmid after transformation into SL5338 cells confirmed 
successful cloning (figure 4.5) 
 
Figure 4.5. Colony PCR and restriction digest screens of putative pTECH2-ZE (s193) clones.                       
A) 0.7% agarose gel showing PCR products from colony PCR using pTETnir15 screening primers to 
determine successful transformation of the pTECH2 vector containing the 579bp Synthetic ZE (193) 
gene fragment into SL5338 Salmonella strain. Following transformation, colonies 1-7 (as shown on 
gel) were boiled before PCR amplification of the plasmid between each screening primer. Positive 
colonies which have successfully taken up the plasmid pTECH2-ZE(193)show a band at 1122bp 
(denoted by arrow). Colonies which have only taken up pTECH2 show a band at approximately 543bp, 
as seen in lane 1.  
B) 0.7% agarose gel showing purified plasmid from colony 2 (see figure 4.5 A) digested with BamHI 
and HindIII, showing an insert band of 579bp (lane 2) which corresponds to the size of the PCR product 
for the truncated Zika envelope gene (lane 1). PD is plasmid pTECH2 digested with the same restriction 
enzymes as a negative control. This putative plasmid from colony 2 was then sent for sequencing using 
the same screening primers as in figure 4.4 A. This construct was made in collaboration with Bethany 
Hunter, a Masters student supervised by myself in the Khan laboratory. 
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4.1.3.3 Construction of pTECH2-Full Wild type ZE (pTECH2-ZE WT) expression plasmid 
 
The 1218bp Wild Type Zika envelope PCR product was cloned into the multiple cloning site of 
the pTECH2 vector using restriction enzymes BamHI and HindIII and ligation with T4 ligase. 
Colony PCR using vector screening primers, showing a band at 1761bp, and informative 
digests of the resultant plasmid after transformation into SL5338 cells confirmed successful 
cloning (figure 4.6) 
 
Figure 4.6. Colony PCR and restriction digest screens of putative pTECH2-ZE (WT) clones.                          
A) 0.7% agarose gel showing PCR products from colony PCR using pTETnir15 screening primers to 
determine successful construction and transformation of the pTECH2 vector containing the 1218bp 
Wild Type Zika E (ZE WT) gene into SL5338 Salmonella strain. Following transformation, colonies 1-10 
(as shown on gel) were boiled before PCR amplification of the plasmid between each screening primer. 
Positive colonies (see lane 3) which have successfully taken up the plasmid pTECH2-ZE(WT) show a 
band at 1761bp. Colonies which have only taken up pTECH2 show a band at approximately 543bp.  
B) 0.7% agarose gel showing purified plasmid from colony 3 (see figure 4.6 A) digested with BamHI 
and HindIII, showing an insert band of 579bp (lane 2) which corresponds to the size of the PCR product 
for the truncated Zika envelope gene (lane 1). PD is plasmid pTECH2 digested with the same restriction 
enzymes as a negative control. This putative plasmid from colony 3 was then sent for sequencing using 
the same screening primers as above. This construct was made in collaboration with Bethany Hunter, 
a Masters student supervised by myself in the Khan laboratory. 
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4.2 Expression of TetC-ZE fusion proteins in Salmonella intermediate strain SL5338 
 
Using colony PCR and informative digest of putative clones, the pTECH2-ZE constructs had 
been confirmed (pTECH2-ZE(s), pTECH2-ZE(s193), pTECH2-ZE(WT)). These were then 
transformed into Salmonella Typhimurium SL5338 cells and checked for expression of the Zika 
envelope protein (or truncated fragment 193) in fusion with TetC (figure 4.7). To ensure that 
each sample on the SDS-PAGE gel prepared for western blot contained an equivalent number 
of cells, the dilutions of cell lysates were corrected for cell density (OD600) to ensure equal cell 
numbers. For the relevant calculations, please refer to Chapter 2, section 2.2.9.1. Following 
confirmation of expression in strain SL5338, the plasmids were then electroporated into 
Salmonella Typhimurium vaccine strains to ensure continued expression and to use in in vivo 
experiments to determine immune response to ZE.  
4.2.1 Expression of TetC-ZE fusion proteins in Salmonella intermediate strain SL5338 
 
The TetC – Zika E fusion proteins can be detected on western blot by both anti TetC polyclonal 
sera and monoclonal anti-Zika E antibodies. The TetC protein is approximately 52kDa and both 
the synthetic and wild type Zika envelope proteins are approximately 45kDa, resulting in a 
97kDa fusion protein expressed (including the hinge region and rest of the poly-linker site). 
The truncated ZE(s193) is approximately 21kDa, resulting in a 74kDa fusion protein (also 
including the hinge and poly-linker). Again, a western blot probed with polyclonal anti-TetC 
mouse sera, show that these constructs clearly express the protein at expected size in SL5338, 
and although some breakdown products are visible, the fusion proteins (97kDa, 97kDa and 
74kDa respectively) are clearly seen at the expected size (see figure 4.7 A). When the same 
samples are probed with a monoclonal anti Zika envelope antibody, the same bands at 97kDa 
are extremely clear, and some breakdown products are also visible, suggesting that the 
epitope (currently unknown) is still present in these shorter products and may still elicit an 
immune response (see figure 4.7 B). It appears that the truncated synthetic ZE protein does 
not contain the epitope for this monoclonal antibody as no bands are visible in this sample 
(figure 4.7 B lane 3). The epitope is therefore situated after the 193rd amino acid of the ZE 
protein.  
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In both of these blots, when cells harbouring the pTECH2-ZE plasmids (both synthetic and wild 
type) it appears that a stronger band is seen in the samples which contain the plasmid with 
the synthetic codon optimised Zika envelope gene. This is probably to be expected as the 
codons used for this construct are more favourably used by Salmonella Typhimurium. 
 
 
 
 
 
 
 
Figure 4.7. Expression of TetC-GP fusion proteins.                   
Western blot showing expression of TetC-ZE fusion proteins (as denoted by arrows) in cell lysates of 
Salmonella Typhimurium SL5338 probed with polyclonal rabbit anti TetC serum (1:1000) followed by 
Goat anti rabbit HRPO (1:3000) (A) and mouse monoclonal anti ZE (1:10000) followed by rabbit anti-
mouse HPRO (1:4000) (B). Lane 1 shows the TetC-ZE (s) fusion at approximately 97kDa, lane 2 the 
TetC-ZE (WT) fusion also at approximately 97kDa and lane 3 the TetC-ZE(s193) fusion at approximately 
74kDa. It appears that while the TetC-ZE(s193) fusion is visible when cells containing this plasmid are 
probed with anti-TetC, the epitope for this particular monoclonal anti Zika E antibody used in (B) is not 
present, suggesting the epitope for this antibody is more towards the C terminal of the envelope 
protein (or at least after the 193rd amino acid). This construct was made in collaboration with Bethany 
Hunter, a Masters student supervised by myself in the Khan laboratory. 
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4.2.2 Expression of TetC-ZE fusion proteins in Salmonella vaccine strains 
 
After expression of TetC- Zika envelope fusion proteins was confirmed in Salmonella 
Typhimurium strain SL5338, the relevant expression plasmids then had to be transformed 
into an attenuated strain so as to allow for in vivo experiments. The constructs were 
electroporated into two vaccine strains: SL326 and C5htrA to determine which would be used 
in vivo (see chapter 2, section 2.1.7, table 2.5 for strain details). Cell lysates from each of these 
strains harbouring either pTECH2-ZE(s) or pTECH2-ZE(WT) were evaluated by western blot to 
determine which background expressed the fusions best )figure 4.8). Again, ensuring that 
equivalent cell numbers were included in each sample, it appears that the SL3261 strain 
expressed the fusion slightly better than C5htrA. 
  
 
 
 
 
 
 
 
Figure 4.8. Expression of TetC-GP fusion proteins in Salmonella vaccine strains.                      
Western blot showing TetC and TetC-ZE fusion proteins (as denoted by arrows at approximately 
97kDa) expressed in either SL3261 (lanes 1-3) or C5htrA (lanes 4-6) Salmonella Typhimurium vaccine 
strains. TetC is also clearly shown expressed by both strains, with a band at approximately 50kDa 
(lanes 1 and 4). Cell lysates were fractionated on SDS-PAGE which was then transferred to 
nitrocellulose. The blot was probed with polyclonal rabbit anti-TetC serum (1:1000) followed by Goat 
anti-Rabbit HRPO (1:3000). It appears that strain SL3261 expresses the fusion proteins slightly better 
(in particular when the synthetic codon optimised gene sequence is used – lane 2) due to the stronger 
bands seen in these samples. This work was carried out in collaboration with Bethany Hunter, a 
Masters student supervised by myself in the Khan laboratory. 
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4.3 Generation and expression of Zika envelope constructs, without TetC 
 
After the three pTECH2 Zika envelope plasmids were confirmed, two alternative constructs 
were made in order to evaluate the contribution of the TetC fusion partner to expression 
levels. These plasmids; pTECH10-ZE(s) expressing ZE alone with no fusion partner and 
pTECH11-ZE(s) which contained only the ribosome binding site of TetC (the first 10 amino 
acids) fused to the synthetic ZE gene, were made using site directed mutagenesis (NEB) to 
delete all or most of the TetC gene (as in chapter 3 with the Ebola GP constructs). It has been 
shown previously (see chapter 3, section 3.2.2) that the Ebola GP protein could not be 
expressed without at least the TetC RBS fusion partner in this system, therefore the pTECH11-
ZE construct was also included here in case the same was true for the Zika envelope protein. 
 
4.3.1 Construction of pTECH10-ZE expression plasmid 
 
Primers were designed to remove the TetC gene from the pTECH2-ZE(s) plasmid using Q5 Site 
Directed Mutagenesis (NEB). The resulting plasmid – pTECH10-ZE(s) (figure 4.9) was 
chemically transformed into NEB5α E. coli cells (NEB). Plasmid DNA from putative clones were 
then purified and digested with EcoRI and the cloning enzyme HindIII. Plasmid DNA from a 
positive clone would result in two bands visible when the digest mix was fractionated on an 
agarose gel. DNA from a negative clone, i.e. if the plasmid had retained TetC, would result in 
three bands visible on an agarose gel due to an EcoRI restriction site present in the TetC gene 
sequence (figure 4.10). 
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Figure 4.9. Plasmid map of the pTECH10-ZE(s) expression vector.                  
This vector was constructed using Q5 Site Directed Mutagenesis (NEB) using the forward (FWD) and 
reverse (REV) primers shown. Inverse PCR allowed the removal of the TetC gene from the pTECH2-
ZE(s) plasmid. Expression of Zika envelope is under the control of the nirB promoter and is expressed 
alone, without TetC as a fusion partner. Plasmid map was made using the commercial software 
Snapgene. 
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Figure 4.10. Restriction digest screens of putative pTECH10-ZE clones.           
0.7% agarose gel showing purified plasmid from 3 colonies of NEB5α E. coli suspected to contain the 
pTECH10-ZE(s) plasmid (lanes 1-3). The plasmid was digested with EcoRI and HindIII showing two 
distinct bands at 1353bp and 2282bp (as denoted by arrows). An extra EcoRI site situated towards the 
C terminal of the TetC gene means that a digested plasmid which has retained the TetC gene would 
show 3 bands (such as lane C – pTECH2-ZE(s) negative control, also digested with the same enzymes). 
 
 
Purified plasmid from colony 1 (lane 1, figure 4.10) was then sent for sequencing (Eurofins) 
and once confirmed, transformed into Salmonella Typhimurium SL5338 cells for expression 
analysis. 
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4.3.2 Construction of pTECH11-ZE expression plasmid - Retention of the TetC ribosome 
binding site (RBS) 
 
As reported in chapter 3, the Ebola GP protein did not express without the TetC fusion 
partner. This was rescued somewhat by retaining the TetC RBS, including 30 bases 
downstream of the start codon (this has been described in more detail in Chapter 3, section 
3.2.2.3). It was therefore decided to create an equivalent construct in the event that the same 
was true for the expression of Zika E. This construct was also made using Q5 site directed 
mutagenesis (NEB) to remove all but the first 10 amino acids of TetC and thus retain the full 
RBS and additional downstream sequence after the initiation codon (figure 4.11).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. Plasmid map of the pTECH11-ZE(s) expression vector. This vector was constructed using 
Q5 Site Directed Mutagenesis (NEB) using the forward (FWD) and reverse (REV) primers shown. 
Inverse PCR allowed the removal of the majority of the TetC gene from the pTECH2-ZE(s) plasmid, 
except the first 10 amino acids (RBS). Expression of Zika envelope is under the control of the nirB 
promoter and is expressed alone, without TetC as a fusion partner. Plasmid map was made using the 
commercial software Snapgene. 
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Figure 4.12. Restriction digest screens of putative pTECH11-ZE clones.                 
0.7% agarose gel showing purified plasmid from 3 colonies of NEB5α E. coli suspected to contain the 
pTECH11-ZE(s) plasmid (lanes 1-3). The plasmid was digested with EcoRI and HindIII showing two 
distinct bands at 1363bp and 2282bp (as denoted by arrows). An extra EcoRI site situated towards the 
C terminal of the TetC gene means that a digested plasmid which has retained the TetC gene would 
show 3 bands (such as lane C – pTECH2-ZE(s) negative control, also digested with the same enzymes). 
 
 
Purified plasmid from colony 2 (lane 2, figure 4.12) was then sent for sequencing (Eurofins) 
and once confirmed, transformed into Salmonella Typhimurium SL5338 cells for expression 
analysis. 
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4.3.4 Expression of ZE alone in Salmonella strain SL5338  
 
After confirming through sequencing that the pTECH10-ZE(s) and pTECH11-ZE(s) plasmids had 
been successfully constructed, additional constructs were made in an attempt to allow 
Salmonella Typhimurium to express the Zika envelope protein when no TetC fusion partner 
was present. 
SL5338 cell lysates were fractionated on SDS-PAGE gel and transferred for western blot to 
nitrocellulose. When probed with a monoclonal mouse anti-Zika E antibody 
(Aaltobioreagents) both of these constructs did express the Zika envelope protein but not to 
the level of which was seen when as a fusion with the full TetC (see figure 4.13). This could 
mean that the TetC RBS and additional downstream sequence is not necessarily contributing 
to increasing the expression of Zika E, as similar levels of expression are seen in the pTECH10-
ZE(s) samples, where this is not present. The stability of the interaction between the 
Salmonella Typhimurium 16S rRNA and RBS of the ZE mRNA could therefore be similar to that 
of TetC, and it could be that the huge increase in expression seen when the full TetC is present 
(pTECH2-ZE(s)) is due to other areas on the TetC mRNA. This indicates that the full TetC 
protein may help to rescue the Zika E expression. 
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Figure 4.13. Expression of Zika E alone in Salmonella Typhimurium.                         
Western blot showing Zika envelope expressed in Salmonella Typhimurium SL5338 with no TetC fusion 
partner (pTECH10 – lanes 1-3) at approximately 45kDa (see arrow) or with only the small TetC RBS 
fusion partner (pTECH11 – lanes 4-6) at approximately 46kDa (see arrow). Cell lysates of SL5338 
colonies harbouring either of these plasmids (three of each) were fractionated on SDS-PAGE and 
transferred to nitrocellulose. The blot was probed with mouse monoclonal anti-ZE (aaltobioreagents) 
(1:10000) followed by Rabbit anti-mouse HRPO (abcam) (1:4000). The positive control lane (+) shows 
the TetC-ZE(s) fusion protein at approximately 97kDa expressed by SL5338 cells as a comparison. Each 
sample was calculated to ensure an equivalent number of cells in each, therefore these results suggest 
that fusion to the whole TetC rescues expression of ZE. This construct was made in collaboration with 
Bethany Hunter, a Masters student supervised by myself in the Khan laboratory. 
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4.4 Generation of a Zika E-Ebola GP fusion protein construct 
 
As shown in chapter 3, it was not possible to express the Ebola GP protein without the 
presence of at least the ribosome binding site (RBS) of TetC as a fusion partner. With the full 
TetC present, the expression of the Ebola GP protein was much higher. In this chapter, the 
same has been explored for the Zika envelope protein and was shown to express both with 
the TetC RBS fusion and alone, but again not to the levels as seen in fusion with the full TetC. 
It was therefore decided to see if rather than TetC, we could use the Zika E as a fusion partner 
to Ebola GP sub fragment DMFL and express a ZE-EBOVGP fusion protein (figure 4.14) 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14. Plasmid map of the pTECH ZE-GP DMFL expression vector. Under the control of the nirB 
promoter, a Zika E-GP DMFL fusion protein is expressed. The GP DMFL gene was cloned in using 
restriction enzymes SpeI and HindIII. Colony PCR was carried out on Salmonella Typhimurium SL5338 
colonies after transformation using the pTECH ZE/DMFL forward and pTETnir15 reverse screening 
primers as shown to confirm putative clones containing the plasmid prior to expression analysis. The 
full-length ZE shown in pink represents the codon optimised synthetic gene (ZEs) and the Ebola GP 
DMFL gene sub fragment is shown in red. Plasmid map was made using the commercial software 
Snapgene. 
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4.4.1 Generation of pTECH ZE-EBOVGP DMFL expression plasmid 
 
The pTECH10-ZE plasmid was digested with restriction enzymes SpeI and HindIII. The 1200bp 
Ebola GP DMFL was then amplified by PCR (see chapter 3) however with new primers to allow 
the addition of SpeI and HindIII restriction sites, digested with these enzymes and purified. 
This DMFL insert was then ligated into the digested plasmid using T4 Ligase (NEB) to create 
the pTECH2-ZE-GP DMFL plasmid, expressing a Zika envelope-Ebola GP DMFL fusion protein. 
The ligation mix was transformed into chemically competent SL5338 cells and the resultant 
colonies were picked and screened using colony PCR. A new screening primer was made for 
this construct to amplify a section of the plasmid which would include the ZE and DMFL gene 
sequences when used with the pTETnir15 REV primer as mentioned previously. If the Ebola 
GP DMFL gene sub fragment has been successfully incorporated into the plasmid, the 
resultant PCR product would be 2880bp, if the DMFL gene is not present (pTECH2-ZE only), 
the product would be 1680bp (figure 4.15).  
 
 
 
 
 
 
Figure 4.15. Colony PCR screen of putative pTECH-ZE-DMFL clones.         
0.7% agarose gel showing PCR products from colony PCR using pTECH screening primers to 
determine successful construction and transformation of the pTECH vector containing both 
the Zika envelope (synthetic, codon optimised) gene and the Ebola GP DMFL gene sub 
fragment. Screening primers amplify a product of 2880bp when the DMFL sub fragment is 
present and 1680 when it is not. This shows 10 colonies out of 19 tested are positive (as shown 
by arrows), some of which will be tested for expression of the fusion. 
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4.4.2 Expression of ZE-GP fusion protein in Salmonella Typhimurium  
 
Eight putative clones (4, 6, 8, 9, 11, 13, 14 and 19) were then prepared for western blot 
analysis and 7 out of these were shown to express the ZE-GP DMFL fusion protein when 
probed with both anti-Ebola GP and anti-Zika E monoclonal antibodies by western blot (see 
figure 4.16). While there is clearly expression of this fusion, it seems that the Zika envelope 
protein does not have the same effect when rescuing expression of Ebola GP as the TetC 
fusion partner. It is therefore decided that this construct will not be taken further into in vivo 
testing as the expression levels may be too low to administer an appropriate antigenic dose. 
 
 
 
 
 
 
 
 
Figure 4.16. Expression of ZE-GP fusion protein in Salmonella Typhimurium.         
Western blot showing ZE-GP DMFL fusion proteins Salmonella Typhimurium strain SL5338. Cell lysates 
of SL5338 cells which had been shown by colony PCR to potentially contain the pTECH ZE-GP DMFL 
expression plasmid were fractionated on SDS-PAGE and transferred to nitrocellulose. Blots were 
probed with either polyclonal mouse anti-EBOV sera (A) or monoclonal mouse anti Zika envelope 
(aaltobioreagents) (B) followed by Rabbit anti mouse HRPO (abcam). In 7 out of the 8 colonies tested, 
there is clear expression of the ZE-GP DMFL fusion as bands were seen at approximately 89kDa (as 
shown by arrows) when probed with both antibodies. This expression however was nowhere near as 
strong as that of TetC-GP or TetC-ZE(s) as shown in lanes labelled with +. This suggests that while ZE 
may rescue the expression of Ebola GP, TetC is a better fusion partner when considering total protein 
expression.  
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4.5 In vitro stability of pTECH2-ZE plasmids in Salmonella Typhimurium vaccine strain 
SL3261 
 
As is the case with the pTECH2 plasmids expressing the Ebola GP proteins, the same must be 
done for the Zika E expression plasmids to ensure that the Salmonella vaccine strain can stably 
retain the plasmid in the absence of ampicillin selection pressure, due to the fact that when 
used in vivo, there will be no antibiotics present. Using the pTECH2 plasmid as a control, which 
shows 100% stability, the ZE(s) and ZE (s193) expressing constructs showed 81.8% and 100% 
stability respectively, allowing these to move forward for in vivo testing.  
 
Constructs Overnight 
Growth media 
Plate growth 
media 
CFU/ml % Stability 
pTECH2 LB LB  8 X 108  
100% LB + AMP 8 X 108 
pTECH2-ZE(s) LB LB 1.17 X 109  
81.8% LB + AMP 1.43 X 109 
pTECH2-
ZE(s193) 
LB LB 1.3 X 109  
108.3% (100%) LB + AMP 1.2 X 109 
 
Table 4.1.  In vitro Stability of pTECH2 constructs expressing Zika envelope. Stability of pTECH2 
constructs expressing Zika envelope. Calculated to show stable retention of the pTECH2 plasmids 
expressing ZE (s) or the truncated ZE (s193) in the absence of selective pressure from ampicillin.  
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4.6 In vivo stability of pTECH2-ZE plasmids in Salmonella Typhimurium vaccine strain SL3261 
 
After confirmation that the pTECH2-ZE expression plasmids were stable in the absence of 
antibiotic selective pressure, an immunisation experiment was carried out in order to 
determine plasmid stability in vivo and ensure expression of the TetC-ZE fusion proteins was 
still possible after Salmonella was recovered from the livers and spleens of immunised mice. 
The work covered in sections 4.6.1 and 4.6.2 was very kindly carried out by Dr Omar Rossi, 
University of Cambridge. 
4.6.1 Initial inoculation of mice with Salmonella vaccine strain SL3261 expressing TetC-ZE 
fusion proteins 
 
As with the Ebola GP vaccines, BALB/c mice were split into groups of 4 and immunised with 
Salmonella Typhimurium vaccine strains harbouring the pTECH2 expression plasmids. These 
are; pTECH2, the TetC only expressing control and pTECH2-ZE(s) which express the TetC-Zika 
envelope fusion protein. Each mouse was immunised intravenously with 5 X 105 CFU SL3261 
in 0.2ml PBS. 
Group Immunisation n BALB/c = 
TETC SL3261 pTECH2 4 
TETC-ZE(s) SL3261 pTECH2-synthetic Zika envelope 4 
TETC-ZE(s193) SL3261 pTECH2-synthetic Zika envelope 193 4 
 
Table 4.2. Mice used in ZE plasmid stability inoculation experiment. Mice immunised in initial 
inoculation experiment to determine plasmid stability and TetC-ZE fusion protein expression after in 
vivo passage.  
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4.6.2 Plasmid stability after in vivo passage 
 
11 days post immunisation, mice were sacrificed and livers and spleens analysed for 
colonisation by Salmonella Typhimurium SL3261 vaccine strain harbouring the pTECH2, and 
pTECH2-ZE(s) plasmids. Vaccine strain cells were recovered from the organs and plated on LB 
agar with and without ampicillin. A count for SL3261 numbers in each organ was calculated 
and the percentage difference between totals grown with and without ampicillin allowed a % 
value for plasmid stability to be calculated (figure 4.17). As in chapter 3, section 3.5.2, mice 
were immunised with pTECH2 as a control (this group is the same TetC group as featured in 
3.5.2). It seems that the pTECH2-ZE(s193) plasmid is stable after in vivo passage, with results 
comparable to the pTECH2 control at about 95%. Plasmid pTECH2-ZE(s) however appears less 
stable at only around 50%. This could again be due to the full ZE fusion partner, which may 
make expression more difficult due to its larger size than the truncated s193 fragment.  
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Figure 4.17. Plasmid stability of recombinant Zika envelope constructs in vivo.         
Graph to show plasmid stability % of pTECH2 constructs expressing Zika E after in vivo passage and 
recovery from the livers and spleens of inoculated mice. pTECH2 controls shown are the same groups 
as in Chapter 3, 3.5.2. Results are presented the mean percentage of all mice in each group plus SD. 
 
 
In vivo plasmid stability of ZE constructs 
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4.6.3 Expression of TetC-ZE fusion proteins after in vivo passage 
 
The pTECH2 and pTECH2-ZE(s193) plasmids were shown to be stable in vivo at over 90% when 
recovered from inoculated mouse livers and spleens. The pTECH2-ZE(s) plasmid however was 
only shown to have around 50% stability. It was decided to check for expression of the TetC-
ZE fusion proteins from the cells recovered from these organs by western blot of cell lysates 
after overnight growth on LB agar containing ampicillin following transport to Newcastle as 
agar stabs.  
Cells recovered from the livers and spleens were all able to express either TetC (SL3261 
harbouring pTECH2 – also shown in chapter 3, section 3.5.3) or the TetC-ZE(s) or TetC-ZE(s193) 
fusion proteins and on western blots, showed an equivalent pattern of bands as SL3261 cells 
from stock agar plates harbouring the same plasmids, which had not been subject to in vivo 
passage (figure 4.18). 
In the case of the pTECH2-ZE(s) plasmid, which showed reduced stability compared to the 
pTECH2 control and also pTECH2-ZE(s193), the TetC-ZE(s) fusion protein is still expressed as 
detected by the anti-TetC antibody, however there seems to be variation between the 
expression levels of each mouse. It was therefore decided that when carrying out the main 
immunisation experiment (see 4.7.1) to determine immune response to the vaccine, SL3261 
cells recovered from the spleen of mouse 1 in the TETC-ZE(s) group (figure 4.18 B) would be 
used to immunise new mice, due to the fact that repeated passage can increase plasmid 
stability when there are no selective antibiotics present (Chabalgoity et al, 1996) and cells 
from this sample appear to express the fusion at higher levels than samples from the other 3 
mice in this group.  
Vaccine strains for the main immunisation (4.7.1) for the other groups however were from 
the same stocks as this pilot experiment as the stability and expression from these was shown 
to be sufficient. 
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Figure 4.18. Expression of TetC-ZE fusion proteins after in vivo passage.                        
Western blot showing expression of TetC and TetC-Zika E fusion proteins from Salmonella 
Typhimurium SL3261 cell lysates after recovery from immunised mouse livers and spleens. Cell lysates 
were fractionated on SDS-PAGE before transfer to nitrocellulose. Blots were probed with Blots were 
probed with polyclonal rabbit anti-TetC serum (1:1000) and Goat anti-rabbit HRPO (1:3000). The TetC 
protein is clearly seen at approximately 50 kDa (A) and the TetC-ZE(s) (B) and TetC-ZE(s193) (C) fusion 
proteins at 97kDa and 74kDa respectively as shown in line with arrows. Cells from a stock plate which 
had not been subject to in vivo passage were used as a positive control (shown in the first lane of each 
blot).  
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4.7 Immune responses to Salmonella based Zika Virus vaccine 
 
It was confirmed through western blot that Salmonella Typhimurium vaccine strain SL3261 
could still express the TetC-ZE fusion proteins following in vivo passage, a new immunisation 
experiment was therefore carried out to determine whether the vaccine strains expressing 
the ZE fusion proteins would elicit an immune response in mice.  
4.7.1 Inoculation of mice with Salmonella vaccine strain SL3261 expressing TetC-ZE fusion 
proteins 
 
Mice were once again inoculated by intravenous injection with Salmonella Typhimurium 
vaccine strain SL3261 expressing TetC (control) or TetC-ZE fusion proteins. 
 
 
 
 
 
 
 
 
 
Table 4.3. Mice used in ZE immunisation experiment. Mice immunised in inoculation experiment to 
determine immune response to TetC-GP fusion proteins. 6 mice were immunised with the SL3261 
vaccine strain expressing either TetC or the TetC-ZE fusion proteins. 4 mice were not immunised so as 
to allow a baseline reading for normal mouse serum. Note: groups TETC and NEG are the same control 
groups as shown in chapter 3 section 3.6.1. 
 
 
Group Immunisation n BALB/c = 
TETC SL3261 pTECH2 
6.41 log10 CFU in 0.2ml PBS 
6 
TetC-ZE(s) SL3261 pTECH2-ZE(s) 
6.22 log10 CFU in 0.2ml PBS 
Taken from Mouse 1, Spleen (after in vivo 
passage) 
6 
TetC-ZE (s193) SL3261 pTECH2-ZE(s193) 
6.22 log10 CFU in 0.2ml PBS 
6 
TetC-ZE(WT) SL3261 pTECH2-ZE(WT) 
6.26 log10 CFU in 0.2ml PBS 
6 
NEG Not immunised  4 
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8 weeks post immunisation, the mice were sacrificed, and blood was collected from each 
mouse. This coagulated before centrifugation and serum only was collected. Sera was kindly 
collected and processed by staff at Cambridge University and sent to Newcastle to be tested 
for immune response. Once received, sera was aliquoted and stored at -80 °C prior to use in 
ELISA assays.  
 
4.7.2 IgG antibody response to Zika envelope protein 
 
The IgG response of immunised mouse serum to Zika envelope was determined by ELISA. 
Plates were coated with 5µg/ml Zika envelope protein (Fitzgerald) and sera diluted 1:25. The 
IgG response was measured at 450nm with Rabbit anti-mouse HRPO (Abcam) as the 
secondary antibody. The assay was developed with TMB and stopped with H2SO4 prior to 
reading.  Again, as was seen with the ELISA assay results from the immunisation with Ebola 
GP expressing vaccine strains, it seems that there is no significant immune response to Zika E 
(figure 4.19). The commercial recombinant Zika Envelope used to coat the ELISA plate was, 
according to the manufacturer (Fitzgerald), derived from an unspecified African strain, 
however all strains share very high identity of this sequence. Monoclonal antibodies directed 
to the Zika Envelope were able to bind to both the commercial and TetC-ZE fusion proteins 
when tested prior to carrying out the ELISA (data not shown). 
There are some potential outliers in the TetC-ZE(s) group, but the TetC negative control group, 
which it would be thought would give a low response to ZE, seems much higher than 
expected.  
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Figure 4.19. IgG antibody response to Zika envelope in ZE immunised mice.               
Graph showing IgG response in immunised mouse sera as measured by ELISA with plates coated with 
5µg/ml recombinant Zika envelope. Readings are presented as an average of triplicate wells + SD. 
Statistical significances compared to normal mouse sera (NEG) were analysed by unpaired t test. P 
values <0.05 were considered significant. Here, none of the means of any of the immunised groups 
(TETC-ZE(s), TETC-ZE(s193), TETC-ZE(WT) and TETC) were significantly different from normal mouse 
sera (ns = not significant). 
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4.7.3 IgG antibody response to TetC 
 
As in chapter 3, it was then decided that the IgG response to TetC should be analysed so that 
a general IgG response could be determined in all immunised mice. It is clear that the TetC 
only immunised control mice, respond as expected well and the non-immunised (NEG) mice 
do not show any IgG response to TetC. The TetC-ZE(s) immunised mice however, also do not 
appear to show any notable response to TetC and the same can be said for the TetC-ZE(s193) 
and TetC-ZE(WT) immunised mice, except for some outliers (figure 4.20) Again however, the 
mean responses of all of the immunised groups (apart from TETC control) are not significantly 
different to non-immunised mice (NEG). The lower IgG response seen in the fusion immunised 
groups was also seen in chapter 3 with the TetC-Ebola GP immunised mice. Assays to 
determine if the overall immune response was lower, potentially due to immunosuppression, 
were therefore carried out by determining IgG response to Salmonella Typhimurium LPS.  
 
 
 
 
 
 
 
 
 
169 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20. IgG antibody response to Tet C in ZE immunised mice.                
Graph showing IgG response in immunised mouse sera as measured by ELISA with plates coated with 
1µg/ml TetC protein. Readings are presented as an average of triplicate wells + SD. Statistical 
significances compared to normal mouse sera (NEG) were analysed by unpaired t test. P values <0.05 
were considered significant. Here, neither of the means of the groups immunised with SL3261 cells 
expressing the TetC-GZE fusion proteins (TETC-ZE(s), TETC-ZE(s193) and TETC-ZE(WT) were 
significantly different from normal mouse sera (ns = not significant). Mice immunised with SL3261 cells 
expressing TetC only however showed a significant IgG response to TetC compared with non-
immunised mice as expected (P = <0.0001 - ***) 
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4.7.4 IgG response to Salmonella Typhimurium LPS 
 
As there appeared to be a lower IgG response to TetC in the mice immunised with 
SL3261(pTECH2-ZE) constructs, expressing the TetC-ZE fusion proteins, it was decided to try 
and elucidate an overall immune response by analysing IgG response to Salmonella 
Typhimurium LPS (figure 4.21). This response, which is unrelated to the expression of TetC or 
TetC-ZE fusion proteins could show whether there is an immunosuppressive effect of the 
vaccine strains. 
Salmonella Typhimurium LPS (Sigma) was coated onto ELISA plates at 5µg/ml and pooled sera 
from each of the groups was titrated from a 1:50 to a 1:6400 dilution. The secondary antibody 
was again Rabbit anti-mouse HRPO and the assay was developed as before with TMB and 
H2SO4. There does not seem to be a clear difference between the anti LPS IgG response in 
mice immunised with SL3261 cells expressing only TetC compared to those immunised with 
SL3261 expressing the TetC-ZE fusion proteins. Compared to the non-immunised mice, which 
as expected did not show an IgG response to LPS as expected, this suggests that the overall 
immune response is not suppressed and therefore there may be alternative reasons as to why 
the IgG response to the Zika envelope protein in any of the three fusion groups, is not as high 
as was expected, when taking the relatively high expression levels of the TetC-ZE fusions into 
consideration. 
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Figure 4.21. IgG antibody response to Salmonella Typhimurium LPS in ZE immunised mice. Graph 
showing titration of IgG response against Salmonella Typhimurium LPS, from 1:50 to 1:6400 dilution, 
of pooled sera from mice immunised with Salmonella Typhimurium SL3261 vaccine strain expressing 
TetC or TetC-ZE fusion proteins. Non- immunised mice (NEG) were used as a control. Readings are 
presented as an average of triplicate wells + SD. Statistical significances compared to TetC immunised 
sera (TETC) were analysed by unpaired t test. P values <0.05 were considered significant and at all 
dilutions, none were significantly different.  
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4.8 Determination of Zika Virus Neutralisation activity in immunised mice 
 
The ELISA data had shown that while there did not appear to be a significant IgG response to 
Zika envelope in immunised mouse sera, there was some outlying samples which may have 
hinted at a response. In order to test this further, sera samples were sent to Professor Arvind 
Patel and Ricardo Sanchez Velazquez (Glasgow University) who kindly carried out micro-
neutralisation assays to determine if the sera from these immunisations had any virus 
neutralising capacity (figure 4.22).  
Vero cells were infected with Zika virus Brazilian strain PE243 (Donald et al, 2016) mixed with 
the experimental sera and incubated for 72 hours. A sandwich ELISA was then carried out to 
determine expression of Zika E from infected cells. From this, the % infection was calculated. 
A lower % infection was related to a lower amount of ZE expressed and thus a higher 
neutralisation capacity of the serum.  
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Figure 4.22. Zika Virus neutralisation activity in ZE immunised mice.              
Graphs showing results of micro-neutralisation assays against Zika Virus by immunised mouse sera. 
Each sample was used in conjunction with ZIKV (PE243) in a series of 3-fold dilutions (1:20 – 1:43740) 
to infect Vero cells. A sandwich ELISA to detect the presence of Zika E by these cells was then carried 
out and the OD450 was converted into a value for % of infection. As a Positive control, mouse sera 
from a mouse immunised with Domain III of ZE was used (shown in red on each graph - Pos). Mice 
from the NEG group (non-immunised) are used as a negative ‘normal mouse serum’ control. Mouse 
groups are A) TETC, B) TETC-ZE(s), C) TETC – ZE(s193), D) TETC – ZE(WT). Results from each mouse are 
presented separately (M1-6). This experiment was very kindly carried out by Professor Arvind Patel 
and Ricardo Sanchez Velazquez (Glasgow University). 
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It appears that there is little in the way of neutralising activity by the immunised mouse sera 
against Zika envelope. There are two potential outliers (see fig 4.22 D), mice M4 and M5 
immunised with TetC-ZE(WT), which show some neutralising activity at high serum 
concentration of 1:20 dilution. These interestingly do not correspond with any of the mice 
shown to have a slight IgG response to Zika E. Assays using these samples were then repeated 
however, and unfortunately shown to have no neutralising activity.  
 
4.8 Discussion 
 
A panel of constructs were generated to allow the expression of the Zika envelope protein by 
attenuated Salmonella vaccine strains. From this panel, the constructs which had shown to 
best express the Zika envelope protein were selected for investigation in in vivo immunisation 
experiments to determine the immune response in vaccinated mice towards the Zika 
envelope. These constructs, which facilitated expression of fusion proteins of the C-fragment 
of Tetanus toxin (TetC) and Zika E, from the pTECH2 expression vector, were transformed into 
attenuated Salmonella vaccine strains and used to immunise mice.  
TetC-ZE(s); TetC fused to the full-length ZE protein utilizing the codon optimised synthetic 
gene for expression in Salmonella Typhimurium, and TetC-ZE(193); TetC fused to a truncated 
193aa ZE protein were both expressed well by the Salmonella vaccine strain SL3261. TetC-
ZE(WT); TetC fused to the ZE protein which used the WT codons was also tested to determine 
if there was an advantage to using synthetic codon optimization to make these constructs. It 
appears that the codon optimised ZE fusion protein was better expressed than the WT. 
Expression was assessed by the western blotting of Salmonella Typhimurium vaccine strain 
SL3261 cell lysates harbouring the relevant plasmids.  
Attempts were also made to express the Zika envelope protein without the addition of the 
TetC fusion partner. Unlike Ebola GP (as reported in chapter 3, section 3.2.2.2), the ZE protein 
was expressed by Salmonella Typhimurium alone in the pTECH10-ZE expression vector. The 
level of expression however was nowhere near that of the pTECH2-ZE construct which has 
the full-length TetC fusion partner. The addition of the sequence of 30 bases downstream of 
the TetC start codon, which had been shown to rescue the expression of Ebola GP (see chapter 
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3, section 3.2.2.3), did not appear to improve the expression of the Zika envelope compared 
to its expression alone. This may be due to a more stable interaction between the Salmonella 
16S rRNA and the ZE mRNA, in contrast to the Ebola GP mRNA, due to potentially higher 
complementarity, and therefore facilitation of expression.  
An alternative construct was also generated which used the Zika envelope as a fusion partner 
to the Ebola GP DMFL sub-fragment. Due to the fact that ZE was successfully expressed alone, 
and GP was not, it was thought that the ZE could perhaps replace the TetC and rescue 
expression of the Ebola GP DMFL sub fragment. The ZE-GP DMFL fusion protein was 
successfully expressed, however not to levels seen with the TetC fusion partner. 
 It was concluded that the TetC fusion partner allowed much higher levels of expression of 
the fusion proteins and therefore the pTECH2 constructs would be brought forward for 
further testing. 
The pTECH2- ZE plasmids were shown to be stably retained in the absence of antibiotic 
selection both in vitro and in vivo, and still expressed the TetC-ZE fusion proteins following in 
vivo passage (figures 4.17 and 4.18). This allowed an immunisation experiment to determine 
mouse immune responses to Zika envelope to be carried out. Mice were immunised with 
intravenous SL3261 harbouring the pTECH2, pTECH2-ZE(s), pTECH2-ZE(193) and pTECH2-
ZE(WT) plasmids and after 8 weeks, sera was analysed by ELISA to determine IgG responses 
(figures 4.19, and 420). Unfortunately, there was no significant IgG response to the Zika 
envelope protein from either of the groups immunised with the Salmonella expressing the 
TetC-ZE fusion proteins.  In addition, the mice immunised with Salmonella harbouring the 
pTECH2 only plasmid, as expected, had a strong IgG response to TetC, however the mice 
immunised with the TetC-ZE fusion expressing plasmids showed a lower response to TetC.  
Overall IgG antibody response to Salmonella Typhimurium LPS was also tested (figure 4.21), 
to determine if the lack of response seen towards Zika envelope in the TetC-ZE fusion 
immunised mice was due to an overall dampened immune response or immunomodulatory 
effect of the attenuated vaccine strains. However, there were no significant differences 
between the responses seen in mice immunised with the SL3261-TetC control or the SL3261-
TetC-ZE fusion experimental groups. 
176 
 
Some potential outliers were found of TetC-ZE immunised mice that showed a hint of an IgG 
response to ZE. The difficulty in procuring a recombinant Zika Envelope protein for use in 
these assays, meant that a commercial protein, expressed using a Baculovirus-insect cell 
expression system was used. This was derived from the African strain which shares high 
identity to all other strains for the E protein. This could have been an explanation for the poor 
IgG response seen in these assays, however the same samples were then subject to virus 
neutralisation assays (figure 4.22) and unfortunately were shown to be unable to neutralise 
the Zika Virus PE243 strain.  
This lack of response could be due to a variety of reasons, including in vivo expression levels 
of the fusion proteins. This is discussed further in chapter 6, section 6.5.  
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Chapter 5 - Exploiting Salmonella Typhimurium 
Outer Membrane Vesicles (OMVs) as a novel vaccine delivery platform 
 
5.1 Introduction   
 
Gram-negative bacteria produce naturally occurring vesicles formed from the blebbing of the 
outer membrane – Outer Membrane Vesicles (OMVs). These spherical packages contain 
periplasmic and outer membrane located molecules (such as virulence factors) which can be 
delivered to host cells (Kulp & Kuehn, 2010).  
It has been considered that these vesicles, due to their immunostimulatory properties and 
cargo delivery abilities, could be used as a non-living vaccine. OMVs contain potent pathogen 
associated molecular patterns (PAMPS) such as lipopolysaccharide (LPS) which are recognised 
by pattern recognition receptors (PRRs) such as TLR-4 (Rossi et al, 2016) and activate the 
innate immune system. Genetic modification of Salmonella, producing knockout strains of 
certain genes has shown to increase the propensity of these cells to produce OMVs (Rossi et 
al, 2016). This combined with the engineering of plasmid constructs to express antigens, such 
as the Zika envelope, could provide a novel vaccine platform to allow delivery of ZE to host 
cells without the need to use living Salmonella vaccine strains.  
OMVs carrying Zika envelope could be purified and used to immunise. This method would 
have the advantage of being able to quantify antigenic dose compared to the living platform, 
and thus could be a more efficient way of antigen delivery at concentrations needed to elicit 
a protective immune response. This vaccine delivery platform could also have the advantage 
of increasing access to these vaccines, due to the contraindications of administering live 
vaccines to vulnerable people, for example, those with compromised immune systems or the 
very young and very old. 
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5.2 Gene Knockouts to increase OMV production   
 
The yield of OMVs naturally produced by Gram-negative bacteria is usually in low quantities. 
To exploit this mechanism in order to develop vaccines, it is important to increase this yield 
to ensure that an adequate antigenic dose is administered.  
Targeted genetic modification to knockout certain genes of some bacteria, for example those 
responsible for enabling the linking of inner and outer bacterial membranes, has shown that 
this yield increase is possible due to an induction of ‘hyperblebbing’ by the cells as a result of 
the knockout (Rossi et al, 2016) 
5.2.1 Constructing gene knockout of tolR in Salmonella Typhimurium strain SL1344  
 
The protein TolR is part of the tol-pal system, which is highly conserved between Gram-
negative bacterial species and involved in upholding outer membrane stability. It has been 
shown that E. coli tol mutants produce an increased quantity of outer membrane vesicles 
(Lazzaroni et al, 1999; Bernadac et al, 1998). 
TolR is part of a complex of proteins in this system which also includes TolQ and TolA and is 
found in the cytoplasmic membrane. TolR is anchored to the inner membrane with the 
majority of the protein situated in the periplasm and helps to facilitate linkage between the 
inner and outer membranes of the bacteria (Lazzaroni et al, 1999; Rossi et al, 2016). 
 In Salmonella Typhimurium, deletion of the tolR gene, and therefore disrupting this system, 
results in a strain in which the integrity of the outer membrane is altered and more likely to 
bleb off creating vesicles (Berlanda Scorza et al, 2012; Rossi et al, 2016). 
It was therefore decided to create a Salmonella Typhimurium ΔtolR strain to determine if it 
was possible to firstly, purify an adequate quantity of OMVs, and secondly to express the Zika 
envelope protein in such a way that it was packaged in these vesicles, showing a viable 
method for which to create this non-living Zika vaccine.  
Using the lambda-red recombinase technique (Datsenko & Wanner, 2000!) the tolR gene was 
knocked out of Salmonella Typhimurium strain SL1344 and replaced with the kanamycin 
resistance gene – KanR, found on bacterial transposon Tn5, encoding neomycin 
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transphospherase and taken here from the plasmid PKD4. A colony PCR was carried out with 
‘tolR check’ primers to confirm a successful knockout (figure 5.1). If the tolR gene was still 
present in the SL1433 genome, the PCR would simply amplify a 515bp product which included 
the 429bp tolR gene. If the knockout, by way of replacing tolR with the kanamycin resistance 
cassette was successful, the primers would amplify a product of 1.5kb.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Colony PCR screen to determine tolR knockout of SL1344.                   
0.7% agarose gel showing PCR products from colony PCR using tolR screening primers of the SL1344 
genomic DNA to determine successful knockout and replacement of the tolR gene with KanR. Colonies 
1-5 (as shown on gel) were boiled before PCR amplification of the genome between each screening 
primer. Positive colonies in which the knockout has been successful show a band at approximately 
1.5kb (see white arrow). A negative control, SL1344 in which the tolR gene is present, shows a band 
at 515bp (see black arrow).  
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5.2.2 Constructing gene knockout of mlaA in Salmonella Typhimurium strain SL1344  
 
An ATP binding cassette (ABC) transport system, the Mla pathway, is found to be highly 
conserved between gram-negative bacterial species. It is thought that this pathway helps to 
prevent phospholipid accumulation at the outer leaflet of the outer membrane (OM) and is 
involved in maintaining the asymmetry of lipids between the inner membrane (IM) and OM 
(Malinverni & Silhavy, 2009).  
Mutations resulting in the repression or deletion of components in this pathway can increase 
the production of OMVs by gram-negative bacteria, as phospholipids accumulate in the OM 
(Reidl, 2016).  
MlaA (also known as VacJ), is a lipoprotein found on the OM, thought to act as a translocation 
channel for phospholipids (Abellón-Ruiz et al, 2017). MlaA works in this system with Yrb 
proteins, trafficking phospholipids from the OM to the IM to prevent accumulation. Deletion 
of the MlaA gene for example, leads to over accumulation of OM outer leaflet phospholipids, 
resulting in asymmetric expansion of the outer leaflet which eventually blebs off to become 
an OMV (Roier et al, 2016). 
It was therefore decided to make SL1344 ΔMlaA as an alternative to ΔtolR, to determine 
which would be the best strain to use for the OMV vaccine platform. 
Again, a colony PCR was carried out with ‘mlaA check’ primers to confirm a successful 
knockout (figure 5.2). If the mlaA gene was still present in the SL1433 genome, the PCR would 
simply amplify an 855bp product which included the 756bp mlaA gene. If the knockout, by 
way of replacing mlaA with the Kanamycin resistance cassette was successful, the primers 
would amplify a product of 1.5kb. 
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Figure 5.2. Colony PCR screen to determine mlaA knockout of SL1344.          
0.7% agarose gel showing PCR products from colony PCR using mlaA screening primers of the SL1344 
genome to determine successful knockout and replacement of the mlaA gene with KanR. Colonies 1-
11 (as shown on gel) were boiled before PCR amplification of the genomic DNA between each 
screening primer. Positive colonies in which the knockout has been successful show a band at 
approximately 1.5kb (see white arrow). A negative control, SL1344 which has the mlaA gene, shows a 
band at 855bp (see black arrow). 
 
Following successful construction of gene knockouts, the KanR gene was removed using the 
FLP-out technique with transformation of the temperature sensitive pCP20 plasmid, 
expressing FLP recombinase. The removal of the KanR gene was checked using sequencing on 
kanamycin sensitive colonies. Each of the confirmed knockout mutant strains were 
transduced by P22 phage containing the genetic knockout lesion, into a fresh SL1344 strain 
to lower the risk of secondary mutations occurring. This resulted in the strains SL1344 ΔtolR 
and SL1344 ΔmlaA, which had sensitivity to kanamycin and ampicillin, allowing for further 
selection of strains when transformed with ZE expression plasmids. 
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5.3 Directing expression of antigens to the cell membrane or periplasm  
 
Once confirmation of the tolR and mlaA knockouts had been carried out, plasmid constructs 
were made to direct expression and targeting of the Zika envelope protein to either the outer 
membrane or periplasm of the SL1344 cells. This would hopefully lead to the incorporation of 
the ZE protein into the OMVs, either on the vesicle surface, or packaged within the lumen. 
5.3.1 Expression plasmid pBAD24-ZE 
 
Firstly, a new expression plasmid was created using the In-Fusion® ligation independent 
cloning kit (Clontech). Using primers which had a 15-base overlap with the ends of the Zika 
envelope insert and the linearised pBAD24 cloning vector, the pBAD24-ZE plasmid was 
successfully constructed and transformed into Stellar® competent E. coli (Clontech) (figure 
5.3). 
This was then checked by informative digest (figure 5.4) and sequencing (Eurofins) with pBAD 
screening primers to confirm the plasmid to allow for further cloning of the protein directing 
signal sequences. The Zika envelope protein would then be expressed under the control of 
the araBAD, arabinose inducible promoter. 
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Figure 5.3. Plasmid map of the pBAD24-ZE expression plasmid.                 
The ZE gene was inserted into the pBAD24 vector using the In-Fusion® cloning kit (Clontech). The Zika 
envelope protein is under the control of the arabinose inducible promoter (araBAD promoter). 
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Figure 5.4. Restriction digest screen of putative pBAD42-ZE clones.                   
0.7% agarose gel, showing pBAD24-ZE digested with Xba and HindIII from two colonies of Stellar® 
competent E. coli, transformed with the In-Fusion® reaction mix. This gives an insert band 
approximately 1.2kb, corresponding to the Zika envelope gene (lanes 1 and 2, see arrow). P is uncut 
plasmid. The pBAD24-ZE plasmid was then further confirmed by sequencing (Eurofins) using the pBAD 
screening primers (see figure 5.3). 
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5.3.2 Utilising the OmpA Signal sequence to target protein expression to the bacterial outer 
membrane 
 
OmpA, Outer Membrane Protein A, is a multifunctional protein, highly conserved amongst 
Gram-negative bacteria, including Salmonella (Krishnan & Prasadarao, 2012). As the name 
would suggest, it is situated on the outer membrane of these bacteria. By using the signal 
sequence of OmpA, it could act to direct the Zika envelope protein to the Salmonella outer 
membrane and therefore would be included in the OMVs.  
The Salmonella Typhimurium OmpA signal sequence is: MKKTAIAIAVALAGFATVAQA. 
 
5.3.3 Constructing pBAD24 vector to express Zika envelope with OmpA signal sequence 
(OmpAss) 
 
First, a construct was made inserting the OmpA signal sequence into the pBAD24-ZE plasmid, 
at the N terminal end of the ZE gene, before the start codon (see figure 5.5 for the resultant 
expressed protein). Oligos of the sense and anti-sense strands of the OmpA sequence were 
synthesised by Eurofins, with inclusion of the nucleotides from ‘digested’ restriction sites XbaI 
and EcoRI, which sit 20 bases apart on the pBAD24 vector. Each OmpA oligo was annealed 
and ligated into the pBAD24-ZE vector using T4 DNA ligase.  
 
 
 
Figure 5.5. Schematic presentation of the OmpAss Zika E construct.              
In the pBAD24 vector, under the control of the arabinose inducible araBAD promoter, the Zika 
envelope protein is expressed with the addition of the signal sequence from Salmonella Typhimurium 
OmpA (OmpA SS). This would hopefully act to direct ZE expression to the outer membrane and 
subsequent incorporation in OMVs.  
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NEB5α E. coli cells (NEB) were transformed with the reaction mix and ampicillin resistant 
colonies were checked with colony PCR with OmpA Forward and pBAD Screen reverse 
primers, a positive colony giving a band at approximately 1.5kb (figure 5.6).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6. Colony PCR screen of pBAd24-OmpAss ZE putative clones.         
0.7% agarose gel showing PCR products from colony PCR of transformed NEB5α competent E. coli 
(NEB), using OmpA forward and pBAD reverse screening primers. Positive colonies which include the 
ompA signal sequence give a band at approximately 1.5kb (see arrow). Colony 6 was chosen for further 
screening by sequencing (Eurofins) using pBAD screening primers and was shown to read the Zika E 
gene through in frame with the OmpA signal sequence and araBAD promoter.  
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5.3.4 Constructing pBAD24 vector to express Zika envelope with OmpA signal sequence 
(OmpAss) membrane spanning region (MSR) of OmpA 
 
It was also decided after successfully constructing the pBAD24-OmpA ss-ZE plasmid, that 
expression and targeting of ZE to the outer membrane could potentially be improved by the 
addition of an extra few bases of the OmpA protein. This would include the first 12 amino 
acids after the signal sequence which in WT Salmonella would be the first membrane 
spanning region (MSR) of OmpA. This would hopefully act to securely anchor the Zika E 
protein to the outer membrane.  
The MSR was added to the pBAD-OmpA ss-ZE plasmid using the In-Fusion® kit with the MSR 
included on the reverse primer. The reaction mix was transformed into Stellar® competent E. 
coli cells and colonies picked the following day after incubation on LB agar with ampicillin. 
Plasmid DNA from a selection of these colonies was purified and sent for sequencing 
(Eurofins) with pBAD screening primers to confirm the inclusion of the MSR. With only a small 
addition of nucleotides, it would have been difficult to differentiate the band size difference 
on a colony PCR gel, so this was not carried out at this time. The sequencing results confirmed 
the successful addition of the MSR to this plasmid. 
The sequence of the Salmonella Typhimurium OmpA MSR is: APKDNTWYAGAK.  
The resulting construct allowed the expression of the Zika Envelope fused to the OmpAss and 
MSR (figure 5.7). 
 
 
 
Figure 5.7. Schematic presentation of the OmpAss MSR Zika E construct.              
In the pBAD24 vector, under the control of the arabinose inducible araBAD promoter, the Zika 
envelope protein is expressed with the addition of the signal sequence and membrane spanning 
region from Salmonella Typhimurium OmpA (OmpA SS). This would hopefully act to direct ZE 
expression and anchor to the outer membrane and subsequent incorporation in OMVs.  
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5.3.5 Utilising the DsbA Signal sequence to target protein expression to the bacterial 
periplasm 
 
Another potential way of incorporating the Zika envelope in the OMVs would be to direct 
expression to the periplasm. A gel-like matrix situated between the inner and outer 
membrane, it contains proteins involved in multiple functions. When OMVs are produced, 
some of the periplasmic material is incorporated in the lumen of the vesicle. By directing 
expression to the periplasm, it is hoped that the Zika envelope protein would also be included. 
It has been shown that proteins can be directed to the periplasmic space by the DsbA, a 
bacterial thiol disulphide oxidoreductase, signal sequence (Schierle et al, 2003). 
The Salmonella Typhimurium DsbA signal sequence is: MKKIWLALAGMVLAFSASAA. 
5.3.6 Constructing pBAD24 vector to express Zika envelope with DsbA signal sequence 
(DsbAss)  
 
As with the OmpAss construct, the DsbA signal sequence was inserted into the pBAD24-ZE 
plasmid, at the N terminal end of the ZE gene, before the start codon (see figure 5.8 for the 
resultant expressed protein). Oligos of the sense and anti-sense strands of the DsbA sequence 
were once again synthesised by Eurofins, with inclusion of the nucleotides from ‘digested’ 
restriction sites XbaI and EcoRI, situated 20 bases apart on the pBAD24 vector. Each DsbA 
oligo was annealed and ligated into the pBAD24-ZE vector using T4 DNA ligase, before 
transformation into NEB5α competent E. coli (NEB). 
 
 
 
Figure 5.8. Schematic presentation of the DsbAss Zika E construct.                
In the pBAD24 vector, under the control of the arabinose inducible araBAD promoter, the Zika 
envelope protein is expressed with the addition of the signal sequence from Salmonella Typhimurium 
DsbA (DsbA SS) This would hopefully act to direct ZE to the periplasmic space and subsequent 
incorporation in the lumen of the OMVs.  
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Successful incorporation of the DsbA signal sequence was confirmed by colony PCR using 
DsbA forward and pBAD screening reverse primers, with positive colonies giving a PCR 
product at approximately 1.5kb (figure 5.9). 
 
 
 
 
 
 
 
 
 
 
Figure 5.9. Colony PCR screen of pBAd24-DsbAss ZE putative clones.           
0.7% agarose gel showing PCR products from colony PCR of transformed NEB5α competent E. coli 
(NEB), using DsbA forward and pBAD reverse screening primers. Positive colonies which include the 
DsbA signal sequence give a band at approximately 15.kb. Colony 1 (see arrow) was chosen for further 
screening by sequencing (Eurofins) using pBAD screening primers and was shown to read the Zika E 
gene through in frame with the DsbA signal sequence and araBAD promoter.  
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5.3.7 Expression of Zika E in SL1344 ΔtolR and ΔmlaA knockout strains  
 
The confirmed plasmids expressing the Zika envelope and the OmpA or DsbA signal 
sequences, were then transformed into the Salmonella Typhimurium knockout strains, 
SL1344 ΔtolR and SL1344 ΔmlaA. Successful transformation was again confirmed by 
sequencing (Eurofins) purified plasmid using pBAD screening primers.  
To determine whether the newly constructed signal sequence plasmids would express the 
Zika envelope protein, cells which had successfully taken up the new plasmids, were grown 
overnight and the following day induced with L-arabinose. Cells were pelleted and lysed in 
preparation for SDS-PAGE and western blot with mouse monoclonal anti Zika envelope (figure 
5.10). 
 
The plasmids that were successfully transformed and strains tested here are: 
SL1344 ΔmlaA pBAD24 OmpAss-ZE 
SL1344 ΔmlaA pBAD24 OmpAss MSR-ZE 
SL1344 ΔtolR pBAD24 OmpAss MSR-ZE 
SL1344 ΔtolR pBAD24 DsbAss-ZE 
Each showing expression of the approximately 45kDa Zika envelope protein. 
Unfortunately, the DsbA plasmid was not successfully transformed into SL1344 ΔmlaA and 
the OmpA (no MSR) was not successfully transformed into SL1344 ΔtolR.  
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Figure 5.10. Expression of Zika E in SL1344 ΔtolR and ΔmlaA knockout strains.              
Western blot showing expression of Zika envelope protein in SL1344 ΔmlaA and SL1344 ΔtolR cell 
lysates harbouring pBAD24 plasmids expressing ZE with the OmpA and DsbA signal sequences or 
OmpA signal sequence plus the membrane spanning region (MSR) of OmpA. The blot was probed with 
monoclonal mouse anti-Zika envelope. Lane 1 is a positive control of SL3261 lysate harbouring the 
pTECH2-ZE plasmid as described in chapter 4, expressing a Tet C-ZE fusion protein (approximately 
97kDa, see arrow). Lanes 2 and 7 are SL1344 ΔmlaA and SL1344 ΔtolR cell only negative controls 
respectively. Each strain harbouring each plasmid was run both with (lanes 2, 5, 8 and 10) and without 
(lanes 4, 6, 9 and 11) L-arabinose induction. The Zika E protein is clearly visible as a band at 
approximately 45kDa in the arabinose induced lysates. 
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5.4 Outer Membrane Vesicle production  
 
Following confirmation that the SL1344 ΔmlaA and SL1344 ΔtolR strains were able to express 
the Zika envelope protein harbouring the pBAD24 expression plasmids with the OmpA or 
DsbA signal sequences included, the Outer Membrane Vesicles were purified from spent 
supernatant from induced SL1344 strains to determine if the Zika envelope would be 
incorporated.   
5.4.1 Fractionation of OMVs   
 
Firstly, the purified OMV fraction from each of the knockout strains was run on SDS-PAGE gel 
to allow comparison between each strain to determine which would have the potential to 
produce more OMVs. After ultracentrifugation of filter sterilised supernatant, the OMV pellet 
was resuspended in 1ml sterile PBS. The same volume of sample from each strain was then 
prepared for SDS-PAGE (figure 5.11) 
  
 
 
 
 
 
 
 
Figure 5.11. SDS-PAGE of the purified Outer Membrane Vesicle fraction from SL1344 knockout 
strains.                         
The pellet resulting from ultracentrifugation of spent supernatant from overnight growth of SL1344 
ΔtolR and SL1344 ΔmlaA strains was resuspended in PBS. Equal volumes of sample were boiled with 
reducing sample buffer before running SDS-PAGE. The gel was subsequently stained with 
InstantBlueTM (Expedeon).  
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It was then decided to proceed with the SL1344 ΔtolR strain as it appeared, due to the band 
intensity on the InstantBlueTM stained gel, that there was a higher amount of OMV production 
from this strain than SL1344 ΔmlaA. 
As shown above, SL1344 ΔtolR cells were transformed with the pBAD24 plasmids expressing 
Zika E with the OmpA signal sequence, plus MSR or the DsbA signal sequence. The OMVs were 
purified from spent supernatant of arabinose induced cultures and run on SDS-PAGE, stained 
with InstantBlueTM to visualise the OMV fraction versus the cell lysates (figure 5.12). 
 
 
Figure 5.12. SDS-PAGE of purified outer membrane vesicles from SL1344 ΔtolR cells.       
OMVs were fractionated by ultracentrifugation of spent supernatant and run on SDS-PAGE. Cell lysates 
were prepared from the pellet of the same cultures. The gel was stained with InstantBlueTM. Lane 2 
shows the OMV fraction from WT SL1344 cells and lane 2 from SL1344 ΔtolR cells. Lanes 3-6 show 
OMVs purified SL1344 ΔtolR cells harbouring the pBAD24-OmpAss(MSR)-ZE or pBAD24-DsbA-ZE 
plasmids. Lanes 8-10 show cell lysates from each of these samples.  
 
 
 
 
 
194 
 
It is clear to see, when compared to the protein profile of purified OMVs, that the SL1344 
ΔtolR cells produce far more than the WT strain, where only very faint bands are visible (figure 
5.12 lane 1). Each sample of the tolR knockout strain, both with and without plasmid, show 
intense bands, showing OMV proteins. These are similar to those shown by Bai et al, when 
OMVs were purified after Salmonella Typhimurium was grown in LB media (Bai et al, 2014). 
The cell lysates from the same samples were also included as a comparison, the decrease in 
the number of bands in the OMV fraction compared to the total cell lysates is very clear and 
shows successful purification of the vesicles.  
Interestingly, a strong band of approximately 70kDa, appears in the OMV samples of SL1344 
ΔtolR strain, when harbouring the construct using the OmpA signal sequence plus MSR (figure 
5.12 lanes 3 & 4). This is not seen when the strain harbours the construct using the DsbA 
signal sequence (figure 5.12 lanes 5 & 6). This protein is not detected with anti-Zika envelope 
antibodies (see figure 5.14), so at present, it is not clear what this is. This could be elucidated 
using MALDI-TOF mass spectrometry to carry out peptide mass fingerprinting and determine 
the sequence of the protein.  
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5.4.2 Expression of Zika envelope in OMVs 
 
Following confirmation of successful purification of outer membrane vesicles, the same 
samples were again run on SDS-PAGE and transferred for western blot, to determine whether 
the OMVs contained the directed Zika envelope protein. When probed with monoclonal 
mouse anti ZE, bands were seen at the expected size of the combined OmpAss (plus MSR) or 
DsbAss and ZE proteins (figure 5.13).  
 
 
 
 
 
 
 
 
 
Figure 5.13. Expression of Zika envelope in SL1344 outer membrane vesicles.       
Western blot showing expression of Zika envelope protein in Outer Membrane vesicles purified from 
spent supernatant of SL1344 ΔtolR cells harbouring pBAD24 expressing the Zika envelope protein with 
the OmpA (plus MSR) or DsbA signal sequences. Lanes 1 and 2 are negative controls from cells 
containing no plasmid, lanes 3 and 4 and lanes 5 and 6 are two samples of each set of purified OMVs 
from SL1344 ΔtolR cells harbouring pBAD24-OmpAss(MSR)-ZE (3&4) or pBAD24-DsbAss0ZE (5&6). 
Lanes 8-10 are cell lysates from the same cells, with negative controls in lanes 8 and 9. Blot was probed 
with 1:2000 monoclonal mouse anti Zika envelope (Aaltobioreagents) followed by 1:4000 Rabbit anti-
mouse HRPO. Bands are seen at approximately 50kDa corresponding to the size of the Zika envelope 
(and in the case of lanes 3 and 4, the extra membrane spanning amino acids of OmpA), denoted by 
arrows. 
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5.4.3 TEM of OMVs produced from SL1344 ΔtolR Salmonella strain 
 
After producing protein profiles which seemed to correspond with successful OMV 
purification (figures 5.11 and 5.12), it was decided that the vesicles should be visualised using 
transmission electron microscopy (TEM). The samples (in PBS) of purified OMVs from SL1344 
ΔtolR cells were adsorbed to Formvar grids for negative staining with uranyl acetate and 
observed with a Philips CM100 Transmission Electron Microscope. These images clearly show 
an abundance of OMVs in the samples from SL1344 ΔtolR cells, both with and without 
plasmid, and much less from SL1344 WT (figure 5.14).  
 
 
Figure 5.14. Transmission Electron microscopy of OMVs.          
OMVs purified from SL1344 (WT) or SL1344 ΔtolR (ΔtolR) cells with and without the Zika envelope 
expressing pBAD plasmids. Magnification was either 46000x (A) or 92000x (B). Bars are 500nm and 
100nm respectively. Images were acquired by Tracey Davey (Newcastle University Electron 
Microscopy Research services). 
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5.5 Discussion 
 
By generating knockouts of the tolR and mlaA genes of Salmonella Typhimurium SL1344, 
strains were successfully able to produce a much higher yield of outer membrane vesicles 
than the wild type strain. Using the pBAD24 expression vector, the Zika envelope protein was 
expressed by these knockout cells genetically fused with the signal sequences from either the 
Salmonella Typhimurium OmpA or DsbA proteins. This allowed the targeting of expression of 
ZE to the outer membrane or periplasm respectively, and subsequent incorporation in the 
OMVs. These OMVs were successfully purified from spent supernatant by ultracentrifugation 
and visualised with transmission electron microscopy. 
From Western blot analysis of purified OMVs, it is clear to see that Zika envelope is detected 
only in the OMV fractions purified from cells harbouring the pBAD plasmids expressing ZE 
(figure 5.13). This suggests that the expression of the Zika envelope protein has been 
successfully directed to either the outer membrane, with the OmpA signal sequence, or the 
periplasm, with the DsbA signal sequence, and that is has been incorporated into the OMVs 
themselves. This shows the potential of this method in producing vesicles which could deliver 
the antigen to the host without the need for a live bacterial delivery system as described in 
chapters 3 and 4. Improvements to expression would need to be investigated so as to allow 
for maximum antigenic dose, however as a proof of concept, it has been shown to be a 
promising possible avenue for further investigation. This will be discussed further in chapter 
6.  
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Chapter 6 – Discussion and future work 
 
The development of vaccinations to some of the most deadly or problematic pathogens the 
world has ever seen is an endeavor that should be continuously explored. The lack of effective 
vaccines licensed for protection against Ebola or Zika Viruses, highlighted with the recent 
widespread outbreaks, have increased efforts into research and clinical trials.  
This project aimed to investigate the uses of Salmonella as vaccine delivery platforms, in an 
attempt to create a prototype vaccine that would have the eventual advantages of oral 
administration, no need for cold storage and also be cost effective to develop and produce in 
comparison with other vaccine strategies. 
6.1 Salmonella based vaccine strategies 
 
Live attenuated Salmonella vaccines have been shown to be more effective in providing 
protection against typhoid than heat killed or phenol inactivated strains, due to their ability 
to grow and persist in intracellular compartments. These strains can also express 
heterologous antigens from a variety of pathogens for delivery to the host immune system 
(Khan et al, 1994a; Khan et al, 1994b; Chabalgoity et al, 1996; Lee et al, 2000; Mckelvie et al, 
2008). It was hoped that similar results would be seen in this study, expressing Ebola GP and 
Zika envelope proteins from Salmonella vaccine strains.   
Mucosal vaccines allow for the induction of both a local mucosal response, followed by a more 
widespread systemic response. A live Salmonella based vaccine would be an ideal vehicle for 
this as, when ingested, the bacterium first infects the intestinal mucosa before propagating 
and persisting systemically. A successful vaccine using this delivery route, would be extremely 
attractive as it would stimulate a protective immune response at the mucosa, and would 
hopefully block pathogen entry at this site (Gayet et al, 2017).  
In the case of Ebola Virus infection, which is primarily transmitted through mucosal surfaces 
(Baseler et al, 2017), this is certainly a logical avenue to take and could be very effective in 
preventing mucosal transmission in the first place. While Zika Virus is a mosquito-borne virus, 
and thus transmitted primarily by arthropod vectors, it has been shown to be present in the 
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body fluids (for example; saliva, tears, breast milk, semen and urine) of those infected and 
reports have been made showing the possibility of sexually transmitted infection. There is 
therefore a suggestion that there could be a risk of Zika Virus transmission via the mucosal 
route, particularly from patients with a high viral load (Newman et al, 2017). An effective 
vaccine using this system, allowing both mucosal and systemic protection would also have 
the advantages of being very easy to administer (orally) and cost effective to produce. 
The live-attenuated poliovirus vaccine, which as discussed in section 1.1.2, is able to provide 
mucosal and systemic protection against the virus is an example of a very successful vaccine 
which is administered orally. The advantage here of the Salmonella based system for vaccine 
delivery, is that this could be taken in pill form (such as Ty21a) and not as a liquid (as with the 
polio vaccine) which can be harder to administer and is known to have a strong and 
unpleasant taste. Thus, a pill could be seen as more acceptable and does not require any 
specialist equipment or training to administer as opposed to parenteral methods of 
vaccination.  
 
While live vaccines can be effective, and are shown to be less likely to induce adverse events 
in patients than killed Salmonella (Engels & Lau, 1998), they are often unsuitable for certain 
patient groups such as the very young (under 2 years of age), the elderly or the 
immunocompromised (Milligan et al, 2018). A non-living vaccine delivery platform, may help 
to widen the access for these vaccines.  
Another potential advantage of using non-living vaccines could be the delivery of the 
antigenic dose. With live vaccines, expressing the antigen as in this study, the dose is limited 
by the in vivo expression within the Salmonella vaccine strain, and the impact that the 
expression of the heterologous antigen has upon the physiological health of the host cell. 
With a non-living vaccine delivery platform, the antigen is already present and can be 
administered in as much quantities as necessary to elicit a protective immune response 
without the need to rely on in vivo expression.  
One potential alternative vaccine delivery system could be the use of synthetic liposomes, 
which can be engineered to incorporate a wide range of antigens and subsequently can elicit 
strong protective immune responses. This system would likely be administered via 
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intramuscular injection, yet could be used for intranasal mucosal immunisation depending on 
the liposome composition (Schwendener, 2014). Such a vaccine would be safer than using live 
attenuated pathogens but could be a less cost-effective method than the use of naturally 
occurring bacterial outer membrane vesicles (OMVs) for example. 
The use of outer membrane vesicles from Gram-negative bacteria as a vaccine delivery system 
is currently receiving growing attention. As well as the potential to carry heterologous 
antigens, they also act as a self-adjuvant due to their incorporation of immunostimulatory 
molecules naturally occurring on the bacterial surface (Van der pol et al, 2015; Tan et al, 
2018). OMVs have been successful in conferring protection in mice against pathogens such as 
Bordetella pertussis (Roberts et al, 2008), Haemophilus influenzae (Roier et al, 2012), 
Streptococcus pneumoniae from heterologous Pneumococcal Protein PspA (Muralinath et al, 
2011) and elicit neutralising antibodies towards heterologous Chlamydia muridarum HtrA 
(Bartolini et al, 2013). An OMV vaccine against Neisseria meningitidis has also been proven 
safe and effective in humans (Holst et al, 2009). The OMV platform clearly has some 
advantages over the live attenuated Salmonella vaccine, yet to allow for a mucosal 
administration route, which could be more effective depending on the pathogen, it is likely 
that a much higher dose would be required compared to an injectable vaccine (Holst et al, 
2009). If this was optimised however, then it is possible that OMVs can be used as a potentially 
safer mucosal vaccine alternative to a live delivery system, mitigating the risk of attenuated 
strains regaining virulence and widening access to these vaccines in vulnerable patient 
groups.  
It is hoped that a protective immune response from Salmonella OMVs containing Zika 
envelope will be elicited in immunised mice to further test this proof of concept idea. 
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6.2 Expression of Ebola GP in attenuated Salmonella vaccine strains 
 
The development of a panel of constructs, allowed exploration of a variety of ways in which 
to try to get the best possible expression of Ebola GP, a feat which has proved difficult for 
many groups. The panel included not only the full-length GP (devoid of the hydrophobic signal 
and transmembrane regions), but also sub fragments of the protein containing known 
epitopes recognised by known protective or neutralising antibodies, including those used in 
therapeutic cocktails (Qiu et al, 2014; Gonzalez-Gonzalez, 2015). This approach, targeting 
known B-cell epitopes, which have been shown to be vital in protection against Ebola Virus 
infection would hopefully ensure that the peptides expressed in the vaccine are able to elicit 
these protective and neutralising antibodies (see figure 6.1). 
 
Figure 6.1. Ebola GP sub fragments, conserved epitopes and panel of generated constructs.  A) 
Schematic diagram showing epitope locations (in yellow) for relevant mouse monoclonal antibodies 
in relation to sub-fragments of Ebola GP and the full-length protein. Epitopes to monoclonal 
antibodies used in therapeutic cocktails such as 2G4 and 4G7 (Zmapp) and 13F6 (MB-003) are also 
shown.  (Qiu et al, 2011; Gonzalez-Gonzalez, 2015). B) Schematic presentation of the panel of Ebola 
GP fusion constructs generated in this study. 
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Referring to figure 3.31 in section 3.3.1, it was shown that there was a variation in expression 
levels between each of the GP expression constructs made. Salmonella harbouring the 
pTECH10-GP plasmid, which was an attempt to express the GP protein alone, did not express 
any GP protein detectable by western blot. This was somewhat rescued by the addition of the 
TetC full RBS, including 30 bases downstream of the initiation codon, resulting in the 
pTECH11-GP plasmids, which Salmonella were able to use to express GP, potentially due to 
an increase in stability of the interaction between the 16S rRNA and GP mRNA (Etchegaray & 
Inouye, 1999) (see section 3.2.2.3 for more detail). The addition of the full TetC protein as a 
fusion partner however, dramatically increased protein expression of the full-length GP.  
The Ebola GP gene was subsequently demarcated into smaller sub fragments (see figure 6.1) 
with differing results in regards to expression. The D and MFL sub fragments, so chosen due 
to their incorporation of known protective epitopes and ability of expression in bacteria (Das 
et al, 2007; Wang et al, 2014) did express in Salmonella as fusions to TetC, but not to the levels 
that were anticipated. The amalgamation of these sub fragments, into the larger DMFL sub 
fragments showed a much higher level of expression when fused to TetC, even it would seem 
higher than the full-length GP. This fragment also incorporates the mucin like domain, which 
has been shown to include an IgG specific immunodominant region, with B-cell epitopes 
eliciting protective antibodies in survivors of Ebola virus infection (Becquart et al, 2014). The 
sub fragment LH also expressed relatively well as a TetC fusion partner.  
The varying levels of expression seen in Salmonella between these constructs made the 
choice of which to take forward to the next stage of development relatively easy. When 
transformed into attenuated Salmonella vaccine strains, the cells harbouring pTECH2-GP and 
pTECH2-GP DMFL consistently gave the strongest bands on western blot when probed with 
an anti-Ebola GP antibody. It was then therefore decided to use vaccine strain SL3261 (which 
showed better expression compared with other vaccine strains – figure 3.33) with these two 
constructs in further stability and then in vivo testing.  
In all of the samples tested, the western blots, probed with both anti-TetC and anti-Ebola GP, 
the proteins expressed showed a ladder-like pattern of multiple bands in each lane. These 
bands of smaller proteins, which appeared lower than the full-length fusion proteins could be 
the result of either protein breakdown or premature termination of translation. These have 
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shown however, to still contain protective epitopes, both linear and conformational, when 
probed with specific monoclonal antibodies to Ebola GP (see section 3.3.1.1, table 3.1, figure 
3.3.2 and section 6.2, figure 6.1). This then is not necessarily a concern, as these smaller 
fragments could still elicit protective antibodies upon immunisation. 
 
6.2.1 Stability of Ebola GP expression plasmids in vitro 
 
In vitro stability testing was carried out to determine whether Salmonella vaccine strains 
stably retained the pTECH2-GP plasmids in the absence of antibiotic selection (here, 
ampicillin). It was shown that when compared with the pTECH2 control plasmid, which was 
shown to be 100% stable, the pTECH2-GP and pTECH2-GP DMFL plasmids were stable at 100% 
and 91.5% respectively (Table 3.3). This was encouraging as when testing these strains in in 
vivo immunisation experiments, it would not be practical to select with ampicillin.  
  
6.2.2 Stability of Ebola GP expression plasmids in vivo 
 
Once the plasmids had been shown to be stable in vitro, a pilot immunisation experiment was 
carried out to ensure stability in vivo. BALB/c mice were immunised intravenously with the 
Salmonella SL3261 vaccine strain harbouring the GP and GP DMFL expressing plasmids. 
Salmonella recovered from the livers and spleens of the animals were grown in the absence 
of ampicillin selection and compared to cells harbouring the pTECH2 plasmid control, which 
had a stability of 95-98%, the cells harbouring the GP expressing plasmids were lower. The 
cells harbouring the pTECH2-GP DMFL plasmid showed good stable retention of 
approximately 90-96%, however the retention of the pTECH2-GP plasmid with no antibiotics 
was 70-76% (figure 3.34).  
The higher retention of the pTECH2-GP DMFL plasmid compared to its full-length GP 
expressing counterpart, pTECH2-GP, could be due to the potential inherent toxicity of the GP 
protein. It has been shown that the full-length GP is difficult to express in bacterial cells (Zai 
et al, 2016; Das et al, 2007). This could mean that the DMFL sub-fragment is less toxic than 
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the full-length GP and therefore the plasmid expressing DMFL, is more likely to be retained 
by the Salmonella when no antibiotic is present. Cells may therefore be less likely to retain 
the pTECH2-GP plasmid in the absence of ampicillin selection. 
These results show that overall, the plasmids are quite stable after in vivo passage, albeit with 
varying results, and importantly, Salmonella strains show continued expression of the TetC 
and TetC-GP fusion proteins after recovery from the livers and spleens (figure 3.35). The 
strains harbouring these plasmids would therefore be testable in a larger scale immunisation 
experiment to determine any immune response to the GP antigen.  
6.3 Expression of Zika envelope in attenuated Salmonella vaccine strains 
 
As with the Ebola GP, a panel of constructs were made in an attempt to facilitate as much 
expression as possible of the Zika envelope protein (figure 6.2). With the increase in 
expression of Ebola GP shown by the constructs expressing TetC-GP fusion proteins it was 
thought that this may also be the case for ZE.  
 
Figure 6.2. Zika Envelope sub fragments, conserved epitopes and panel of generated constructs. A) 
Schematic diagram of domains I, II and III of Zika E, including approximate locations for some known 
protective epitopes (shown by red boxes). Adapted from Dai et al, 2016 (Sapparapu et al, 2016; Zhao 
et al, 2016). B) Schematic presentation of the panel of Zika E fusion constructs generated in this 
study. 
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Three TetC-Zika envelope expressing constructs were made and showed some variation in 
expression. The most notable, being the clear difference between the constructs containing 
the wild type ZE gene sequence and the synthetic, codon optimised sequence. It was clear to 
see from western blot analysis when probed with both anti-TetC and monoclonal anti-ZE (see 
chapter 4, section 4.2.1, figure 4.7), the codon optimised ZE sequence offers better expression 
than the wild type. The enhanced expression of the synthetic optimised sequence, designed 
to use as many Salmonella Typhimurium favoured codons as possible, shows that this is one 
simple method that can act to improve heterologous protein expression in bacterial systems 
such as this. 
The construct expressing the TetC - truncated Zika envelope fusion protein, the first 193 
amino acids –pTECH2- ZE 193s, appears to express about as well as the full-length synthetic 
ZE. This construct was not recognised however by the monoclonal anti-ZE that was used 
(aaltobioreagents). It was not possible to determine what the epitope for this antibody was 
as it has not been mapped, however we can ascertain from these results that it lies towards 
the C terminal of the ZE protein, or at least after the first 193 amino acids.  
Again, as with the Ebola GP constructs, the ZE constructs were expressed in a panel of 
Salmonella Typhimurium vaccine strains to determine which to use for the in vivo analysis. As 
the best expression for the Ebola GP constructs came from the C5htrA and SL3261 strains, 
these were tested with the ZE constructs. Once again, it was determined that slightly better 
expression was seen in the SL3261 strain and this was therefore chosen to take forward.  
Expression of the TetC-ZE fusion proteins had been confirmed, and additionally, seemed to 
express better than the Ebola GP fusion proteins. This could be due to the ZE protein being 
less toxic to cells and therefore easier to express. It was decided that it would also be tested 
whether the ZE protein could be expressed alone, with no TetC fusion partner. Constructs 
were made which allowed this, pTECH10-ZE(s) and pTECH11-ZE(s) which contained none or 
only the RBS plus a 30bp downstream sequence of TetC respectively. In contrast to the 
pTECH10-GP construct, where no GP expression was seen at all, the Zika envelope protein 
was expressed successfully with no fusion partner. This again could be due to the lower 
toxicity of the ZE compared with Ebola GP. The pTECH11 construct, which had rescued the 
Ebola GP expression however, did not appear to improve expression for the Zika envelope. 
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With both of these constructs, while ZE was still expressed by the Salmonella, it was again not 
to the level of TetC-ZE fusion protein expressed by the pTECH2 constructs. Therefore, it was 
decided not to take these constructs forward for in vivo testing.  
As it had been shown that the Zika envelope could be expressed alone in this system, it was 
thought that it may be possible to rescue the expression of the Ebola GP by way of 
constructing a ZE-GP fusion. In this system, GP is unable to be expressed with no fusion 
partner, as shown with the pTECH10-GP construct, however expression is rescued by fusion 
with TetC. By creating the construct pTECHZE-DMFL, it was shown that a Zika E-Ebola GP 
DMFL fusion protein could be expressed by the Salmonella cells (see section 4.4.2 figure 4.16). 
Once again however, this was nowhere near the level of expression seen with the TetC-GP or 
TetC-ZE fusions and therefore it was decided not to pursue this construct further as TetC is 
considered a superior fusion partner when total protein expression is considered.  
6.3.1 Stability of Zika envelope expression plasmids in vitro 
 
In vitro stability testing was carried out to determine whether Salmonella vaccine strains 
stably retained the pTECH2-ZE plasmids in the absence of antibiotic selection (here, 
ampicillin). It was shown that when compared with the pTECH2 control plasmid (100% stable), 
the pTECH2-ZE(s) and pTECH2-ZE(s193) plasmids were stable at 81.8% and 100% respectively 
(table 4.1). This again showed that the plasmids were stably retained by the Salmonella 
vaccine strain even without exogenous ampicillin selection and would allow the pilot in vivo 
immunisation to be carried out without the fear that the plasmids would be lost. 
 
6.3.2 Stability of Zika envelope expression plasmids in vivo 
 
Once the plasmids had been shown to be stable in vitro, a pilot immunisation experiment was 
carried out to ensure stability in vivo. BALB/c mice were immunised intravenously with the 
Salmonella SL3261 vaccine strain harbouring the ZE(s) and ZE(s193) expressing plasmids. 
Salmonella recovered from the livers and spleens of the animals were grown in the absence 
of ampicillin selection and compared to cells harbouring the pTECH2 plasmid control, which 
207 
 
had a stability of 95-98%, the cells harbouring the GP expressing plasmids were lower. The 
cells harbouring the pTECH2-ZE(s193) plasmid showed good stable retention of 
approximately 91-98%, however the retention of the pTECH2-ZE(s) plasmid with no 
antibiotics was approximately 50% (figure 4.17). This could mean that the plasmid expressing 
the truncated ZE protein is more stably retained as expression of the smaller protein may not 
negatively impact the physiology of the host cell, compared to the full-length ZE. 
The Salmonella recovered from the organs was tested for expression of the TetC-ZE fusion 
protein and all samples were shown to express when analysed on western blot, probed with 
anti-TetC (figure 4.18). There did appear to be variation in expression between samples 
recovered from different mice, so it was therefore decided that the sample which showed the 
highest expression of TetC-ZE (Mouse 1, spleen) would be used to immunise mice in the main 
experiment, as it has previously been shown that further passage in vivo can improve plasmid 
stability, (Chabalgoity et al, 1996) an issue seen with this construct. The expression of the 
stable TetC-ZE(s193) fusion protein was shown to be high, which hopefully would mean that 
there would be a good antigenic dose at immunisation. 
 
6.4 Immunogenicity of Ebola GP expressed in attenuated Salmonella vaccine strains 
 
From the results of the ELISA assays, it appears that there was no significant IgG response to 
Ebola GP in mice immunised with Salmonella Typhimurium vaccine strain SL3261 expressing 
either of the TetC-GP fusion proteins (figure 3.36) 
It was initially postulated, as there was also a decreased IgG response to TetC (figure 3.37), 
this may be due to an overall immunosuppressive effect from the vaccine strain. This has been 
shown before by Eisenstein and colleagues, who reported that mice immunised with the aroA- 
Salmonella Typhimurium strain SL3235, showed notable mitogenic suppression, while also 
being highly immune to Salmonella challenge. This effect assumed to be immunomodulatory, 
rather than a poor overall response, appeared to be mediated by macrophages (Lee et al, 
1985). It could be, that this immunomodulatory effect, may result in a lower IgG response due 
to the lower mitogenesis of B and T cells.  
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 However, when the same sera were tested for IgG response against Salmonella Typhimurium 
LPS (figure 3.38), there was no obvious lack of response seen. This therefore could mean that 
other factors are the cause of this unexpected lack of response. As has been shown, the 
expression plasmids continue to express the TetC and both TetC-GP fusion proteins after 
Salmonella recovery from immunised mouse livers and spleens, 11 days post immunisation. 
As these cells were grown on LB agar post organ recovery however, it could be that expression 
of the fusion proteins is for some reason decreased when the Salmonella is actually persisting 
in vivo. It could also be that the fusion proteins themselves are somehow degraded, resulting 
in a lower antigenic dose and thus lack of IgG response. It could also be that the known 
cytotoxicity of the Ebola GP protein is making the Salmonella cells sick and thus unable to 
persist for long enough in vivo in the absence of the selective antibiotic advantage. 
 IgG response was only examined in these assays, given the time limitations of this project. 
Further immunological insights could be provided by determining the cytokine profiles in the 
sera of the immunised mice. This would indicate if there was a T cell response, and depending 
on which cytokines present, what kind of T cell response this may be. 
To determine if the apparent lack of response is due to minimal in vivo expression, the organs 
from the immunised mice could be analysed to determine antigen expression, for example 
using immunohistochemistry on liver and spleen tissue. It may be possible that this would 
show a difference in expression from Salmonella cells growing in vivo to those growing in vitro 
(even after recovery from the organs). If this was the case, then this may explain that the lack 
of response is due to a sub-optimal antigenic dose.  
 
6.5 Immunogenicity of Zika envelope expressed in attenuated Salmonella vaccine strains 
 
From the results of the ELISA assays, it appears that there was no significant IgG response to 
Zika envelope in mice immunised with Salmonella Typhimurium vaccine strain SL3261 
expressing either of the TetC-ZE fusion proteins. In the group immunised with pTECH2-ZE(s) 
there are potentially one or two mice that show some response, however when taking into 
account the surprisingly high values from the sera from TetC only immunised mice, it would 
be difficult to say that this was a true response (figure 4.19).  
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Again, as with the GP immunised mice, there is a marked decrease in immune response to 
TetC (figure 4.20), although interestingly one mouse from each of the TetC-ZE (193s) and 
TetC-ZE(WT) groups show an IgG response to TetC, comparable to what is seen in the TetC 
only negative control mice. These results could again point to the fact that the expression of 
the fusion protein in vivo is in some way decreased or the protein is degraded and thus 
lowering the antigenic dose to sub-sufficient levels. Sera was also tested for response to 
Salmonella Typhimurium LPS (figure 4.21), to determine if there was an overall 
immunosuppression, however as with the Ebola GP groups, this did not appear to be the case 
and IgG response to LPS was not significantly different in fusion protein immunised groups, 
compared with the TetC only immunised control group.  
Again, further analysis on the immunised mouse sera or organs could be carried out to provide 
insight into the cytokine profiles and true in vivo expression levels, as discussed in section 6.4. 
 
6.5.1 Measurement of neutralisation activity by Zika E immunised mouse sera 
 
Despite the overall lack of response in immunised mouse sera to Zika E, there were some 
samples which appeared to be outliers and show a slightly stronger response. It was decided, 
with the kind help of Professor Alain Kohl and Professor Arvind Patel (Glasgow University) 
micro-neutralisation testing could be carried out to determine if any of the mice had 
produced neutralising antibodies to Zika envelope (figure 4.22). It appeared however that this 
was not the case and no virus neutralisation was seen in any samples from the immunised 
mice. This again could be due to a sub-sufficient antigenic dose, possibly due to a lack of 
sufficient in vivo expression of the fusion proteins. It could be that taking a more epitope 
focused approach when designing the Zika envelope constructs may have yielded more 
favourable results in terms of virus neutralisation. 
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6.6 Potential improvements to enhance immune response – Future work 
 
It appears in this study, that there were unfortunately no protective immune responses 
generated towards either the Ebola Glycoprotein or Zika envelope protein, in mice immunised 
with Salmonella vaccine strains expressing these antigens. Given more time, other avenues 
could be explored which may act to improve the immune response seen here. 
One potential method of increasing immunogenicity is to use tandem repeats of known 
protective epitopes, rather than the full-length protein. Previous studies have shown that by 
using this approach, antibody responses to a peptide of the P28 Glutathione S-Transferase, 
from the parasitic worm Schistosoma mansoni, increased when more copies of the epitope 
were fused to the TetC in the pTECH2 plasmid, with an ‘octameric repitope’ eliciting the 
strongest response (Khan et al, 1994 a). Also, genetic fusions which expressed 2 or 4 repeated 
epitopes from glycoprotein D of Herpes Simplex virus (HSV), again in the pTECH2 plasmid as 
used in here, resulted in an antibody response to HSV, however fusions expressing only one 
epitope copy only elicited a response to TetC (Chabalgoity et al, 1996). In this study, known 
protective epitopes of either Ebola GP or Zika E could be cloned repeatedly into the pTECH2 
plasmid which may make for a more directed and specific immune response to these antigens. 
This would be a relatively simple avenue to explore given more time. 
It has also been shown that using an alternative vaccine strain could have an effect on the 
levels of expression seen of heterologous guest antigens. It has been shown that the C5htrA 
strain may express longer antigens better than the aroA- SL3261 strain. SL3261 has been 
shown to be unable to elicit an antibody response to the guest peptide of P28 Glutathione S-
Transferase, compared to C5htrA (see above) in immunised mice (Chabalgoity et al, 1996). In 
this study, there was no evidence in vitro of the C5htrA strain showing better expression of 
the TetC fusion proteins (with either Ebola GP or Zika E), however this was not tested in vivo 
and a further immunisation study to compare between the two strains could elicit more 
favourable immune responses.  
Another possible element to consider is the promoter by which expression of the fusion 
protein is controlled. There does need to be a balance between antigen expression (yet 
ensuring a sufficient antigenic dose) and potential toxicity to the Salmonella which could 
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reduce its effectiveness, so unregulated antigen expression, which may be high, may in fact 
be detrimental. This could be solved by the use of in vivo inducible promoters.  In this study, 
the pTECH2 expression vector utilised the nirB promoter to express the TetC-GP or TetC-ZE 
fusion proteins, aed anaerobically and when the Salmonella enters host cells, including 
macrophages (Everest et al, 1995). Possible alternative promoters could be used to try and 
increase in vivo expression of antigens. For example, the htrA promoter, which is dependent 
on the σE transcription initiation factor, was shown to increase expression of LacZ in 
attenuated Salmonella in the presence of H2O2, which could be seen in the macrophage 
environment (Everest et al, 1995). Another study has shown that the use of the dmsA3 
promoter (which like the nirB promoter is part of the FNR dependent family and induced by 
anaerobic conditions), to express TetC in Salmonella Typhi vaccine strain CVD 908-htrA, does 
not show an apparent difference in TetC expression, compared to the use of the nirB 
promoter, however elicits a significantly higher IgG response to TetC in immunised mice (Orr 
et al, 2001).  
An alternative method of heterologous antigen expression, may also improve the immune 
response seen in immunised animals. It could be that retaining the heterologous antigen in 
the cytoplasm of the Salmonella, as seen here with the live vaccine approach, may not be 
optimal in the elicitation of high antibody titres. It could be that targeting expression of the 
heterologous antigen to allow it to be displayed on the Salmonella surface, may be more 
successful in inducing higher antibody titres (Clark-Curtiss & Curtiss III, 2018). This approach 
has been considered when designing constructs for the Outer Membrane Vesicle, non-living 
vaccine platform (see section 5.3), however incorporating this strategy in the live vaccine 
could yield more favourable results.  
A booster vaccination after a certain time point, for example when the Salmonella infection 
is expected to have been cleared, could also potentially increase the immune response seen 
to the guest antigens in this study. For example, Doggett and colleagues showed that mice 
immunised with a Salmonella Typhimurium vaccine strain expressing either a single copy or 
three tandem repeats of the Streptococcus sobrinus antigen SpaA, showed an increase in 
serum anti-SpaA IgG titres when boosted intranasally 26 weeks after first immunisation. This 
was despite the fact that mice immunised initially with the single antigen copy strain did not 
show a significant IgG titre (Doggett et al, 1993). Again, time limitations prevented this from 
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being investigated in this case, but this also highlights the potential of using recombinant 
tandem repeats of antigen to significantly increase antibody response.  
Given more time in this project, the methods mentioned above could have been investigated, 
in an attempt to improve the expression of the guest antigens and subsequent immune 
response in vaccinated mice. It was thought at the time that the level of expression seen of 
both the Ebola GP and Zika envelope fusion proteins, would have been sufficient to elicit a 
protective response, but this was unfortunately not the case. The lessons learned here would 
be to create an even wider ranged panel of constructs, focusing on adding tandem epitope 
repeats, instead of single peptides (sub-fragments) or full-length proteins, and investigating 
the use of alternative promoters at the construct design stage and a variety of vaccine strains 
in the immunisation study. This would potentially allow a more varied approach by ‘casting a 
wider net’ and may have a higher chance of a construct which is successful in eliciting a 
protective immune response.  
6.7 Salmonella Typhimurium Outer Membrane vesicles (OMVs) as a non-living vaccine 
platform 
 
Alongside the live vaccine work, another avenue was investigated to determine the feasibility 
of using Salmonella Typhimurium outer membrane vesicles as a non-living vaccine delivery 
platform. This platform could have numerous advantages over the live Salmonella delivery 
system, not least of which, the immunisation would not rely on the survivability and antigen 
expression capacity of the Salmonella, but antigen could be purified (in vesicles) to specific 
quantities, allowing control over antigenic dose. As a non-living vaccine delivery platform, it 
could also potentially be safer and possibly allow previously contra-indicated groups, such as 
infants, the very old or immunocompromised to be vaccinated with this platform. 
6.7.1 Knockouts to increase OMV production (tolR vs mlaA) 
 
As with most Gram-negative bacteria, Salmonella naturally produce OMVs, however at 
relatively low levels. It has been shown however that certain gene specific knockouts can 
increase the propensity of strains to produce these vesicles. Knockouts of the genes tolR and 
mlaA have been shown to have this effect in a variety of Gram-negative organisms (Berlanda 
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Scorza et al, 2012; Rossi et al, 2016; Lazzaroni et al, 1999; Bernadac et al, 1998; Reidl, 2016; 
Roier et al, 2016).  
Using the one step gene disruption, lambda-red recombinase technique (Datesnko & Wanner, 
2000), ΔtolR and ΔmlaA strains of Salmonella Typhimurium SL1344 were made and OMVs 
successfully purified from spend supernatant. When these OMV fractions were viewed using 
transmission electron microscopy and negative staining it was immediately apparent that the 
two knockout strains produced more OMVs than the wild type SL1344 (see figure 5.1.3, 
chapter 5 section 5.4.2). When the OMV fractions from both knockout strains were analysed 
using SDS-PAGE, it appeared that there was more protein and therefore likely more OMVs 
produced by the ΔtolR strain compared with the ΔmlaA strain. It was therefore decided that 
SL1344 ΔtolR would be taken forward for further consideration as the more vesicles 
produced, the easier it may be to purify a sufficient antigenic dose. 
6.7.2 Targeting of the Zika envelope protein for inclusion in OMVs 
 
Following successful purification of OMVs, the question of antigen presentation then needed 
to be answered. It was decided that a cost-effective and relatively easy method would be to 
engineer a plasmid which would hopefully direct the expression of the Zika envelope antigen 
so that it would be contained in the OMVs.  
By engineering expression plasmid, pBAD24-ZE, made using In-Fusion® ligation independent 
cloning (Clontech), to include signal sequences from known Salmonella proteins situated 
either on the outer membrane or periplasm. It was decided to use the signal sequences for 
the outer membrane situated OmpA and periplasmically situated DsbA. It was hoped that the 
Zika E protein, directed by these signal sequences would be either anchored to the outer 
membrane, and thus displayed on the outside of the OMV, or situated in the periplasm and 
therefore contained within the lumen of the OMV which contains periplasmic material.  
6.7.2.1 Expression of Zika envelope in OMVs 
 
Signal sequence constructs were successfully made, their identity confirmed by DNA 
sequencing, and transformed into the SL1344 knockout strains. These were then tested for 
expression of Zika E by western blot of cell lysates and this was shown to be very effective.  
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Following confirmation of Zika E expression by the Salmonella cells themselves, the OMVs 
were purified from the spent supernatant of these transformed strains and analysed by 
western blot, probed with monoclonal anti-Zika E to determine, showing that the Zika 
envelope protein was present in the OMV fraction. This suggests that outer membrane 
targeting by the OmpA by the signal sequences was successful. The addition of 12 extra 
residues, corresponding with the membrane spanning region (MSR) of the OmpA protein, 
hopefully would assist with anchoring the fused ZE to the membrane.  
6.7.3 Future work for the OMV platform 
 
The initial results from the OMV platform are very encouraging. It has been shown here that 
a simple gene knockout can vastly increase the production of OMVs in Salmonella as expected 
and described by other groups. Here however, it has also been shown that these OMVs could 
be potentially used to make multi-valent vaccines by way of utilising them as a non-living 
antigen delivery system. The antigen ‘cargo’, here Zika E, is loaded into the OMVs using signal 
sequences to direct its expression from a plasmid to the outer membrane or periplasm of the 
Salmonella, subsequently appearing in the OMVs when they are formed.  
To further confirm evidence of the expression of Zika E, either displayed on the outside of the 
OMVs or contained within the lumen, the next step would be to use immuno-gold staining on 
OMV fractions in TEM to visualise the Zika E in these locations. Further work here, given more 
time, could also be to use the pBAD24-ZE plasmid as a non-SS control, transforming this into 
the knockout strains should result in no ZE being detected in the OMV fraction, thus providing 
evidence that the ZE seen here in the OMV fraction is not due to cytoplasmic contamination 
of the sample.   
It would then need to be determined whether these ZE carrying OMVs, would elicit an 
immune response when used as a vaccine. OMVs themselves are highly immunogenic due to 
the outer membrane components such as LPS that they contain, which are known to be 
potent activators of the innate immune system, in particular, from recognition by Toll-like 
receptors (TLR). TLR4 recognises LPS, an abundant and very potent immunostimulatory 
component of the OMV membrane. This potency could lead to unwanted and dangerous 
reactions such as fever or even septic shock in humans when immunised with certain doses 
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of OMVs (Rossi et al, 2014). In order to progress to in vivo studies, steps would therefore need 
to be taken in order to reduce the reactogenicity and potential toxicity of the LPS. This would 
allow a higher OMV dose and thus a higher and hopefully sufficient antigenic dose.  
Lipid A anchors the LPS to the membrane and is the endotoxic region of the molecule (Rossi 
et al, 2014).  Modifications, again using specific gene knockouts, have been shown to address 
its reactogenicity and activation of TLR4.  The classic hexa-acylated structure of Lipid A, is also 
its most endotoxic. Inactivation of the msbB and pagP genes in Salmonella, result in a solely 
penta-acylated Lipid A with a reduction in the stimulatory potentials of their OMVs, thus 
possibly resulting in a safer vaccine, where the immunogenic dose is not yet known (Rossi et 
al, 2016).  
Further strategies to increase the expression of the Zika envelope (such as mentioned in 
section 6.6) could be investigated to increase the chances of a protective immune response. 
The expression of ZE repitopes (tandem repeats) or even just smaller peptides containing 
known protective epitopes and displaying these, rather than the full-length ZE, on the OMV 
surface or contained in the periplasm may help to promote a stronger immune response. 
Following these modifications and investigations into the ZE expression, the ZE carrying OMVs 
could then be used to immunise mice and determine immune response. One recent study by 
Martins and colleagues has shown that a fusion of OMVs from Neisseria meningitidis and Zika 
Virus expressed from infected C6/36 cells is immunogenic in mice, eliciting antibodies and 
both TH1 and TH2 responses towards the Zika Virus (Martins et al, 2018). While this method 
did not utilise molecular biology to target the expression of the antigen, it still highlights the 
possibility of using OMVs from bacterial pathogens in a multivalent vaccine, affording 
protection against other pathogens, Zika Virus in particular.  
Another interesting method which could be employed to decorate the OMV surface with a 
heterologous antigen is to exploit natural bacterial autotransporter proteins, usually used to 
allow gram negative bacteria to translocate proteins across the cell envelope and secrete 
virulence factors. Daleke-Schermerhorn and colleagues have shown that the E. coli 
autotransporter, haemoglobin protease (Hbp) has side domains which are not necessary for 
translocation. These side domains can be replaced with heterologous polypeptides, in this 
case a selection of antigens from Mycobacterium tuberculosis, which can then be displayed 
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on the surface of OMVs if the Hbp-antigen fusions are expressed in hypervesiculating bacterial 
mutants (such as the tolR knockout mutants as mentioned above) (Daleke-Schermerhorn  et 
al, 2014)  
If a response to ZE is seen when these OMVs containing the Zika Envelope antigen are used 
to immunise, this would be an incredibly attractive and cost-effective vaccine platform not 
only for Zika Virus but could be engineered to carry antigens from a variety of other 
pathogens.  
 
6.8 Overall discussion 
 
As outlined in chapter 1, section 1.10, the overall aims and scope of this thesis was to test 
both living and non-living Salmonella vaccine delivery platforms for Ebola and Zika viruses. 
These were met by the generation of panels of constructs, allowing expression of the both 
the full-length and sub-fragments of, the Ebola Glycoprotein and Zika envelope protein, either 
with or without a fusion partner of the C-fragment of Tetanus Toxin (TetC). These proteins 
were selected as target antigens as they are known targets for protective and neutralising 
antibodies (Stettler et al, 2016; Sapparapu et al, 2016; Takada et al, 1997; Cook & Lee, 2013), 
and successful expression of these antigens was observed in Salmonella Typhimurium.  
It has been shown that bacterial expression of Ebola GP is particularly difficult, with no reports 
on successful expression of the full-length protein alone or at 37°C possibly due to its toxicity 
(Zai et al, 2016). Here, the full Ebola GP protein was expressed with only a very small fusion 
partner (the first 10 residues of the TetC protein), albeit at levels which are probably 
insufficient for use in a vaccine. This success however, could lead to further ideas for 
strategies to improve expression of challenging proteins. 
The constructs which were determined to be the best expressed by the Salmonella vaccine 
strain SL3261 were those which included the full TetC fusion partner. These strains were 
therefore taken forward into in vivo experiments where plasmid stability and continued 
fusion protein expression were confirmed. Following this, a larger scale immunisation 
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experiment was carried out to determine immune response to the Ebola or Zika antigens, 
however unfortunately there did not appear to be any significant IgG response to these. 
The fact that mice are so widely used in biological research, yet do have significant differences 
in immune development and response compared to humans, could also be a factor when 
considering the immune response to these vaccine platforms. There are differences in 
expression of Ig receptors and different Ig isotypes in mice and humans, and also in B and T 
cell development (Mestas & Hughes, 2004). It may therefore be unwise to assume that the 
response (or lack of) to experimental vaccines in mice would be the same as seen in humans. 
Clearly there are ethical barriers towards the testing of drugs in humans before efficacy is 
seen in an animal model, but perhaps a more humanized mouse model, or alternative animal 
model altogether could give different and more favourable results.  
An alternative vaccine delivery platform, exploiting Salmonella Typhimurium Outer 
Membrane Vesicles (OMVs) was also investigated. It was found that generating knockout 
strains of SL1344, ΔtolR and ΔmlaA, made it possible for the cells to produce a much higher 
yield of OMVs than a wild type strain. This, combined with generating new plasmid constructs 
to target expression of Zika envelope to the bacterial outer membrane or periplasm, by use 
of OmpA or DsbA signal sequences, allowed the incorporation of ZE into purified OMVs. This 
could be a more effective strategy as antigen dose can be more accurately determined and 
as a non-living platform, could widen access to such a vaccine in vulnerable patient 
populations who are not able to receive living vaccines. 
All in all, while there was a lack of immune response seen here with the living platform, this 
thesis has allowed insight into how it may be best to go about creating live attenuated 
Salmonella vaccine delivery platforms for emerging viral pathogens and potentially, which 
strategies to avoid. There are encouraging developments, particularly in the now growing 
field of Outer Membrane Vesicle based vaccines, which could lead to exciting future research 
into Salmonella based vaccine delivery systems. This non-living vaccine platform could have 
the potential to widen access to bacterial vaccines and act as a safe delivery system for 
antigens of other pathogens. 
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